Mechanism of valproic acid induced dysmorphogenesis via oxidative stress and epigenetic regulation at the Hoxa2 gene promoter by Wang, Xia
Mechanism of Valproic Acid Induced Dysmorphogenesis 
Via Oxidative Stress and Epigenetic Regulation at the Hoxa2 
Gene Promoter 
A Thesis Submitted to the College of 
Graduate Studies and Research 
In Partial Fulfillment of the Requirements 
For the Degree of Doctor of Philosophy 
In the College of Pharmacy and Nutrition 
University of Saskatchewan 
Saskatoon 
By 
Xia Wang 
© Copyright Xia Wang, July 2013. All rights reserved. 
i 
PERMISSION TO USE 
     In presenting this thesis in partial fulfillment of the requirements for a postgraduate degree from 
the University of Saskatchewan, I agree that the libraries of this University make it freely available for 
inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, 
for scholarly purposes may be granted by Dr. Adil J. Nazarali, who supervised my thesis work or, in 
his absence, by the Dean of the College of Pharmacy and Nutrition in which my thesis work was done. 
It is understood that any copy or publication or use of this thesis or parts thereof for financial gain 
shall not be allowed without my written permission. It is also understood that due recognition shall be 
given to me and to the University of Saskatchewan in any scholarly use which may be made of any 
material in my thesis.  
    Requests for permission to copy or to make other use of material in this thesis in whole or part 
should be addressed to: 
     Dean of the College of Pharmacy and Nutrition 
     University of Saskatchewan 
     110 Science Place 
     Saskatoon, Saskatchewan S7N 5C9  
     Canada 
ii 
ABSTRACT 
     Valproic acid (2-propylpentanoic acid, VPA) is a clinically used anti-epileptic drug and an 
effective mood stabilizer. VPA is also a histone deacetylase inhibitor and can induce embryonic 
malformations in both humans and mice. The mechanism(s) of VPA-induced teratogenicity are not 
well characterized. The objectives of my study were three fold, to: (i) investigate the effect of VPA on 
mouse embryonic development, (ii) characterize the putative mechanism(s) of VPA-induced 
teratogenicity and, (iii) investigate VPA associated epigenetic regulation of Hoxa2 gene in cell lines 
and in developing embryos. Whole mouse embryo cultures were treated with VPA at doses of 0, 50 
(0.35 mM), 100 (0.70 mM), 200 (1.4 mM), and 400 µg/mL (2.8 mM), encompassing the therapeutic 
range of 0.35 mM to 0.70 mM. Van Maele-Fabry’s morphologic scoring system was used to 
quantitatively assess embryonic organ differentiation and development.  Hoxa2 gene expression was 
measured by quantitative real-time RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction). To 
assess epigenetic changes on the Hoxa2 gene promoter, DNA methylation was determined by bisulfite 
(BSP) sequencing and pyrosequencing. Histone “bivalent domains” H3K4me3 (histone 3 lysine 4 
trimethylation) and H3K27me3 (histone 3 lysine 27 trimethylation) associated with gene activation 
and repression, respectively, were analyzed with qChIP-PCR (quantitative chromatin 
immunoprecipitation-PCR). Telomere length and telomerase activity were analyzed in mouse 
embryos and in NIH3T3 cell line treated with VPA.  
     Results indicate significantly increased incidence of dysmorphogenesis in embryos (11.8%, 35.3%, 
47.0% and 88.3%) exposed to increasing doses of VPA (0.35 mM, 0.70 mM, 1.4 mM and 2.8 mM 
respectively). Van Maele-Fabry’s quantitative differentiation assessment of developing embryos 
demonstrated a significantly lower score for the circulation system, central nervous system, 
craniofacial development and limb development in VPA treated embryos (0.35 mM to 2.8 mM) 
compared to the untreated control group. Glutathione homeostasis was altered as indicated by 
decreased total glutathione content and increased GSSG/GSH ratio in all VPA treatment groups. In 
addition, a dose-dependent inhibition of Hoxa2 gene expression was observed in embryos and in the 
NIH3T3 cell line exposed to VPA. Pre-treatment with ascorbic acid [1000 µg/mL (5 mM)] restored 
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glutathione level and normalized Hoxa2 gene expression in embryos exposed to VPA. DNA 
methylation status was characterized on the Hoxa2 gene promoter at the three CpG islands; CpG 
island 1 (-277 to -620 bp), CpG island 2 (-919 to -1133 bp), and CpG island 3 (-1176 to -1301 bp) in 
the two cells lines (NIH3T3 and EG7) and in developing embryos. CpG sites remained unmethylated 
on the Hoxa2 gene promoter in the NIH3T3 cell line which expresses the Hoxa2 gene, whereas these 
same CpG sites were methylated in EG7 cells that did not express Hoxa2. CpG island 1 is closest to 
Hoxa2 transcription start site and its methylation status was most affected. In developing embryos, 
CpG island 1 was found to be highly methylated at E6.5 when Hoxa2 is not expressed, whereas the 
methylation status of CpG sites on the CpG island 1 declined between E8.5 and E10.5 when Hoxa2 
expression is present. VPA induced methylation of several CpG sites on CpG island 1 in NIH3T3 cell 
line and in E10.5 embryos when Hoxa2 expression was down regulated following VPA exposure. In 
addition, embryos and the NIH3T3 cell line treated with VPA impacted the “bivalent domains” 
resulting in increased H3K27me3 enrichment and decreased H3K4me3 enrichment on Hoxa2 
promoter. Pre-treatment with ascorbic acid normalized Hoxa2 expression and histone bivalent domain 
changes and prevented increased DNA methylation following VPA exposure. Moreover, the 
telomerase activity and telomere length were both impacted by changes in glutathione redox potential 
induced by VPA.  Oxidative stress following VPA treatment reduced telomerase activity and 
accelerated telomere shortening. 
     These results are the first to demonstrate: (i) a correlation between VPA dose and total 
morphologic score in the developing mouse embryos. VPA impacted embryonic tissue differentiation 
and neural system development in the dose range of 0.35 mM to 2.8 mM; (ii) VPA altered glutathione 
homeostasis in cultured mouse embryos and inhibited Hoxa2 gene expression; (iii) Histone bivalent 
domains of H3K27 and H3K4 trimethylation and DNA methylation status at the Hoxa2 gene 
promoter region were altered following treatment with VPA.  This appears to be the epigenetic event 
in transcriptional silencing of Hoxa2 gene expression after VPA exposure; and (iv) Ascorbic acid 
normalizes glutathione homeostasis, H3K27 and H3K4 trimethylation and DNA methylation status, 
restoring Hoxa2 gene expression following VPA exposure. Taken together our results show VPA-
induced altered glutathione homeostasis, telomere shortening and telomerase dysfunction, and an 
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inhibition of Hoxa2 gene expression leads to developmental abnormalities. Exposure to ascorbic acid 
had a protective effect on developing embryos exposed to VPA. 
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CHAPTER 1: OBJECTIVES AND HYPOTHESES 
HYPOTHESES 
1. Valproic acid (VPA) is teratogenic and induces oxidative stress in mouse embryo organ
culture in vitro. Change in embryonic antioxidant status will affect Hoxa2 gene expression 
during VPA-induced teratogenesis. 
2. Exposure to VPA will lead to alterations in histone bivalent modification patterns at Hoxa2
gene promoter and inhibit Hoxa2 gene expression. Hence, an increase in trimethylated 
histone 3 lysine 27 (H3K27me3) will be accompanied by a decrease in trimethylation of 
H3K4 (H3K4me3) at Hoxa2 gene promoter inducing transcriptional repression.  
3. VPA will induce DNA methylation at Hoxa2 CpG-enriched-promoter region in NIH3T3
cell line and in mouse embryos with active Hoxa2 gene transcription and inhibit Hoxa2 gene 
expression.  
4. Depletion of GSH and changes in GSSG/GSH redox potential induced by VPA will reduce
the telomerase activity and telomere length. This will be blocked by the addition of ascorbic 
acid in VPA treated NIH3T3 cell line  and in developing embryos. 
OBJECTIVES 
1. To determine the effect of VPA-induced teratogenicity and VPA-induced oxidative stress
on Hoxa2 gene expression in mouse embryo cultures in vitro. 
2. To determine the effect of VPA on DNA methylation status and histone modifications at
the Hoxa2 gene promoter in a cell culture system and in the developing mouse embryo.  
3. To investigate the role of redox potential impacted by VPA on the regulation of the
telomerase activity and the telomere length. 
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CHAPTER 2: LITERATURE REVIEW 
2.1. Valproic acid: an antiepileptic drug 
     Valproic acid (2-n-propylpentanoic acid; VPA) is one of the most widely prescribed 
antiepileptic drug (AED) since its introduction into clinical use in 1974 (Fig.2.1).  
Fig. 2.1 Chemical structure of valproic acid (2-n-propylpentanoic acid; VPA) 
VPA is used to treat a wide spectrum of seizures including absence seizures, tonic-clonic 
seizures, complex partial seizures, and juvenile myoclonic epilepsy. It is also used in the 
treatment of bipolar disorder, migraine headaches, addiction, amyotrophic lateral sclerosis 
(ALS), and neuropathic pain (Chateauvieux et al., 2010; Loscher, 1999). In the recent years, 
VPA has been associated with treatment or clinical trials for other neurological disorders, 
such as mood disorders, schizophrenia, and attention deficit hyperactivity disorder 
(Chateauvieux et al., 2010).  The neurochemical and neurophysiological mechanisms of VPA 
on anticonvulsive action are complex and not well-defined. One mode of action of VPA is to 
increase levels of the neurotransmitter γ-aminobutyric acid (GABA) in the brain. GABA is an 
important inhibitor of seizures and a reduction in GABA levels potentiate seizures (Owens 
and Nemeroff, 2003; Perucca, 2002; Shorvon, 1990). However, it is not known whether the 
effect of VPA on GABA is due to activation of the GABA synthesizing enzyme, glutamic 
acid decarboxylase (GAD), or due to inhibition of the catabolic enzymes, succinic 
semialdehyde dehydrogenase (SSAD) and GABA transaminase (GABA-T) (Davis et al., 
1994; Sztajnkrycer, 2002). VPA can reduce the release of the epileptogenic γ-hydroxybutyric 
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acid and attenuates neuronal excitation mediated by activation of N-methyl-D-aspartate 
(NMDA)-type glutamate receptors (Porter and Meldrum, 2001). VPA also exerts a direct 
effect on the potassium channels of the neuron membrane (Porter and Meldrum, 2001). For 
daily seizure control, VPA doses range between 300 mg to 2 g to achieve therapeutic plasma 
levels of 50-100 g/mL [0.35 mM-0.70 mM] (Ornoy, 2009). Lower doses are usually used in 
the treatment of bipolar disorder and migraine (Ornoy, 2009).  
     VPA is a histone deacetylase inhibitor (HDACI) (Phiel et al., 2001), that has wide 
implications in the treatment of various cancers including multiple myeloma  (Schwartz et al., 
2007), glioma (Ciusani et al., 2007), and melanoma (Valentini et al., 2007). Most of the 
clinical data on the antitumor effect of VPA has come from studies  of combining VPA and 
DNA methylation inhibitors. Recently, some completed phase I/II studies included combined 
action of decitabine and VPA (Garcia-Manero et al., 2006), or azacitidine, VPA and retinoic 
acid (Soriano et al., 2007) in hematological malignancies. VPA shows potent antitumor effect 
in a wide variety of cancers in preclinical studies, both in vitro and in vivo, by modulating 
multiple pathways including cycle arrest, angiogenesis, apoptosis, differentiation and 
senescence (Chateauvieux et al., 2010).  
The use of VPA in monotherapy or polytherapy for leukemia diseases is promising. VPA 
exerts different effects in different cell types, including inducing proliferation in early stem 
cells and inhibiting angiogenesis, which could be beneficial in the treatment of leukemic 
pathologies (Chateauvieux et al., 2010). Clinical studies on the use of VPA have shown the 
beneficial effect especially on myelodysplastic syndrome (MDS) (Batty et al., 2009; 
Chateauvieux et al., 2010; Kuendgen et al., 2005; Kuendgen et al., 2006).  
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2.2. Teratogenic effects of VPA 
2.2.1.  Effect of VPA during pregnancy 
     Many anti-epileptic drugs (AEDs) are teratogenic to the embryo and fetus when used 
during pregnancy (Diav-Citrin et al., 2008; Dravet et al., 1992; Kaneko et al., 1999; Kini et 
al., 2006; Kultima et al., 2004; Morrow et al., 2006; Ornoy, 2003). In a majority of epileptic 
women, even when pregnancy is planned, AEDs cannot be discontinued because the risk of 
seizures during pregnancy can be harmful to both mother and child (Ornoy, 2006). As a result, 
adverse effects of AEDs on fetuses are a major concern for millions of women with epilepsy 
(Perucca, 2005). Studies have suggested that the rate of malformation among the offspring of 
women with untreated epilepsy is similar to that in non-epileptic control women (Fried et al., 
2004), which indicate that epilepsy by itself was not associated with a high risk of congenital 
malformations in the offspring. VPA can cross the human placenta, and is likely the most 
potent teratogenic anticonvulsant drug (Diav-Citrin et al., 2008; Dravet et al., 1992; Kaneko 
et al., 1999; Kini et al., 2006; Morrow et al., 2006). VPA clearance is increased during 
pregnancy, and the accumulated VPA levels in placental cord serum are often up to 5 times 
higher than levels in maternal serum at term (Albani et al., 1984; Nau, 1982). Intrauterine 
exposure to AEDs can result in increased rate of major and minor congenital anomalies, 
especially if exposure occurred during the first trimester of pregnancy (Ornoy, 2009). Many 
studies have described an association between the VPA administration in the first trimester 
and the occurrence of fetal anomalies (Ardinger et al., 1988; DiLiberti et al., 1984). These 
anomalies can be anatomical or functional or both, and can include neurological, behavioural 
and cognitive defects (Ardinger et al., 1988; DiLiberti et al., 1984).  
     Teratogenic effects of VPA could be due to impaired methionine synthesis (Alonso-
Aperte et al., 1999), as VPA interrupts the folic acid cycle and subsequent synthesis of 
methionine (Ubeda-Martin et al., 1998) and/or due to the induced oxidative stress, to which 
the brain is more susceptible than the other fetal organs (Ornoy, 2009; Zhang et al., 2010).  
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2.2.2.  Valproate syndrome 
     VPA associated facial dysmorphic features in the developing embryo and fetus were first 
described by DiLiberti et al., (1984). The use of VPA during pregnancy causes a 1-2% 
incidence of neural tube defects (NTDs) mainly associated with spina bifida aperta and is 10-
20 times higher than in the general population (Bjerkedal et al., 1982; Dalens et al., 1980; 
Fried et al., 2004; Gomez, 1981; Lindhout et al., 1992; Omtzigt et al., 1992; Robert et al., 
1983). Many of the children affected by VPA developed a typical “fetal valproate syndrome”. 
Features of VPA exposure in utero include intrauterine growth restriction (IUGR) and facial 
dysmorphism recognized by mid-facial hypoplasia, hypertelorism, epicanthal folds, short 
nose with a broad nasal bridge, thin upper lip but thick lower lip, and micrognathia; and other 
abnomalies found in limbs, heart and brain (Dean et al., 2000; DiLiberti et al., 1984). Animal 
studies in monkeys, mice, rats, hamsters and rabbits have also documented VPA-induced 
teratogenic effects including craniofacial, skeletal, cardiac, limb, renal, and central nervous 
system anomalies including NTDs and encephaloceles (Lyon et al., 2003; Nulman et al., 
1997). 
2.2.3.  VPA-induced neurodevelopmental defects 
VPA associated intellectual ability studies have noted children exposed in utero exhibit 
developmental delay including reduced cognitive function, attention deficit disorder and 
learning difficulties. Most of them have the typical facial dysmorphic features as part of the  
“valproate syndrome” (Christianson et al., 1994; Dean et al., 2002; Dean et al., 2000; 
Eriksson et al., 2005; Kini et al., 2006; Koch et al., 1996; Langer et al., 1994; Moore et al., 
2000; Perucca and Tomson, 2006; Viinikainen et al., 2006). Christianson et al., (1994) first 
described a relationship that may exist between VPA exposure and autistic spectrum disorder 
(ASD). In their study, four children exposed in utero to VPA demonstrated developmental 
delay, and one of these children also had ASD. Later studies on children associated with 
typical facial features of VPA embryopathy were also described to have developed typical 
features of autism (Williams et al., 2001). Recently, more findings of VPA exposure 
6 
associated with ASD have been reported (Adab et al., 2004; Dean et al., 2002; Meador, 2006; 
Moore et al., 2000; Rasalam et al., 2005; Viinikainen et al., 2006).  
2.2.4.  VPA in animal studies 
     Many animal studies attempting to mimic effects of VPA on human embryos were carried 
out to elucidate mechanisms of VPA teratogenicity (Arndt et al., 2005; Wagner et al., 2006; 
Wegner and Nau, 1991; Wegner and Nau, 1992; Zhang et al., 2010). VPA induces multiple 
organ malformations in mice, rats, and gerbils; kidney and skeletal defects in rabbits; NTDs 
in mice and hamsters; and craniofacial and appendicular skeletal defects in primates (Binkerd 
et al., 1988; Ehlers et al., 1996; Ehlers et al., 1992; Emmanouil-Nikoloussi et al., 2004; 
Holmes et al., 2005; Narotsky et al., 1994). High doses of VPA in rhesus monkeys are 
associated with IUGR and craniofacial and skeletal anomalies, all of which are similar to 
effects demonstrated in the human fetus (Hendrickx et al., 1988).  
     A number of animal studies have been conducted to further characterize VPA-induced 
ASD (Ingram et al., 2000; Rodier et al., 1996). When VPA is administered to pregnant mice 
and rats, a set of behavioural changes in the offspring that resemble the behavioural changes 
in human ASD were observed (Ingram et al., 2000; Rodier et al., 1996). Recently, one study 
showed mice exposed to VPA at embryonic day 12.5 (E12.5) exhibited social interaction 
deficits, anxiety-like behaviour and memory deficits at age 4-8 week (wk). VPA treatment 
also decreased the number of Nissl-positive cells in the prefrontal cortex and somatosensory 
cortex in mice at 8 wk of age (Kataoka et al., 2011). Furthermore, VPA exposure caused a 
transient increase in histone acetylation in the embryonic brain. It was followed by increased 
cell death in the neocortex and decreased cell proliferation in the ganglionic eminence. This 
study implicated a dysfunction in HDAC activity during pregnancy as a key risk factor of 
ASD in the offspring (Kataoka et al., 2011).  
     These findings strengthen the possible relationship between in utero VPA exposure and 
ASD that has been suggested in humans (Arndt et al., 2005; Wagner et al., 2006). 
Furthermore, VPA has a toxic effect on the development of central nervous system (CNS) in 
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animals, with respect to biochemical and morphological changes such as reduced number of 
neurons in motor cranial nerve nuclei in the brain (Arndt et al., 2005; Emmanouil-Nikoloussi 
et al., 2004; Rodier et al., 1996; Ingram et al., 2000). Interestingly, the timing of the effect of 
VPA that increased the risk of ASD is coincident with the timing of neural tube closure 
(Wagner et al., 2006).  
2.3. Proposed mechanism(s) of VPA-induced teratogenicity 
2.3.1.  Folic acid deficiency 
     One mechanism of AED-induced birth defects is believed to be due to a reduction in folic 
acid level that occurs after treatment with VPA and other AEDs. Lower folic acid levels in 
embryos can result in disruption of gene expression and changes in protein syntheses and also 
induce embryonic oxidative stress (Wegner and Nau, 1991; Wegner and Nau, 1992). VPA 
appears to interfere with the metabolism of folic acid, whereas other AEDs appear to act 
specifically on the intestine and reduce intestinal absorption of folic acid (Wegner and Nau, 
1991; Wegner and Nau, 1992; Yerby, 2003). However, the mechanism of the disturbances in 
folic acid metabolism only plays a partial role in VPA-induced teratogenicity (Graf et al., 
1998; Ornoy, 2009).  
2.3.2.  Oxidative stress 
2.3.2.1. Redox homeostasis and glutathione 
     Redox homeostasis is very important for vital cellular functions. The disruption of redox 
homeostasis is accompanied by an increase in the level of reactive oxygen species (ROS), 
and causes oxidative damage to lipids, DNA, and proteins (Oktyabrsky and Smirnova, 2007).  
     Glutathione (GSH), a widely distributed thiol in animal organisms, is the major redox 
buffer in cells (Zuelke et al., 2003). It has antioxidative properties and protects eukaryotic 
cells against ROS (Luberda, 2005). GSH also plays a role during oocyte maturation, 
fertilization and the pre-implantation stage of embryo development. The GSH level in a cell 
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is determined by the rate of its synthesis and the rate of export and conjugation. Apoptosis is 
an important process in the cell and can be initiated by alterations in redox homeostasis 
(Ghibelli et al., 1998; Gulbins et al., 2000; Kern and Kehrer, 2005; Kwon et al., 2003). An 
early event during apoptosis is the efflux of reduced GSH from cells through specific 
channels across the cytoplasmic membrane. GSH efflux can cause disruption of redox 
balance and ultimately lead to oxidative stress (Kern and Kehrer, 2005).  
2.3.2.2. Teratogenic effect of oxidative stress 
     Similar to diabetic teratogenicity, the intermediate metabolites of AEDs can induce 
oxidative stress, and increased oxidative stress can cause irreversible damage to the 
developing fetus especially since the embryonic antioxidant defense systems are immature 
and develop slowly with the advancement in gestational stage (Danielsson et al., 2007; Ornoy, 
2007). Studies conducted in rats have suggested enhanced oxidative stress is more harmful to 
the developing brain than to other fetal organs (Ornoy, 2007).  
2.3.2.3. Oxidative stress induced by VPA 
     There is a growing body of evidence indicating VPA exposure can cause excessive 
oxidative stress, as a result of VPA biotransformation or alterations in GSH homeostasis or 
cofactors required for antioxidant reactions (Cotariu et al., 1990; Graf et al., 1998; (Hurd et 
al., 1984; Tabatabaei and Abbott, 1999; Yuksel et al., 2001; Zhang et al., 2010). VPA-
induced testicular toxicity is reported to be associated with elevated oxidative stress and an 
over-production of free radicals, accounting at least in part the testicular injury associated 
with VPA exposure (Hamza and Amin, 2007). Children with epilepsy treated with VPA 
showed increased oxidative stress that linked to obesity (Verrotti et al., 2008).  
     Oxidative stress has also been implicated in VPA-induced idiosyncratic hepatotoxicity 
(Tabatabaei and Abbott, 1999; Weber et al., 1991). In vitro studies have revealed decreased 
GSH content in liver homogenates from rats administered with a single intraperitoneal (i.p) 
dose of VPA (Cotariu et al., 1990; Seckin et al., 1999). Interestingly, VPA toxicity in 
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cultured rat hepatocytes could be attenuated by antioxidants such as ascorbic acid (Jurima-
Romet et al., 1996). Recently, it has been demonstrated that VPA is capable of producing 
elevated levels of mitochondrial ROS in glioma cells, leading to loss of matrix 
metalloproteinases (MMP) and mitochondrial injuries and causing cytotoxicity and ultimately 
cell death (Fu et al., 2010). Another study was also the first to directly localize ROS in mouse 
embryos by whole-mount immunofluorescence with CM-H2DCFDA (chloromethyl-2’,7’-
dichlorofluorescein diacetate), a dye sensitive to ROS (Tung and Winn, 2011). A significant 
increase in fluorescent staining was observed in the heads of mouse embryos that were 
exposed to VPA, and these increased ROS levels were attenuated by coculture with PEG-
catalase (Polyethylene glycol – catalase). PEG-catalase catalyzes the decomposition of 
hydrogen peroxide to water and molecular oxygen, preventing VPA-induced ROS formation 
(Tung and Winn, 2011). The incidence of embryonic and fetal defects induced by VPA was 
prevented by catalase in both whole-embryo culture and in vivo models (Tung and Winn, 
2011). Increased apoptosis in the neuroepithelium caused by VPA-induced ROS production 
and alterations in embryonic signaling may be the underlying causes of NTDs in this model. 
They postulated that VPA may be mediating teratogenesis by alterations in redox-sensitive 
signaling pathways (Tung and Winn, 2011).  
     Study reported in this thesis on VPA induced teratogenicity in whole mouse embryo 
culture system showed that VPA decreased GSH content, increased GSSG/GSH ratio and 
induced oxidative stress. VPA also inhibited Hoxa2 gene expression in a dose-dependent 
manner (see section 4.1). Pre-treatment with the antioxidant, ascorbic acid, prevented VPA-
induced reduction in GSH and normalized Hoxa2 expression in the whole mouse embryo 
cultures (see Section 4.1)(Zhang et al., 2010) 
2.3.3 VPA as an inhibitor of histone deacetylase (HDAC) 
      Phiel et al. (2001) were the first to describe VPA induced inhibition of histone 
deacetylase (HDAC). They demonstrated in HeLa cell lines that VPA is a potent inhibitor of 
histone deacetylases and reduced the level of histone deacetylation, resulting in the change of 
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chromatin structure and the accessibility of transcription factors and RNA polymerase to the 
DNA to regulate gene expression (Orney, 2009).  
     There is good congruency between VPA’s teratogenic potency and its HDAC inhibition 
(Eikel et al., 2006b), prompting the widely known term “valproate syndrome” for 
consideration to be renamed as the “HDACi syndrome” (Eikel et al., 2006a). Indeed, there is 
direct correlation between the axial abnormalities and the specific hyperacetylation levels in 
the embryonic axial organs such as the somites (Eikel et al., 2006a; Menegola et al., 2005). 
Mouse embryos between E8 and E10 stage of development exposed to VPA in utero induced 
hyperacetylation of histone 4 (H4) and caused embryonic tissues to be hyperacetylated in the 
caudal neural tube and somites (Eikel et al., 2006a; Menegola et al., 2005). VPA induces 
growth retardation and a number of congenital anomalies in Xenopus and zebrafish embryos 
as a result of its inhibition of HDAC (Wiltse, 2005). HDAC inhibitors can interrupt cell cycle, 
arrest cell growth, and induce apoptosis (Ornoy, 2009). Hence, inhibition of cell proliferation 
after VPA could be one mechanism for its teratogenicity (Ornoy, 2009). This has been 
demonstrated in cultured brain microglial cells obtained from 2-day-old rats exposed to VPA 
which induces apoptosis, suggesting specific brain damage can occur in the offspring of rats 
exposed to VPA in utero (Chen et al., 2007; Ornoy, 2009).  
     VPA specifically targets 2 of the 4 classes of HDACs: class I (HDAC 1, 2, 3 and 8) and 
class IIb (HDAC6 and 10), components of HDAC complexes [REST corepressor 1 
(CoREST), NuRD, Sin3, Nuclear receptor co-repressor 1 (NCoR) complex], and putative 
novel complex components or targets  (Bradbury et al., 2005; Bantscheff et al., 2011). It is 
interesting to mention that HDAC classes I and II have been reported to be strongly 
implicated in neuronal function, which could partially explain the action of VPA in neural 
pathologies (Chateauvieux et al., 2010). 
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2.3.4 VPA or HDAC inhibitor and oxidative stress 
     HDAC inhibitors cause histone hyperacetylation and influence chromatin stability by 
inducing profound changes in chromatin structure (Eot-Houllier et al., 2009). These changes 
can release tightly packed DNA, thereby increasing exposure to potential damage (Eot-
Houllier et al., 2009; Rajendran et al., 2011).  
     HDAC inhibition may also disrupt the expression of DNA repair genes by affecting the 
timing of their expression, leading to improper cellular responses to DNA damage and 
accumulation of strand breaks and modified bases (Eot-Houllier et al., 2009). HDAC 
inhibitors such as vorinostat, PCI-24781 (a broad-spectrum phenyl hydroxamic acid HDAC 
inhibitor) (Adimoolam et al., 2007) and VPA (Kachhap et al., 2010) have been shown to 
decrease the expression of DNA repair proteins such as Ku70 (a protein that binds to DNA 
double-strand break ends and is required for the non-homologous end joining pathway of 
DNA repair) (Chen et al., 2007), BRCA1 (breast cancer type 1 susceptibility protein) (Zhang 
et al., 2007), RAD51 (a protein family highly similar to bacterial RecA and Saccharomyces 
cerevisiae Rad51)(Adimoolam et al., 2007), and CtIP (C-terminal-binding protein 1)(Robert 
et al., 2011). Moreover, these studies have found that DNA damage was related to ROS 
generation and GSH depletion (Sestili et al., 2010). 
     ROS, hydrogen peroxide, and hydroxyl radicals, represent major sources of endogenous 
DNA damage (Eot-Houllier et al., 2009). Normal cells control ROS concentrations through 
the actions of enzymatic and non-enzymatic ROS scavengers (Eot-Houllier et al., 2009). 
However, cells with particularly high ROS concentrations, or with defective or damaged ROS 
scavengers, enter a state of genotoxic oxidative stress that eventually leads to apoptosis 
(Sancar et al., 2004). A number of studies have reported that HDAC inhibition by several 
HDAC inhibitors, such as Vorinostat, MS-275 (a benzamide HDAC inhibitor), or NCH-51 
(non-hydroxamic acid HDAC inhibitor) lead to accumulation of ROS (Ruefli et al., 2001; 
Rosato et al., 2003; Sanda et al., 2007; Ungerstedt et al., 2005; Xu et al., 2006). The resulting 
oxidative stress seems to be involved in HDAC-induced apoptotic effects, since co-treatment 
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with ROS scavengers, such as N-acetylcysteine decreased HDAC inhibitor-induced cell death 
(Ruefli et al., 2001; Rosato et al., 2003; Sanda et al., 2007). The HDAC inhibitor, LAQ-824, 
also triggered ROS production, with increased γH2AX (phosphorylation of histone H2AX) 
and Ku70 acetylation (Rosato et al., 2008). 
     Consequently, HDAC inhibitors may enhance oxidative DNA damage by changing the 
chromatin conformation or inducing histone hyperacetylation of DNA repair proteins (Eot-
Houllier et al., 2009), causing ROS accumulation, disrupting intracellular redox balance and 
impacting mechanisms involved in the repair of oxidative DNA lesions (Driscoll et al., 2007). 
HDAC inhibition may also disrupt the regulation of ROS concentration or mitotic 
progression. Thus, HDAC inhibitors can likely induce extensive oxidative DNA damage 
(Eot-Houllier et al., 2009).  
     HDACIs also alter cellular functions through having effects on non-histone proteins (Tang 
et al., 2013). These non-histone proteins were involved in the regulation of gene expression, 
pathways of apoptosis, cell-cycle progression, mitotic division, redox pathways, DNA repair, 
cell migration and angiogenesis (Seuter et al., 2012; Shan et al., 2012). Therefore, HDACIs 
might have an effect on immune responses, inflammation, cell survival, cellular 
differentiation and proliferation (Tang et al., 2013).  
2.3.5 Impact of VPA exposure on gene expression 
     Many molecular approaches have been used to evaluate the expression of genes vital for 
normal and abnormal neural tube closure in intact, mutant, and chemically induced NTD 
mouse models (Finnell et al., 2002). A significant increase in the expression of transforming 
growth factors α and  which regulate the maintenance of neural viability has been reported 
in the neural tube of mouse embryos exposed to VPA. Okada et al. (2004) employed a 
GeneChip system to catalog the expression of genes in mouse embryos that exhibited VPA-
induced failure of neural tube closure. They report an increase in expression of Gadd45b, 
Ier5, Per1, Phf13, Pou3f1, and Sox4, and decrease in Ccne2, Ccnl, Gas5, Egr2, Sirt1 and 
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Zfp105 expression in the heads of mouse embryos after 1 h of i.p. injection of VPA (600 
mg/kg at E8.0). These changes of gene expression are strongly correlated with VPA’s 
teratogenic potency. Egr2 and Zfp105 are zinc finger protein genes, which are DNA-binding 
transcription factors (Gommans et al., 2005). Sir1 is an HDAC enzyme protein that exhibits 
NAD-dependent activity, regulating transcription, apoptosis and stress resistance (North and 
Verdin, 2004). Sir1 binds directly to p53 and suppresses p53-dependent apoptosis in response 
to DNA damage (Gasser and Cockell, 2001; Guarente, 2000; Imai et al., 2000). An analysis 
of these genes demonstrates VPA disrupts gene expression that is essential for the regulation 
of the cell cycle and the apoptosis pathways of the neural tube cells during neurulation in 
mice.  Mechanism of VPA-induced teratogenicity has also involved investigations on 
changes in gene expression (Chen et al., 2007; Menegola et al., 2006; Stodgell et al., 2006; 
Wiltse, 2005). For example, VPA induces down-regulation of protein kinase C isoforms 
(Menegola et al., 2006), and up-regulation of Bcl-2 (Chen et al., 2007), Hoxa1 (Stodgell et al., 
2006) and activated Wnt-dependent gene expression (Wiltse, 2005). In our study, we found 
VPA induces a dose-dependent down-regulation of Hoxa2 gene in whole mouse embryo 
culture system (see Section 6.1).  
     In a recent study, researchers used CodeLink whole-genome expression microarrays in 
undifferentiated R1 mouse embryonic stem cells exposed to VPA to define VPA-responsive 
genes that correlate with teratogenicity (Jergil et al., 2011). Many of the genes that were 
found to be deregulated by VPA and correlating with teratogenicity, appear to related to 
embryonic development and morphogenesis including neural tube formation and closure. 
This indicates genes that are important in embryonic development are putative teratogen 
targets of VPA in this in vitro system (Jergil et al., 2011).  Genes important for cell division 
and cell differentiation were downregulated and upregulated by VPA, respectively, in 
agreement with cellular effects of VPA for inhibiting proliferation and promoting 
differentiation (Jergil et al., 2011). A large number of genes that are crucial for neural tube 
morphogenesis (Harris and Juriloff, 2007; Harris and Juriloff, 2010) were significantly 
deregulated by VPA. Taken together, Jergil et al., (2011) concluded that an accumulation of 
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minor anomalies in the expression of several developmentally important genes leads to 
disturbances in embryonic development following VPA exposure. VPA also induced an 
increase in the acetylation of histones H3 and H4 in R1 cells and imply that HDAC inhibition 
may be a key factor responsible for changes in a majority of gene expression patterns induced 
by VPA (Jergil et al., 2011). It has been demonstrated that VPA triggers proteasome-
mediated degradation of HDAC2 (Kramer et al., 2003). A significant decrease of HDAC2 
protein levels is found in vivo in the mice treated with VPA. The results have suggested 
VPA-induced overexpression of Ubiquitin conjugating enzyme 8 (Ubc8) is most likely a 
determining factor for the degradation of HDAC2 (Kramer et al., 2003). This VPA-induced 
HDAC2 turnover specifically depends on the E2 ubiquitin conjugase Ubc8 and the E3 
ubiquitin ligase RLIM (ring finger protein, LIM domain interacting). This study has provided 
evidence that the response of HDAC2 protein levels to VPA is indirect rather than being a 
direct response (Kramer et al., 2003).  
2.4. Telomere and telomerase activity 
2.4.1.  Telomere 
2.4.1.1 Structure and Function 
     Eukaryotic nuclear genome is packed condensely into linear chromosomes. The natural 
ends of linear chromosomes resemble DNA breaks; however, their ends differ from DNA 
breaks and avoid DNA repair processes that would result in chromosome end-to-end fusions, 
illegitimate recombination, and genomic instability (Cesare and Reddel, 2010; Savage and 
Bertuch, 2010). A specialized ribonucleoprotein structure termed telomere is assembled at the 
ends of chromosome to avoid inappropriate DNA repairs (O'Sullivan and Karlseder, 2010).  
     In most eukaryotes, telomeric DNA has short tandem repeats that can be synthesized de 
novo by a reverse transcriptase enzyme, telomerase (Rhodes and Giraldo, 1995).  The 3 end 
of telomere is G-rich sequence and referred to as the G-strand, whereas the 5-end containing 
complementary strand is referred to as the C-strand. In all vertebrates the telomeric repeat 
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sequence is 5-TTAGGG-3. The length of the duplex telomeric tract ranges from < 30 bp in 
some ciliates, to 200-300 bp in budding yeast, to 5-15 kb in humans, and up to ~50 kb in 
mice (Chai et al., 2006; Klobutcher et al., 1981).  
     For linear chromosomes, the second fundamentally important problem is their ends cannot 
be fully replicated by the DNA-replication machinery. Due to this ‘end-replication problem’, 
telomeres shorten in each round of DNA replication (Olovnikov, 1973; Watson, 1972). 
However, in stem cells, germ cells and lineage progenitor cells, this telomere shortening can 
be compensated by the telomerase enzyme complex, which use the 3OH of the G-overhang 
as its substrate to add newly synthesized repeats (Griffith et al., 1999).  
     Moreover, telomere can fold back on itself, and the single-stranded terminus can enter into 
duplex telomeric DNA, forming a telomere loop called T-loop (Blasco, 2007). The 
configuration of the telomeric T-loop provides a protective cap that not only defines the 
natural end of the chromosome, but also masks the telomere from DNA damage response 
(DDR) machinery. Therefore, the generation and manipulation of the telomeric G-overhang 
by telomerase in telomerase-positive cells is an important convergence both for chromosome 
end protection and telomere length maintenance (O'Sullivan and Karlseder, 2010).  
2.4.1.2. Shelterin organizes and defines telomeres 
     In mammals, telomere structure and function is maintained and associated with a protein 
complex called shelterin. This complex consists of six individual proteins: telomeric repeat-
binding factor 1 (TRF1), TRF2, repressor and activator protein 1 (RAP1), TRF1-interacting 
nuclear protein 2 (TIN2), protection of telomeres 1 (POT1) and TIN2-interacting protein 
(TPP1) (Palm and de Lange, 2008). TRF1 and TRF2 bind to the double–stranded telomeric 
repeats, whereas POT1 attaches to the single-stranded G-overhang. These DNA binding 
modules are then bridged by TPP1 and TIN2 (Bianchi et al., 1997; Griffith et al., 1998). 
Recent studies have shown that although consisting of only six proteins, the shelterin plays an 
immensely complex role in protecting chromosome ends from enzymatic attack, regulation of 
telomere length, recruitment of telomerase complex, and control of signalling cascades from 
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the natural chromosome ends (O'Sullivan and Karlseder, 2010). Moreover, telomerase 
activity is regulated by telomere-binding proteins to achieve telomere length homeostasis 
(Lingner and Hug, 2006). Recently, there are a growing number of proteins found to localize 
to telomeres that are involved in the assembly and regulation of telomerase in cells (Park et 
al., 2009; Venteicher et al., 2009; Venteicher et al., 2008).  
2.4.1.3. Telomere-lengthening mechanisms 
     In somatic cells, telomeres natural lack of length-maintenance machinery is due to (1) the 
inability of conventional polymerases to completely replicate the telomeric parent DNA by 
lagging-strand synthesis (termed the end replication problem) (Watson, 1972), and (2) the 
requirement to enzymatically generate G-overhangs on both leading and lagging replication 
product strands. As a result, chromosomes lose 100-200 bp of telomeric sequence in every 
cell division during the process of replication and the post-replicative restoration of the 
protective cap at chromosome ends (Makarov et al., 1997; McElligott and Wellinger, 1997; 
Wright et al., 1997). Because of this so called replication-associated telomere shortening, a 
somatic cell only undergoes a defined number of doublings before telomeres become 
critically short (Bodnar et al., 1998; Meyerson et al., 1997), which is visualized as a 
mechanism to limit the proliferative ability of the dividing cells (Bianchi and Shore, 2008).  
     Therefore, a critical length of telomere repeats is required to ensure proper telomere 
function and avoid the activation of DNA damage pathways that result in replicative 
senescence of cell death (Smogorzewska and de Lange, 2004). Cancer cells and some human 
cells, such as stem cells, germ cells and activated lymphocytes, are able to maintain and/or 
extend their telomere lengths by two independent mechanisms: synthesis of telomere DNA 
by the holo-enzyme telomerase (Counter et al., 1992), or homologous recombination of 
telomeres by an alternative telomere-lengthening mechanism (ALT) (Bryan et al., 1997; 
Bryan et al., 1995).  However, the heterogeneity of telomere length in chromosomes of 
normal cells is complicated for identifying the role of factors that regulate telomere length. 
The length of telomere repeats reflects the balance between additions and losses of telomere 
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repeats. In most somatic cells, additions of telomere repeats by telomerase are outbalanced by 
losses from the proteins that bind to telomeres, telomerase levels, and telomeric chromatin 
status (Aubert and Lansdorp, 2008).  
2.4.2. The telomerase complex 
     The most common way to conquer the end replication problem of chromosome occurs 
through the ribonucleoprotein (RNP) enzyme called telomerase. The enzyme was discovered 
in the holotrichous ciliate Tetrahymena thermophila by Carol Greider and Elizabeth 
Blackburn in 1985 (Greider and Blackburn, 1985), and the components of the telomerase 
complex vary depending on the organism (Collins, 2006). In most species, the enzyme 
complex contains an RNA moiety (Greider and Blackburn, 1987) with a complementary 
sequence to the telomeric repeats (Greider and Blackburn, 1989), serving as a template for 
repeat addition (Feng et al., 1995; Nakamura et al., 1997). The complex also contains the 
protein dyskerin that is required for proper folding and stability of telomerase RNA and 
ribonucleoprotein maturation (Mitchell et al., 1999). The telomerase reverse transcriptase 
subunit (TERT) composed of enzyme complex catalyzes reverse transcription of the RNA 
template into telomeric repeats (Lingner et al., 1997b). The telomere elongation steps include 
the enzyme complex binds to the telomere end, associates with ssDNA at 3 telomere 
terminus containing the TTAGGG repeat, and finally adds successive telomeric repeats to the 
ends (Autexier and Lue, 2006; Ouellette et al., 2000; Westin et al., 2007).  
     The elongation analysis of single telomere molecules suggests that not all telomeres are 
elongated by telomerase in every cell cycle (Teixeira et al., 2004). The expression of 
telomerase is limited in human and mice fibroblasts, suggesting telomerase notably exhibits a 
significant preference for telomeres as their lengths go shorter (Liu et al., 2002; Ouellette et 
al., 2000; Teixeira et al., 2004). However, the mechanisms that govern the correct timing of 
the recruitment of telomerase enzyme to the telomeres have remained unknown (Stern and 
Bryan, 2008). More recently, regulation of telomerase activity has been found not only 
controlled at the TERT transcriptional level, but also determined at the post-transcriptional 
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level (Liu et al., 1999). Phosphorylation of telomerase and followed nuclear translocation 
play an important role in the post-transcriptional regulation of telomerase (Liu et al., 2001; 
Zhu et al., 2011).  
     New roles of telomerase have also been recently suggested. For example, loss of TERT 
does not alter short-term telomere integrity but, instead, affects the overall configuration of 
chromatin and impairs the DNA damage response (Masutomi et al., 2005). Moreover, 
telomerase serves as a cofactor in a β-catenin transcriptional complex and directly modulates 
Wnt/β-catenin signalling pathway (Park et al., 2009). Wnt/β-catenin signalling plays a crucial 
role during embryogenesis and the normal adult tissue genesis involved in cardiac 
differentiation and development (Gessert and Kuhl, 2010), angiogenesis, cardiac hypertrophy, 
and cardiac failure and aging (Rao and Kuhl, 2010).  
2.4.3 Telomere and telomerase dysfunction 
2.4.3.1 Telomere shortening 
     Telomere structures are essential for chromosome end protection (Martinez and Blasco, 
2011). As a consequence of loss of telomere protection, chromosome ends could activate 
DNA damage response pathway, causing cell cycle arrest, senescence, or even apoptosis 
(Karlseder et al., 1999; Smogorzewska et al., 2002; van Steensel et al., 1998).   
     Shortening telomeres within each replication cycle could subsequently activate DNA 
damage signals (d'Adda di Fagagna et al., 2003; Takai et al., 2003; Verdun and Karlseder, 
2006). As telomere length decreases with age, the effect of DNA damage originating from 
shorterning telomeres is expected to increase.   
     Defects in shelterin or telomerase components directly and adversely affect telomere 
structure and telomere length (Martinez and Blasco, 2011). Telomerase deficiencies were 
first implicated in the inherited genetic disorder dyskeratosis congenital (DC, a rare and 
progressive bone marrow failure syndrome) with the discovery of mutations in the dyskerin 
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gene (DKC1) associated with the X-linked inheritance form of the disease (Heiss et al., 1998; 
Mitchell et al., 1999).  
     Telomerase activity in all eukaryotes is directly linked to cellular proliferation and  
maintenance of telomeric DNA relies on telomerase activity. Loss of telomerase activity 
results in an even shorter telomere that finally leads to cell cycle arrest or cell death 
(Lundblad and Szostak, 1989; Nakamura et al., 1997). In humans, telomerase activity varies 
in different cell types during development. In germ line cells, telomerase activity is stable to 
allow telomere length to be maintained throughout the life. However, in most other cells or 
fully differentiated cells, telomerase is down-regulated, having little or no detectable 
telomerase as a result of decreased TERT expression, and the limited telomerase is not 
sufficient to entirely compensate cell-cycle associated telomere shortening (Aubert and 
Lansdorp, 2008; Flores et al., 2006; Geserick and Blasco, 2006).  
2.4.3.2 Telomere dysfunction and genomic instability 
    Genomic instability is a prominent characteristic of tumorigenesis by accelerating the 
accumulation of genetic changes that are responsible for cancer cell progression (Hanahan 
and Weinberg, 2000; Lengauer et al., 1998). The acquisition of malignant traits through the 
alteration of key genes as a result of genomic instability thus fuels cancer evolution (Artandi 
and DePinho, 2010; Halazonetis et al., 2008; Tsantoulis et al., 2008). Critical telomere 
shortening that is associated with excessive proliferation of preneoplastic cells might be an 
important source of genomic instability (Engelhardt et al., 1997a; Engelhardt et al., 1997b; 
Meeker et al., 2004a; Meeker et al., 2004b; Odagiri et al., 1994; van Heek et al., 2002). 
Studies in cells and mice that are deficient for telomerase or some of the shelterin proteins 
support a model in which the telomere dysfunction either due to the loss of telomeric repeats 
or to the loss of the telomere protective structure, induces genome instability and thereby 
affect tumorigenesis (Artandi et al., 2000; Blanco et al., 2007; Blasco et al., 1997; Chin et al., 
1999; Else et al., 2009; Martinez et al., 2009; Munoz et al., 2005; Tejera et al., 2010) .  
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     Decreasing telomere function in the aged life may even promote genome instability and 
therefore contribute to the higher incidence of cancer (Maser and DePinho, 2002; Wright and 
Shay, 2000). In humans, telomere length has been tied to several types of cancers. Compared 
to control, the shorter telomeres of leukocytes have been implicated as a risk factor or 
biomarker for solid tumors (Lundblad, 2003; Reichenbach et al., 2003). Studies in colorectal 
cancer suggested the shortening telomere length contributes to tumorigenesis and genetic 
instability of cancer cells (Hughes et al., 2000). Patients with ulcerative colitis or developed 
cancer were associated with telomere shortening (Lingner et al., 1997a).  
2.4.3.3 Aging 
     Telomere and telomerase have received considerable attentions because any changes in 
their structure and function can lead to the development of cancers and aging (Zhu et al., 
2011). Aging can be defined as the progressive functional decline of tissues and organs or 
cell senescence that eventually results in mortality (Aubert and Lansdorp, 2008). The role of 
telomere biology in the development of aging-related diseases is only partly understood (Zhu 
et al., 2011).  
     Studies of increasing generations of telomerase-null mice (Kim et al., 1999) indicated that 
telomere shortening along successive mouse generations (Espejel et al., 2002a; Espejel et al., 
2002b; Herrera et al., 1999) was accompanied by a progressive decrease in both median and 
maximum longevity (Donate and Blasco, 2011).  
     Additionally, telomerase-deficient mice developed premature aging pathologies with 
increasing mouse generations, in agreement with inheritance of shortening telomeres after 
each generation in humans (Donate and Blasco, 2011).   
2.4.3.4 Telomere shortening and oxidative stress 
     Recently, telomeres have emerged as sensitive indicators of inflammation and cumulative 
oxidative stress that accumulates in human body in vivo (Georgin-Lavialle et al. 2010). These 
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factors are associated with telomere shortening acceleration (von Zglinicki, 2002), suggesting 
a connection between the telomere/telomerase system and autoimmune and/or inflammatory 
disease.  
     Chronic life stress is linked to shorter telomeres and has been associated with reduced 
telomerase activity (Hsu et al., 2006).  
     For instance, compared to age-matched healthy individuals, the telomere length of 
peripheral blood mononuclear cells (PBMC) is shorter in patients with systemic lupus 
erythematosus (Fritsch et al., 2006; Honda et al., 2001; Kurosaka et al., 2003; Kurosaka et al., 
2006; Wu et al., 2007), rheumatoid arthritis (Koetz et al., 2000; Salmon and Akbar, 2004; 
Schonland et al., 2003; Steer et al., 2007), Wegener’s granulomatosis (Vogt et al., 2003), 
sarcoidosis (Guan et al., 2007), systemic sclerosis (Artlett et al., 1996), idiopathic pulmonary 
fibrosis (Armanios et al., 2007; Tsakiri et al., 2007) and type I diabetes (Fyhrquist et al.; 
Jeanclos et al., 1998).  It is suggested oxidative stress induces shortened telomeres and 
decreased telomerase activity in blood cells during aging (Aubert and Lansdorp, 2008; von 
Zglinicki et al., 2005). In vitro studies demonstrate that oxidative stress and inflammation 
reduce telomerase activity and shorten telomere length in cultured endothelial progenitor 
cells, human-derived fibroblasts and neoplastic cells (Dixit et al., 2009; Makpol et al. 2010; 
Scalera et al., 2009). Stress and senescence affect telomerase levels in lymphocytes (Saretzki, 
2009; Choi et al., 2008).  
      It has also been demonstrated that mitochondrial dysfunction via induction of telomere 
damage is an important component in the occurrence of senescence within dividing cellular 
process (Hsu et al., 2006; Passos et al., 2007; Saretzki, 2009; Xia et al., 2008).      
Telomerase activity is associated with cellular homeostasis as it maintains the length of the 
telomeres (Indran et al., 2009). Telomerase activity is reported to be modulated by a shift in 
glutathione redox potential, and changes in telomerase activity are coordinated with changes 
in cell cycle proteins (Borras et al., 2004). The relationship between telomerase activity, cell 
cycle regulatory proteins and GSH contents revealed a mechanism that connects telomerase-
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mediated cell survival, cell proliferation control and oxidative stress (Borras et al., 2004). 
Minamino et al. (2001) also reported that hypoxia up-regulates telomerase activity in vascular 
smooth muscle cells. Furthermore, antioxidants are known to inhibit nuclear export of 
telomerase reverse transcriptase and can delay replicative senescence of endothelial cells 
(Haendeler et al., 2004).  
2.5. Whole mouse embryo cultures 
2.5.1.  Culturing embryos at gastrulation and early organogenesis 
     The ability to grow in vitro cultures of whole post-implantation mouse embryos provides 
an unique opportunity to study development through direct experimental manipulation (Tam, 
1998). The developmental stages during which whole embryo culture can be applied range 
from egg cylinder to about 60 pairs of somites. However, the highest efficiency and reliability 
of this technique is obtained from early somite (E7.5-8.0 in the mouse) to organogenetic stage 
(E10.5-11.5; 30-40 pairs of somites), allowing normal embryonic development to continue 
for up to 2 days in culture. During this period of time, major processes of differentiation and 
organ development take place, including neurulaton, somitogenesis, and development of the 
cardiovascular, digestive, and locomotor systems (Calegari et al., 2004; Tam, 1998) (Table 
3.1). 
2.5.2  Applications of whole mouse embryo culture 
2.5.2.1 Teratological studies in whole mouse embryo cultures 
     Whole embryo culture has mostly been applied to teratological and toxicological studies 
(Calegari et al., 2004). Such studies constitute the majority of experiments seeking to 
elucidate the effects of metabolic compounds and teratogenic agents on mouse development 
(Bavik et al., 1996; New, 1978). Since the early 1970s, the whole embryo culture system has 
become particularly popular in the study of teratogenic mechanisms, without having 
interference from maternal absorption, distribution, metabolism and excretion (Cockroft, 
1980; Cockroft, 1987; New, 1978).  
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     However, recently several sophisticated techniques have been successfully applied to 
whole embryo culture, such as cell or tissue transplantation, antibody interference, cell 
lineage tracing, infection with viral vectors, and electroporation of nucleic acids (Drake and 
Little, 1991; Inoue et al., 2000; Lee et al., 2012; Oback et al., 2000; Osumi and Inoue, 2001; 
Pryor et al., 2012; Tam, 1998). These techniques combined with whole embryo culture has 
offered novel opportunities to study mammalian development at the morphological, cellular, 
and molecular levels (Calegari et al., 2004; Gray and Ross, 2011; Huang et al., 2012).  
2.5.3.  Gene targeting with antisense oligodeoxynucleotides and siRNA 
     A mechanism of disrupting gene expression has been devised by injecting antisense 
oligodeoxynucleotides (ODNs) into the amniotic cavity of day 9 (plug day = day 1), 4-6 
somite mouse embryos (Augustine et al., 1993). The ODNs are 20-25 bases long and are 
directed to specific sequences of targeted mRNA (Fakler et al., 1994). The probes are 
phosphorothioated to resist degradation by nucleases, begin to enter cells 30-45 min after 
injection by endocytosis (Loke et al., 1989; Yakubov et al., 1989), and are distributed 
throughout the embryo (Augustine et al., 1993). By 3 h they reach a peak concentration and 
remain high for at least an additional 9 h (Augustine et al., 1993).  
     The recent findings that small interfering RNA (siRNAs) can be used to knock down gene 
expression (Betancur et al., 2012; Elbashir et al., 2001) led to the application of siRNAs in 
whole mouse embryo cultures (Calegari et al., 2002; Calegari et al., 2004; Gratsch et al., 
2003; Calegari et al., 2004). The technology of topical injection and directional 
electroporation of siRNAs induces silencing of gene expression during the mouse post-
implantation embryonic development. This offers several advantages as compared to classical 
techniques of gene knock-down (Calegari et al., 2004). First, the technique constitutes a 
practical approach to obtain silencing of gene expression in post-implantation mouse 
embryos without the labor-intensive generation of genetically modified transgenic animals. In 
addition, the temporal limitation of whole embryo culture can be overcome by in utero 
electroporation (Takahashi et al., 2002).  
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2.5.4.  Application of in vivo electroporation in functional studies of genes important in 
neural tube development 
     Electroporation is a standard method used to deliver molecules into cells (Calegari et al., 
2004). In vivo electroporation as a means of gene transfer for functional studies has been 
applied to the developing neural tube both in mouse and chick embryos in culture. This is 
because the onset of neurogenesis in neural development coincides with the time period 
during which whole embryo culture is carried out with a high rate of success. Moreover, 
electroporation is particularly easy and effective when nucleic acids ONDs, siRNA, or gene 
DNA are injected into the lumen of the neural tube (Inoue and Krumlauf, 2001). Hence the 
whole embryo culture technology allows researchers to study the effects of the introduced 
nuclei acids ODN, siRNA or gene DNA, such as the functional consequences of a given 
transgene expression or loss of gene expression, on embryonic neural tube development 
(Calegari et al., 2004).  
2.5.5.  Micro-manipulation in vitro 
     The direct micro-manipulation of the embryo includes: the micro-surgical ablation of 
groups of cells or parts of the conceptus; labelling of single embryonic cells, groups of cells 
or the entire germ layer; transplantation of cells or embryonic fragments; and the retroviral 
transfection of embryonic cells (Beddington and Lawson, 1990).  
2.5.5.1 Elucidation of mouse gastrulation through micro-manipulation 
     An important contribution of the micro-manipulation experiments of post-implantation 
embryos is the construction of fate maps of cells in the germ layers of the mouse gastrulae. 
Cells in specific regions of the germ layer can be labelled in situ with enzymes or fluorescent 
dyes (Lawson et al., 1986; Lawson et al., 1991). The fate of the cells is then assessed by 
studying certain types of embryonic tissues colonized by the descendants of cells that have 
been marked (Tam, 1998).  
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2.5.5.2 Cell fate mapping and establishment of body plan 
     Fate-mapping studies performed on mouse embryos in vitro have led to the construction of 
fate maps of the epiblast and the primitive endoderm of the early-primitive-streak-stage 
embryo (El Ouakfaoui et al., 2012; Hang et al., 2012; Lawson et al., 1986; Lawson et al., 
1991; Lawson and Pedersen, 1987; Parameswaran and Tam, 1995; Quinlan et al., 1995), the 
mesoderm of the early-, mid- and late-primitive-streak-stage embryos (Quinlan et al., 1995), 
and the ectoderm of the late-primitive-streak-stage embryos (Beddington, 1982; Beddington, 
1981; Hang et al., 2012; Tam, 1989). These fate maps can provide a description of the 
geographical distribution of the precursor cells of specific lineages in the germ layers at 
successive stages of gastrulation (Tam and Behringer, 1997). The study of the cell fate maps 
can be further analyzed for the functional role of the primitive streak and the organizer in the 
establishment of the body plan (Gray and Ross, 2011; Lawson et al., 1991; Pryor et al., 2012). 
Table 2.1 Fundamental development events occurring during the early organogenesis stages in mouse 
embryos (E8.5-10.5) 
Embryonic Stages Developmental Events 
E 8.0 
 Start of regionalization of the heart
 Closed neural tube from a point opposite the
outflow tract to the proximal port of the tail
E 9.0 
 Closed rostral extremity of neural tube
 1st branchial arch of mandibular process is visible
E 9.5 
 Formation of posterior neuropore
 Subdivision of forebrain vesicle into telecephalic
and diencephalic vesicles
 Formation of forelimb bud and appearance of a
distinct condensation of hind limb bud
 Lung development begins
 Closure of posterior neuropore
 Hind limb bud is visible, and tail bud appears as a
short stump
 3rd and 4th branchial arches are distinctly
concave.
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E 10  Formation of Rathke’s pouch and nasal processes
E 10.5 
 Conspicuous division of 1st branchial arch into
maxillary and mandibular components
 Advanced development of the brain tube
 Elongation of the tail
 Appearance of pancreatic bud
 (Summary from http://embryology.med.unsw.edu.au/OtherEmb/mouse1.htm) 
2.6. Epigenetic regulation 
2.6.1  Role of chromatin during transcription 
2.6.1.1 Nuclear architecture 
      The nuclear structure of eukaryotic cells is well-organized and the architectural integrity 
and organization of the nucleus is related to how the genome is organized, and how this 
dynamic arrangement is reflected in genome function (Francastel et al., 2000; Lamond and 
Earnshaw, 1998; Parada and Misteli, 2002). Genomes are distinct non-randomly organized 
structures within cell nuclei  (Parada and Misteli, 2002) and nuclear positioning of the 
genome is closely associated with its function (Kumaran and Spector, 2008). In eukaryotes, 
chromosomes are organized in distinct territories of the nucleus and have an essential role in 
cell division to ensure genetic diversity and survival of cell progeny (Cremer et al., 1982). 
Gene-rich chromosomes tend to reside in the centre of the nucleus, whereas gene-poor 
chromosomes tend to localize towards the nuclear periphery (Gilbert et al., 2005; Sproul et al., 
2005). Such spatial organization of chromosomes and genes in the nucleus correlates with 
genomic activities that have been documented in numerous cell differentiation systems and in 
embryonic development (Marshall, 2003; Taddei et al., 2004).   
2.6.1.2 Chromatin structure and organization  
a) Dynamics of chromatin structure
     The eukaryotic genome is assembled into chromatin structures that can undergo various 
forms of dynamic changes. The lowest order of chromatin structure is like ‘beads on a string’, 
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consisting of the basic repeat element nucleosomal unit that is wrapped around by DNA. This 
structure can be further assembled into higher-order structures through the interactions of 
protein effectors, RNA and surrounding cations (Meshorer and Misteli, 2006). The spatial 
organization of chromatin into a higher-order structure has recently emerged as a key 
contributor to genomic regulation (Loden and van Steensel, 2005). The physiological 
chromatin structure plays a vital role in DNA function in which chromatin regulates DNA 
accessibility through its structural variation, ranging between ‘condensed’ heterochromatin 
and more ‘open’ euchromatin (Cremer et al., 1982; Parada et al., 2004).  
b) Maintenance of chromatin organization
     Chromatin structure within the nucleus is determined and largely maintained by the 
binding of chromatin structural proteins as well as other regulatory proteins. Chromatin 
structural proteins include six classes of histones (H1, H2A, H2B, H3, H4, and H5) that are 
organized into two super groups: core histones (H2A, H2B, H3 and H4) and linker histones 
(H1 and H5). Two copies of each of the core histones assemble together to form an octamer 
as a nucleosome core particle, which is wrapped around by 146 base pairs of DNA (Luger et 
al., 1997; Phair et al., 2004; Shigetomi et al., 2011). Linker histone H1 locks DNA into place 
by binding the nucleosome with the entry and exit sites of DNA, resulting in the formation of 
the proteinaceous structural backbone of the chromatin (Luger et al., 1997). At the same time, 
many other DNA-binding proteins interact with chromatin in vivo. For most transcription 
factors, chromatin remodelers, and structural proteins such as heterochromatin protein (HP1) 
and the high mobility group (HMG) proteins, their residence time on chromatin can range 
from a few minutes to just a few seconds (Kimura and Cook, 2001; Phair et al., 2004). 
Although the functional relationship between protein effectors and chromatin has not been 
completely elucidated, recent observations in embryonic stem (ES) cells have indicated that 
the dynamic interplay of structural proteins on the chromatin is crucial for genome function 
(Meshorer et al., 2006). Furthermore, the highly compacted DNA within chromatin in each 
mammalian cell reveals hierarchical levels of complexity in genome regulation.  
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     Epigenetic regulation is part of a highly complex and interwoven genetic network, 
including multiple feed-forward and feedback pathways (Cedar and Bergman, 2009; Graff et 
al., 2011; Latham and Dent, 2007; Lee et al., 2006a) that occur at the DNA and the histone 
level as well as higher order chromatin structure. On many occasions, several epigenetic 
modifications can be jointly altered or facilitated, however the precise mechanisms behind 
these observations remain not completely understood (Graff et al., 2011). 
2.6.2. Epigenetic modifications in mammalian genomes 
     Epigenetics is an inheritable event where a change in phenotype or gene expression can 
occur without a change in DNA sequence (Szyf, 2009). At least three mechanisms associated 
with chromatin include: DNA methylation, histone modifications, and ATP-dependent 
nucleosome remodeling (Bernstein et al., 2007; Cairns, 2007; Graff et al., 2011).  
     Nucleosome remodeling refers to a process by which change in the structure of chromatin 
is produced. The process is carried out by nucleosome remodeling complexes that are 
catalytically dependent on ATP. In eukaryotes, ATP-dependent complexes contain 
SWI2/SNF2-like ATPases and regulate the position of nucleosomes on DNA (Eisen et al., 
1995). They facilitate the sliding of histone octamers to adjacent DNA sequences and thereby 
enrich transcription factors to accessible DNA on the surface of nucleosomes (Becker and 
Horz, 2002).  
2.6.2.1. DNA methylation 
     In vertebrates a major component of epigenetic regulation is the pattern of DNA 
methylation of the genome. DNA methylation is a covalent modification where methylation 
occurs primarily at the cytosine residue in the di-nucleotide CG sequence (Kar et al., 2012; 
Razin and Riggs, 1980; Straussman et al., 2009) (Fig. 2.2). In vertebrates, different CG sites 
are methylated in different tissues, creating a pattern of DNA methylation which is gene and 
tissue specific (Razin and Riggs, 1980; Straussman et al., 2009). Hence, the pattern and 
distribution of DNA methylation in different cells and tissues have produced a layer of 
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information that gives a specific cell type identity to its genome. More importantly, 
patterning of DNA methylation in vertebrates is tightly correlated with histone post-
translational modifications that regulate chromatin structure and modulate DNA 
transcriptional states. In general, the active regions on chromatin with loose chromatin 
structure are associated with hypomethylated DNA, enabling gene expression, whereas 
inactive and condensed chromatin regions are associated with hypermethylated DNA and 
repress gene expression (Razin and Cedar, 1977; Straussman et al., 2009).  
     The unmethylated CpG dinucleotides regions are generally characterised by 
transcriptionally permissive chromatin and punctuate the genome at transcription start sites at 
approximately 70% of gene promoters (Illingworth and Bird, 2009; Straussman et al., 2009). 
However, the mechanisms that establish and maintain unmethylated CpG islands (CGIs) 
remain largely unknown, although DNA methyltransferases (DNMTs), histone modifications, 
transcription factors and chromatin-modifying complexes are known to be involved 
(Blackledge and Klose, 2011; Brenner and Fuks, 2007; Fuks, 2005; Illingworth and Bird, 
2009; Ndlovu et al., 2011; Straussman et al., 2009). 
Fig. 2.2 DNA methylation occurs at the 5 position of the cytosine pyrimidine. 
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     The latest technological advances have revealed new insights into the dynamics of DNA 
methylation . First, the bisulfite ultra-deep sequencing methods have confirmed the presence 
of extensive 5
me
C in a non-CpG sequence context (Laurent et al., 2010; Lister et al., 2009;
Ramsahoye et al., 2000). These studies have shown methylation of CpHpG and CpHpH 
trinucleotides (H=A, T, C) was present in both human embryonic stem cells (hESCs) and 
differentiated cells. In addition, the methylation profile for 5
me
CpA was found to be
conserved in differentiated cells and hESCs at the same sites (Ndlovu et al., 2011).  
     A second confounding factor in DNA modifications of the genome is the identification of 
a novel DNA nucleotide, 5-hydroxymethylcytosine (5
hm
C), which is generated from 5
me
C
within a CpG context in the regulation of gene expression (Feng et al., 2010; Laurent et al., 
2010; Lister et al., 2009). Moreover, the studies have revealed a diverse genomic distribution 
of eukaryotic DNA methylation in which intragenic DNA methylation plays a major role in 
mammalian gene regulation (Maunakea et al., 2010; Medvedeva et al., 2010). 
   DNA methylation is catalyzed by a family of enzymes called DNA methyltransferases 
(DNMTs) (Razin and Cedar, 1977; Szyf, 2009). Methylation of DNA occurs immediately 
after DNA replication. The reaction is catalyzed by DNMT and completed by transfer of a 
methyl group from the methyl donor S-adenosyl-L-methionine (SAM) to 5carbon position of 
cytosine (Razin and Cedar, 1977; Szyf, 2009). Three distinct DNA methyltransferases have 
been identified in mammals. DNMT1 is the most abundant DNA methyltransferase and has 
been found to be the key methyltransferase in mammalian cells. DNMT1 functions as both a 
de novo methylation and a maintenance methyltransferase, showing preference of 
methylation on hemimethylated CpG di-nucleotides in vitro. It has been suggested that 
DNMT1 shares a conserved function with the methylation binding co-factor ubiquitin-like 
containing PHD and ring finger domains in maintaining gene-body methylation in various 
organisms (Feng et al., 2010). DNMT2 is the first RNA cytosine methyltransferase identified 
in humans (Goll et al., 2006). Since 2006, DNMT2 has been renamed to TRDMT1 (tRNA 
aspartic acid methyltransferase 1) (Goll et al., 2006). DNA methyltransferase 3 (DNMT3) 
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includes DNA methyltransferase 3 alpha (DNMT3a), DNA methyltransferase 3 beta 
(DNMT3b) and DNMT3L (DNMT3-like). All three (DNMT3a, DNMT3b and DNMT3L) 
can methylate the unmethylated and hemimethylated DNA at the same rate (Okano et al., 
1998). DNMT3a and DNMT3b can interact with DNMT1, acting as co-operators during 
DNA methylation. DNMT3L is required for establishing maternal genomic imprints during 
early embryonic development. Although both DNMT1 and DNMT3 classes of enzymes are 
required for DNA methylation, a distinction between de novo and maintenance DNMTs is not 
always evident and studies have indicated that these two classes of enzymes may participate 
in both de novo and maintenance methylation (Szyf, 2009).   
2.6.2.2 Mechanisms of DNA methylation to silence gene expression 
     DNA methylation is an effective mechanism for epigenetic silencing of gene expression in 
mammals. It is a key factor that can induce formation of heterochromatin and inhibit binding 
of transcription factors to target DNA sequences (Comb and Goodman, 1990; Graff et al., 
2011; Inamdar et al., 1991). DNA methylation represses gene expression also by attracting 
methylated DNA-binding proteins (MBDs) to block the binding sites on DNA (Graff et al., 
2011; Nan et al., 1997). MBD family is composed of five members including Methyl CpG 
binding protein 2 (MeCP2), MBD1, MBD2, MBD3 and MBD4. Each protein contains a 
methyl-CpG binding domain that can recognize methylated CG dinucleotide (Hendrich and 
Bird, 1998). These MBD family members share a similar mechanism for suppression of gene 
expression (Fujita et al., 1999; Graff et al., 2011; Hendrich and Bird, 1998; Ng et al., 1999).  
In addition, MBD proteins can recruit other histone modifying proteins such as SIN3A 
(Switch Independent 3 homolog A) and chromatin remodeling complexes to methylated sites, 
resulting in the formation of more condensed chromatin structures to silence gene expression 
(Nan et al., 1997; Szyf, 2009; Ndlovu et al., 2011). For instance, MBD3 is associated with the 
nucleosome remodeling and deacetylase complex (such as NurD) that contains MBD2 as the 
methylated DNA-binding factor, indirectly binding to methylated DNA (Zhang et al., 1999).  
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     However, as highly methylated stretches of DNA have also been found both in the 
promoter and coding regions of actively transcribed genes, the functional impact of DNA 
methylation on transcriptional activity (Ndlovu et al., 2011) is not that clear-cut (Suzuki and 
Bird, 2008; Weber et al., 2007). Indeed, many questions remain regarding the details of the 
extent and how 5meC residues specifically distribute on the promoters to affect their 
transcriptional activity (Graff et al., 2011).  
2.6.2.3 Histone modifications and gene transcription 
2.6.2.3.1 Post-translational modifications of histone 
     The eukaryotic genome is packed into chromatin, and the nucleosome serves as its 
fundamental organization unit, which is composed of an octamer of core histone proteins 
(two copies of H2A, H2B, H3 and H4) wrapped by ~146 bp of DNA (Ruthenburg et al., 
2007). The superhelical turn of DNA is hidden under the radial-like surface of histone 
octamer, and the histone unstructured N-terminal ‘tails’ is projected from the α-helical 
protein core of the nucleosome (Fig. 2.3). Investigations on histone modifications have found 
the majority of histone post-translational modifications (PTMs) occur on the unstructured 
tails, particularly at the N termini (Cosgrove, 2007). However, recent studies have suggested 
a growing number of modifications can also take place on residues within the secondary 
helical structure and loops of folded histones (Cosgrove, 2007). It appears that histone 
isoforms which are diversified from nucleosome core particle and commonly known as 
histone variants play essential roles in various stages of DNA management as well (Bernstein 
and Hake, 2006; Clarkson et al., 1999; Henikoff and Ahmad, 2005; Pidoux and Allshire, 
2005). 
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Fig. 2.3 Nuclear DNA resides in a nucleosomal structure where approximately 146 bp of 
DNA are wrapped around a histone octamer consisting of two molecules of H2A, H2B, H3 
and H4) (Adapted from the figure at http://www.fastbleep.com/biology-notes/40/116/1191).  
2.6.2.3.2 Functions of histone modifications 
a) Global chromatin environments
     The functions of histone modifications are to establish either globally modified chromatin 
environments or genomic DNA transcription-based processes (see section below for 
description) (Kouzarides, 2007). Globally modified chromatin environments are achieved by 
forming distinct chromatin domains through histone modifications, which occur on positively 
charged amino acids lysine and arginine within histone tails (Berger, 2002). Global chromatin 
environments specify distinct chromatin domains such as euchromatin, on which DNA is 
kept “accessible” for transcription; or heterochromatin where DNA is “inaccessible” and 
results in gene silencing (Berger, 2002).  
34 
     Euchromatin structure formed by histone modifications has been demonstrated to 
represent a high proportion in the genome. The pattern of modification to euchromatin 
reflects an open choice for DNA activity. Hence, DNA in euchromatin state has flexibility as 
to its biological consequences (Kouzarides, 2007). For instance, DNA can be “unraveled” for 
replication or repair, or held in a transcriptional active or repressive state, ready for gene 
expression to be turned “on” or turned “off”. It has been suggested that low levels of histone 
acetylation, methylation (depends on type of PTM) , and phosphorylation are associated and 
observed on genes in the transcriptionally inactive state, whereas high levels of histone 
acetylation and trimethylation at histone 3 lysine 4 (H3K4), histone 3 lysine 36 (H3K36), and 
histone 3 lysine 79 (H3K79) are typically found in actively transcribed euchromatin 
(Kouzarides, 2007). Heterochromatin structure, on the contrary, is a tightly packed DNA 
silent state, and believed to have functions in both gene regulation and the protection of 
chromosome integrity. DNA in heterochromatin state is densely packed, making it less 
accessible for protein regulators and other associated factors. Mainly, heterochromatin limits 
gene expression through the repression of transcription initiation (Fisher and Merkenschlager, 
2002). In mammals, heterochromatic state is associated with low levels of histone acetylation 
and high levels of histone methylation at specific sites such as H3K9, H3K27, and H4K20 
(Zhang and Reinberg, 2001).  However, histone bivalent domains, histone 3 lysing 27 
(H3K27) and H3K4 trimethylation, have recently been shown to coordinate activating and 
repressive effects on developmental genes (Bernstein et al., 2005). The enrichment of 
bivalent domains is associated with low-level of gene expression (Bernstein et al., 2005). In 
addition, CCCTC-binding factor (CTCF) is found at boundary elements, forming a chromatin 
barrier between silent heterochromatin and active euchromatin by preventing the spread of 
heterochromatin structures (Kim et al., 2007; Xie et al., 2007). Studies in fission yeast 
indicate heterochromatin boundaries are established by the presence of methylation at H3K4 
and histone 3 lysine 9 (H3K9) in adjacent euchromatic regions. Therefore, one critical 
function of chromatin modifications is to establish and maintain the different chromatin 
environments (Kouzarides, 2007).     
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b) Genomic DNA-based functions of histone modifications
     DNA-based functions of histone modifications refer to the unraveling of chromatin to 
expose DNA for either more genome wide or more local effect on such events as DNA 
replication, gene transcription or DNA repair (Kouzarides, 2007). It is known that these 
biological tasks require well-organized recruitments of protein regulators to unravel and 
manipulate DNA in a proper chromatin state (Kouzarides, 2007). Within euchromatin 
environments, the regulation of gene expression requires the binding of transcription factors 
to the promoter of the gene, followed by the delivery of chromatin-modifying enzymes to 
initiate a cascade of modification events (Kouzarides, 2007). The term “histone code” is used 
to describe the combination of histone modifications specifying the transcriptional output of 
genes. The information constituted from these marks can be read by transcriptional effectors 
to determine its association with DNA activity (Jenuwein and Allis, 2001; Liu et al., 2005; 
Verrier et al., 2011).   
    Post translational modifications (PTMs) function as a single platform to recruit effectors to 
local chromatin. It is the effectors as “readers” that ultimately determine the functional 
outcome of certain PTM (Grzenda et al., 2011). So far a number of protein domains have 
been identified to interact with specific PTMs, such as bromodomain for acetylated lysines, 
chromodomain for methylated lysines, and Plant Homeo Domain (PHD) for methylated 
lysines and arginines (Bottomley, 2004). The interactions between histone modifications and 
proteins could be classified as: 1) cooperative for two or more marks act together to facilitate 
protein stabilization or recruitment; 2) independent for several modifications existing together 
but do not interfere with each other’s associated proteins; or 3) antagonistic for the present 
modification will block interaction with an adjacent modified residue (Oliver and Denu, 2011; 
Seet et al., 2006).  
     There is still no comprehensive understanding of how transcription factors cope with 
chromatin (Margueron and Reinberg, 2011). However, interesting examples have highlighted 
their potential sensitivity and interaction with DNA in the context of nucleosomes (Schwartz 
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et al., 2006). Most transcription factors require exposure of their binding sites either within 
linkers or by nucleosome remodeling (Hawkins et al., 2010; Leeb et al.; Rosenfeld et al., 
2009; Tolhuis et al., 2006). A diverse set of transcription factors involved in liver 
differentiation has been found with markedly different extents of mitotic chromosome 
binding (Caravaca et al., 2013). FoxA1, one of the pioneer factors exhibits the greatest extent 
of mitotic chromosome binding. The study reveals ~15% of the FoxA1 interphase target sites 
are bound in mitosis, including at genes that are important for liver differentiation (Caravaca 
et al., 2013). Results from biophysical, genome mapping, and mutagenesis studies of FoxA1 
have shown two different modes of FoxA1 binding to mitotic chromatin: specific binding of 
FoxA1 in mitosis occurs at sites that continue to be bound at interphase; nonspecific binding 
of FoxA1 in mitosis occurs across the chromosome due to the intrinsic chromatin affinity of 
FoxA1. Both specific and nonspecific binding are implicated to contribute to reactivation of 
post-mitosis target genes in a time specific manner (Caravaca et al., 2013).  
       Histone modification patterns can be widely found on a gene within the upstream region 
of the promoter, the core promoter region, the 5 end of the open reading frame (ORF) and 
the 3 end of the ORF. Within these regions histone marks are notably distributed (Vakoc et 
al., 2005) and the location of a specific modification is tightly regulated and is crucial for its 
effect on gene transcription (Li et al., 2007).  
2.6.2.3.3. Several types of histone modifications 
a) Histone Acetylation
     This modification occurs by adding an acetyl group to specific lysine residues at N-
terminal tail of the histone protein (Allfrey et al., 1964; Pan et al., 2012; Roth et al., 2001). It 
is one of the major histone modifications and plays a positive role in gene transcription (Roth 
et al., 2001; Sterner and Berger, 2000). Histone acetylation has been associated with 
transcriptional activation. The addition of the acetyl group neutralizes the positive charge of 
the ε-amino group of the lysine, thereby weakening the interaction between the histone tail 
37 
 
and the negatively charged DNA (Brownell and Allis, 1996) and increasing nucleosome 
fluidity (Workman and Kingston, 1998).  
     Histone acetylation is catalyzed by enzymes called lysine acetyltransferases (KATs).  
KATs are divided into three main families, based on their sequence homologies and the 
similarities in their biological functions, GCN5-related N- acetyltransferases (GNAT), MYST 
(named for the founding members MOZ, Ybf2/Sas3, Sas2, and Tip60), and p160 coactivator 
(Sterner and Berger, 2000). The GNAT family is the best characterized nuclear KATs. It 
includes GCN5 (general control nonderepressible 5) and PCAF (P300/CBP-associated factor) 
as well as related proteins. Each member of GNAT protein family contains a C-terminal 
catalytic HAT domain and a 110-residue bromodomain that specifically interacts with lysine-
acetylated histone tails (Sterner and Berger, 2000; Roth et al., 2001). Members of MYST 
family possess a highly conserved 370 residue MYST domain (Ikura et al., 2000). Their 
functions demonstrate a variety of DNA-mediated reactions including promoter-driven 
transcriptional regulation, double-stranded DNA break repair and licensing of DNA 
replication (Iizuka et al., 2006; Ikura et al., 2000; Utley and Cote, 2003).  Finally, p160 
coactivators are involved in nuclear hormone receptor-dependent gene transcription (Sterner 
and Berger, 2000; Roth et al., 2001). Other groups such as p300/CBP (protein p300/CREB 
binding protein, each contain a histone acetyltransferase domain and a bromodomain) and 
TAFII250 (TATA-binding protein-associated factors) have also been shown to act as KATs 
to regulate transcription of many genes (Bannister and Kouzarides, 1996; Mizzen et al., 1996; 
Ogryzko et al., 1996).  
b) Histone Deacetylation  
     Histone acetylation is a highly dynamic event particularly since the presence of histone 
deacetylase (HDAC) can catalyze the removal of acetyl groups (Yang and Seto, 2003), 
leading to repression of transcriptional activity (Santini et al., 2007). HDACs are a group of 
enzymes conserved in mammals, plants, bacteria and fungi (Santini et al., 2007). There are 
four distinct families of HDACs in mammals, based on structural homologies with yeast 
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HDACs: class I HDACs (HDAC1, 2, 3 and 8) have homology with the yeast protein reduced 
potassium dependency 3 (Rpd3); class II HDACs (HDAC 4, 5, 6, 7, 9 and 10) have a high 
degree of homology to the yeast HDAC1 protein (Fischle et al., 2001); class III HDACs are 
homologous to the yeast silencing information regulator 2 (Sir2)/homologue of Sir2 (Hst) and 
include SIRT 1 to 7 in mammals , and HDAC11 is the sole member of the class IV HDAC 
(de Ruijter et al., 2003; Mehnert and Kelly, 2007).  The classes I, II and IV contain an active 
zinc domain site and their structures are closely related, whereas the class III are NAD
+
-
dependent enzymes of Sirtuin (Sirt) family and consists of two distinct domains that bind 
NAD and acetyl-lysine substrate, respectively, and is shared with catalytic domain among all 
sirtuins (Grozinger and Schreiber, 2002). The role of HDACs is not limited to histone 
modifications and is also involved in multiple signaling pathways.  Class I HDACs also 
control cell proliferation and survival; class II HDACs are capable of shuttling between the 
nucleus and cytoplasm, and have been implicated in cell maturation and differentiation (de 
Ruijter et al., 2003; Grozinger and Schreiber, 2002; Leipe and Landsman, 1997); class III 
HDACs or sirtuins can also deacetylate cytoplasmic proteins with some family members 
being localized in the nucleus, cytoplasm or mitochondria (Luo et al., 2001). In general, these 
enzymes are present in numerous repressive chromatin complexes in mammals, but may not 
show faithful specificity of any particular residues on histone proteins (Vaquero et al., 2006).  
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Fig. 2.4 The figure shows the capacity of VPA to inhibit the activity of HDAC classes I and 
II [Redrawn from (Bolden et al., 2006)]  
 
c) Lysine methylation 
      Lysine methylation involves transfer of a methyl group from the methyl donor SAM to 
lysine residues within histones, and this modification commonly occurs on histones H3 and 
H4 (Kouzarides, 2002; Shilatifard, 2006). Unlike histone acetylation, which generally 
correlates with transcriptional activation, histone methylation can induce either 
transcriptional activation or transcriptional repression depending on the specific modified 
residues within histone proteins. Compared to other modifications, histone methylation is 
more stable under physiological conditions, and lysine residue can be mono-, di-, or tri-
methylated by lysine methyltransferases (Bannister and Kouzarides, 2005; Cuthbert et al., 
2004; Margueron and Reinberg, 2011; Shi et al., 2004; Wang et al., 2004b; Whetstine et al., 
2006; Yamane et al., 2006). All identified lysine methyltransferases have been found to 
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contain a 140 amino acid catalytic region known as SET domain (Suppressor of variegation-
Enhancer of zeste-Trithorax). In addition, lysine methyltransferases have more extensive 
specificity than histone acetyltransferases (Santos et al., 2002). Methylation at H3K4, H3K36, 
and H3K79 is associated with transcriptional activation and in particular, H3K4me and 
H3K36me are involved in transcriptional elongation (Kouzarides, 2007). Methylation of K36 
at H3 is conserved from yeast to human (Barski et al., 2007). H3K36me has been suggested 
in several processes including RNA splicing, DNA repair, repression of cryptic transcription 
and histone exchange (Wagner and Carpenter, 2012). In contrast, methylation at H3K9, 
H3K27, and H4K20 are linked to transcriptional repression, which results from either 
silencing of euchromatic genes or forming a heterochromatin structure in combination with 
other enzyme factors (Vakoc et al., 2005).  
d) Histone deacetylases (HDACs) in early mouse development
     Genome activation in early mouse development occurs by the 2-cell stage in the transition 
from highly differentiated oocyte into totipotent blastomeres (Schultz, 2002). Epigenetic 
regulation of genome activation during this early stage is suggested to develop a chromatin-
mediated transcriptionally repressive state, which results in reprogramming and correct 
pattern of gene expression that are required for continued embryonic development (Schultz, 
2002). 
     Transcript profiling has suggested that oocytes and preimplantation mouse embryos 
express most class I and II HDACs including HDACs 1, 2, 3, 4, 5, 6, 9, and Sir2, and 
possibly HDAC7 and 11, although no convincing signal is detected for HDAC8 (Pan et al., 
2005; Verdel et al., 2003; Zeng et al., 2004; Zeng and Schultz, 2005). It has also suggested 
that class II HDACs (e.g., 4 and 6) are not linked to transcription repression following 
genome activation (Pan et al., 2005; Kageyama et al., 2006; Verdel et al., 2003). Thus, class I 
HDACs may be involved in development of the transcriptionally repressive state, and among 
these, HDAC1 may participate in numerous interactions in a gene network that could 
contribute to development of the transcriptionally repressive state (Zeng and Schultz, 2005).  
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Previous studies in somatic cells have shown that acetylation of histone H4 occurs initially on 
K16, and then on K8 or K12, and ultimately on K5 (Ren et al., 2005; Turner and Fellows, 
1989). This is an order that is also observed in mouse embryonic stem cells (Keohane et al., 
1996). Thus, acetylation of histone 4 lysine 5 (H4K5) reflects hyperacetylated histone H4, 
which is strongly correlated with transcriptionally permissive chromatin (Urnov and Wolffe, 
2001). Hdac1 gene expression has been implicated in development of transcriptionally 
repressive state that is initiated during the 2-cell stage (Davis et al., 1996; Wiekowski et al., 
1993) and becomes more crucial with further embryonic development (Christians et al., 1994; 
Henery et al., 1995). Treatment of 2-cell embryos with VPA results in an increase in 
acetylation of H4K5 and a global increase in transcription (Aoki et al., 1997). 
2.6.2.4 Mechanisms of histone modification and regulation 
     Although the fundamental role of histone modification has been recognized, detailed 
mechanism(s) of what impact this modification has is still not clear. One of the mechanisms 
considered for histone modification is that it disrupts the affinity between nucleosomes to 
“unravel” chromatin. DNA can thus be accessed by enzyme regulators (Kouzarides, 2007). A 
second more characterized mechanism of the impact of histone modification is recruitment of 
nonhistone proteins (Kouzarides, 2007). This model suggests a sequential binding or 
exclusion of a group of protein regulators on chromatin based on the components of specific 
histone modifications. Protein regulators are associated with enzymatic activities [e.g., 
remodeling adenosine triphosphatases (ATPases)] which can further modify chromatin 
structures (Kouzarides, 2007). Investigations have revealed certain transcription regulators 
consist of a chromodomain which can bind to specific histone lysine methylation site (An, 
2007). One characterized example is the recognition of heterochromatin protein 1 (HP1) to 
tri-methylated H3K9 triggering chromatin reorganization (Bannister et al., 2001; Jacobs and 
Khorasanizadeh, 2002; Lachner et al., 2001; Nakayama et al., 2001). Chromatin compaction 
and gene repression involves recruitment of HP1 (HP1α and HP1β) (Margueron and 
Reinberg, 2011; Verschure et al., 2005). HP1 specifically recognizes and binds methylated 
H3K9 and can oligomerize to bridge nearby nucleosomes. Thus, H3K9me-dependent 
42 
 
repression is thought to involve nucleosome remodeling by HP1. This can generate a 
condensed chromatin template, thereby reducing protein accessibility to the genomic 
template (Karanikolas et al., 2009; Kleer et al., 2003; Varambally et al., 2002). HP1 proteins 
not only promote the propagation of heterochromatin but also recruit protein complexes with 
various enzymatic activities that are essential for the assembly of repressed chromatin 
(Grewal and Jia, 2007). 
     Histone modifications also have influence on higher-order chromatin structure by 
impacting connections between different histones or the interaction between histones and 
underlying DNA (Kouzarides, 2007). Although chromatin structure activity is difficult to 
observe in vivo, biophysical analysis has demonstrated internucleosomal contacts are 
important for stabilizing a higher-order chromatin structure (Kouzarides, 2007).   
     Moreover, a given histone methylation mark is often associated with specific positions 
along DNA sequence (Verrier et al., 2011). For example, methylation of histone H3 at Lys-9 
(H3K9me3/me2) on promoters and methylation of histone H3 at Lys-27 (H3K27me3) on 
promoters as well as on the gene coding region correlate with transcriptional repression. In 
contrast, methylation of histone H3 at Lys-4 (H3K4me3) around the transcription start site 
and methylation of Lys-79 (me1, me2 or me3) and Lys-36 (me3) on the gene coding region 
are associated with gene activation (Campos and Reinberg, 2009; Kouzarides, 2007; Li et al., 
2007).  
2.6.2.4.1 Enzymatic machinery associated with histone methylation 
     During the past few years, significant progress has been made in identifying the enzymatic 
machinery that catalyzes the modification of histones methylation (Kouzarides, 2007). These 
enzymes have been grouped into several classes, including (1) the lysine-specific SET 
domain-containing histone methyltransferases (HMTases) involved in methylation of lysines 
4, 9, 27, and 36 of histone H3 and lysine 20 of histone H4; (2) non-SET domain-containing 
lysine methyltransferases involved in methylating lysine 79 of histone H3; and (3) arginine 
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methyltransferases involved in methylating arginine 2, 17, and 26 of histone H3 as well as 
arginine 3 of histone H4 (Kouzarides, 2007). 
a) Histone H3 lysine 4 methylation enzyme complex 
     The past decade of biochemical and cellular studies have revealed that HMTs are the key 
component in regulation of gene transcription (Shilatifard, 2008). After the function of 
Su(var)3-9 (Suppressor of variegation 3-9), a SET (Suppressor of variegation-Enhancer of 
zeste-Trithorax) domain HMTase was identified, several other SET domain-containing 
proteins were discovered as HMTases (Rea et al., 2000). Methylation of H3K4 is extensively 
associated with gene transcriptional activation (Kouzarides, 2007; Shilatifard, 2006; Sims et 
al., 2006). COMPASS (Complex Proteins Associated with Set1) is a multiple complex that 
contains the Saccharomyces cerevisiae SET domain-containing protein Set1 and another 
yeast protein related to the human thioredoxin (trx) protein ASH (Abundant Src homology). 
The first identified H3K4 methylase was COMPASS composed of Set1/KMT2 (SET domain-
containing protein 1/Histone-lysine N-methyltransferase 2) and seven other polypeptides 
referred to as Cps60-Cps15 (Miller et al., 2001). Set1/KMT2 is only capable of mono-, di- 
and tri-methylating H3K4 within COMPASS (Krogan et al., 2002; Miller et al., 2001; Nagy 
et al., 2002; Roguev et al., 2001; Schneider et al., 2005; Shilatifard, 2006; Shilatifard, 2008; 
Wood et al., 2007). Recently, mammalian homologs of MLL (human mixed lineage leukemia) 
proteins including MLL1-4, hSet1A and B were found as COMPASS-like complex, and 
function to methylate H3K4 (Hughes et al., 2004; Shilatifard, 2006; Tenney and Shilatifard, 
2005). MLL is a SET domain-containing protein that is largely associated with the 
pathogenesis of hematological malignancies including acute myeloid leukemia (Hess, 2004; 
Rowley, 1998; Tenney and Shilatifard, 2005; Ziemin-van der Poel et al., 1991).  
     Mixed lineage leukemia (MLLs) are primarily recognized as playing critical roles in gene 
activation via H3K4 methylation of promoters. H3K4 trimethylation is thought to recruit 
various transcriptional coregulators during transcription activation (Ansari and Mandal, 2010). 
The maintenance of the newly trimethylated H3K4me3 is largely accomplished by 
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phosphorylation of histone 3 at threonine 6 (H3T6) (Garske et al., 2010; Metzger et al., 2010) 
Phosphorylation eliminates the ability of lysine specific demethylase (LSD1) to demethylate 
H3K4me2/1 and prevents lysine (K)-specific demethylase 5B (JARID1B) from 
demethylating H3K4me3/2 (Xiang et al., 2007). Trimethylation of H3K4 recruits the basal 
transcription factor II D (TFIID) (Vermeulen et al., 2007), which results in an enhanced 
recruitment or stability of the RNA polymerase II preinitiation complex (Vermeulen et al., 
2007). This provides the basis for its role as a transcriptional coactivator (Ansari and Mandal, 
2010). 
b) Histone H3 lysine 27 methylation  
     Drosophila polycomb group (PcG) proteins maintain transcriptional silencing of many 
genes through epigenetic mechanisms in a wide range of developmental processes (Grimaud 
et al., 2006; Kwong et al., 2008; Pietersen et al., 2008; Ringrose, 2007; Schwartz and Pirrotta, 
2008).  Recent molecular and genetic studies have shown that the PcG protein subunits are 
HMTases, and part of their silencing function is mediated by the HMTase activity. PcG 
family combine three different PcG complexes referred to as polycomb repressive complexes 
1 (PRC1), PRC2, and Pho-repressive complex (PhoRC) (Klymenko et al., 2006; Ringrose 
and Paro, 2004). PRC1 is composed of four subunits: polyhomeotic (Ph), posterior sex combs 
(PSC), dRING (Drosophila Really Interesting New Gene), and Polycomb (Pc) (Francis et al., 
2001; Lavigne et al., 2004; Levine et al., 2002; Saurin et al., 2001; Shao et al., 1999). PRC2 
includes Eed (Embryonic ectoderm development), Ezh2 (Enhancer of Zeste) and Suz12 
(Suppressor of zeste 12 homolog) proteins. Studies from several laboratories have showed 
that following the binding of PRC2 to chromatin, Ezh2 (which contain the SET domain 
within PRC2 complex) catalyzes H3 trimethylation on lysine 27 within nucleosomes (Cao et 
al., 2002; Muller et al., 2002), which is then recognized by Pc, one of components of PRC1, 
through its chromodomain (Fischle et al., 2003; Min et al., 2003). Hence, PRC1 facilitates  
PcG-mediated repression by forming a heterochromatin structure that interferes with the 
transcription machinery (Francis et al., 2004; Ringrose and Paro, 2004; Sarma et al., 2008). In 
this case Ezh2 is a critical factor as further investigation revealed that without Ezh2 activity, 
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PRC1 cannot be recruited to chromatin and PcG-associated repression does not occur (Cao et 
al., 2002; Rastelli et al., 1993). More recently, it has been proposed that H3K27me3 signals 
for PRC1 recruitment at target promoters.  PRC1 subsequently mediates ubiquitylation of 
core histone 2A at 119 (H2A119ub). This ubiquitylation represses transcription by interfering 
with polymerase elongation (Ernst et al., 2010). PRC1 components can promote compaction 
of nucleosomal arrays in vitro (Nikoloski et al., 2010) and mediate long-range interactions in 
vivo, suggesting a role for polycomb proteins in establishing repressive higher-order 
chromatin structure (Karanikolas et al., 2010; Pasini et al., 2007).  In Drosophila embryos, 
the four major components of PRC2 complex include the ESC (Extra sex combs), E(Z) 
(Enhancer of Zeste in Drosophila), SU(Z)12 (Suppressor of zeste 12), and NURF-55 
(Nucleosome remodeling factor 55). Methyltransferase activity on histone H3 lysine 27 
associated with this complex can be reconstituted from these four subunits, and mutations in 
the E(Z) SET domain led to disruption of the methyltransferase activity (Muller et al., 2002). 
The human homologue of this complex, the EED-EZH2 (human homologue of Eed and Ezh2) 
complex, is also capable of methylating histone H3 on lysine 27 (Cao et al., 2002).  
2.6.2.5 Histone methylation and transcriptional memory 
     Epigenetic marks that are stable to DNA synthesis and mitosis have been proposed as a 
mechanism for the maintenance of epigenetic memory (Beck et al., 2010).      
     Effect of histone methylation has implicated a functional memory mark of modification 
during gene transcription process (Bernstein et al., 2002; Santos-Rosa et al., 2002; Tenney 
and Shilatifard, 2005). A close relationship between transcriptional activity of RNA 
polymerase II (RNAPII) and methylated levels of histone H3 lysine 4 has been observed 
(Gerber and Shilatifard, 2003; Guenther et al., 2005; Krogan et al., 2003; Ng et al., 2003). An 
experiment was carried out on GAL10 (encoding H. jecorina UDP-glucose 4-epimerase 10) 
gene which showed that the occupancy of Set1/COMPASS and levels of H3 lysine 4 
methylation at the 5' coding region of GAL10 went up significantly during and after 
activation; however, Set1/COMPASS levels fall rapidly when the gene is ‘turned off’. The 
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changes in methylated levels of H3K4 and the occupancy of catalytic enzymes are similar to 
the dynamic transcriptional process of RNAPII (Krogan et al., 2003). In contrast to 
Set1/COMPASS, the levels of histone H3 lysine 4 di- and trimethylation dropped relatively 
slowly (Guenther et al., 2005; Krogan et al., 2003). Additional analysis of RNA polymerase 
associated factor (Paf1) gene expression also demonstrated that trimethylation of histone H3 
lysine 4 is lost by a slow process. This phenomenon can be considered as a “short-term 
memory” model for histone H3 lysine 4 methylation. In this model, the transcriptional status 
of a given gene can be distinguished by the level of H3K4 methylation (Gerber and 
Shilatifard, 2003; Guenther et al., 2005; Krogan et al., 2003).   
2.6.2.6 Crosstalk between epigenetic modifications 
     Chromatin cross-talks allow an accurate co-ordination between these modifications 
(Verrier et al., 2011).   Recent reports indicate that the mutual exclusion between H3K4 and 
H3K9 is an active process. This cross-talk can be mediated by various mechanisms and is 
clearly representative of how such mechanisms can be integrated to specify a mutual 
exclusion between two distinct chromatin modifications (Verrier et al., 2011).  
2.6.2.6.1 DNA methyltransferases and histone modifying enzymes 
     DNA methylation patterns can directly affect chromatin modification, where for example, 
methylated DNA binding protein MeCP2 can interact with SUV3-9 histone methyltransferase 
(Fuks et al., 2003). Histone modifying enzymes such as HDAC1 and HDAC2 can also 
interact with DNA methyltransferases such as DNMT1 and DNMT3b, and histone 
methyltransferases, SUV3-9 and EZH2 (Fuks et al., 2000; Fuks et al., 2003; Rountree et al., 
2000; Vire et al., 2006). Recruitment of HDACs to heterochromatin protein 1 that binds to 
methylated H3K9 would induce a stable heterochromatin structure (Smallwood et al., 2007). 
One of the most important associations between chromatin and DNA methylation was found 
in tumor suppressor genes which exhibit a relationship between EZH2 and DNA methylation 
(Rauch et al., 2007). On these tumor suppressor genes in lung cancers, methylated CpG 
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islands were also the binding sites for EZH2 histone methyltransferase. As a result, sites that 
are bound by EZH2 are poised to become methylated (Rauch et al., 2007).  
     Similar to DNA methylation, DNA demethylation during transcription is also 
accompanied by chromatin modification changes. In the case of gene transcriptional 
activation, transcription factors recruit KATs to bind to promoter regions of genes, triggering 
gene-specific acetylation and recruitment of RNAPII, a process that is followed by DNA 
demethylation (D'Alessio et al., 2007).  
     ‘‘Crosstalk’’ between modifications appears to be due to the accumulated modification 
abundance on histone tails. Many different types of histone modifications can occur on single 
or multiple histone residues, hence, interactions can be found in the same type of lysine 
residue modifications, or adjacent different type of modifications. For instance, 
phosphorylation of histone 3 serine 10 (H3S10) can change the binding of HP1 to methylated 
H3K9 (Fischle et al., 2005). Additionally, the enzyme catalytic activity can be compromised 
resulting from modification at its substrate recognition site (Kouzarides, 2007). One example 
is that the isomerization of histone 3 proline 38 (H3P38) subsequently affects methylation of 
H3K36 by Set2 (Nelson et al., 2006). A study of GCN5 acetyltransferase activity shows that 
the enzyme activity becomes more effective with a second modification (when H3 is 
phosphorylated at S10) (Clements et al., 2003). Finally, interactions can also occur when the 
modifications are on different histone tails. The best studied example is ubiquitination of 
H2B which is required for the methylation of H3K4me3 (Kouzarides, 2007). 
2.6.2.6.2 DNA methylation and methylation of H3K4 and H3K9 
     Genome-wide DNA methylation screen suggests that DNA methylation is better 
correlated with histone methylation patterns than to the underlying genome organization and 
arrangements (Meissner et al., 2008). Methylation of H3K4 has been demonstrated 
(Shilatifard, 2008) to protect promoters from de novo DNA methylation in somatic cells 
(Appanah et al., 2007; Weber et al., 2007). There is an inverse relationship existing between 
H3K4 methylation and allele-specific DNA methylation (Delaval et al., 2007; Fournier et al., 
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2002; Meissner et al., 2008; Vu et al., 2004; Yamasaki et al., 2005). A recent genome-scale 
analysis has further confirmed this inverse correlation between DNA methylation and H3K4 
methylation. DNA methylation is associated with the absence of H3K4 methylation (Laurent 
et al., 2010). In contrast, DNA methylation is positively correlated with the presence of H3K9 
methylation (Dindot et al., 2009). One study has shown inhibiting DNA methylation with the 
methyltransferase inhibitor 5azaC leads to a loss of H3K9 methylation (Nguyen et al., 2002).  
     De novo DNA methyltransferases and associated factors bind to unmethylated H3K4 (Ooi 
et al., 2007), whereas the H3K4 methyltransferase MLL preferentially binds to unmethylated 
DNA (Birke et al., 2002), providing a molecular correlation between H3K4me and DNA 
methylation levels (Meissner et al., 2008). This interplay suggests that when DNA 
methylation is present, it may serve as a reinforcing signal for preexisting but less stable 
epigenetic signatures such as histone modifications (Bonasio et al., 2010) .  
2.7.  Epigenetics and development 
2.7.1.  DNA methylation during development 
     DNA methylation patterns in mammals are dynamic and essential for development (Bird, 
2002; Jackson-Grusby et al., 2001; Li et al., 1992; Okano et al., 1999) where patterns of DNA 
methylation are established early in development. In mammals, the paternal genome 
undergoes rapid demethylation within a few hours of fertilization (Mayer et al., 2000; 
Nonchev and Tsanev, 1990; Oswald et al., 2000), although the mechanism(s) of how this 
occurs is not known. The maternal genome is passively demethylated during subsequent 
mitotic divisions (Li, 2002; Reik et al., 2001; Santos et al., 2002). The overall effect of 
genome-wide DNA demethylation in pluripotent cells is to produce cells in which all genes 
are transcriptionally active (Burdge and Lillycrop, 2010). At the time of blastocyst formation, 
the genome of the blastocyst undergoes de novo methylation at distinct levels in order to 
establish cell differential patterns between the inner cell mass of blastocyst (ICM) and those 
of trophectoderm (Jaenisch and Bird, 2003). For example, Oct4 gene is associated with 
cellular pluripotency and is permanently silenced by hypermethylation around E6.5 in mice 
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(Gidekel and Bergman, 2002). Hoxa5 and Hoxb5 are involved in early embryonic 
development pattern and are not silent until early postnatal life (Hershko et al., 2003). Other 
genes, however, undergo graded changes in the level of DNA methylation and transcription 
during development (Burdge and Lillycrop, 2010). Ultimately, loss of pluripotency and cell 
differentiation and the establishment of adult tissue function are dependent on the changes in 
the methylation status of individual genes at different times in development (Burdge and 
Lillycrop, 2010). In addition to the normal coordinated DNA methylation status during 
development, DNA methylome undergoing aberrant characteristic changes can induce cancer 
(Jones and Baylin, 2002).  
a) CpG islands in genome 
     CpGs tend to cluster in specific regions of the genome. The clustered CpGs are termed 
CpG islands, and they are featured by high G+C content (Bird, 2002). Genomic studies 
indicate that 0.7% of the human genome contains CpG islands, and these regions contain 70% 
of the genome CG dinucleotides (Fazzari and Greally, 2004; Lander et al., 2001). CpG 
islands are associated with DNA methylation relating to gene regulation. In humans, about 60% 
of gene promoters are characterized by CpG islands. In normal cells most CpG islands are 
found unmethylated. However, a small subset of CpG islands may be subject to gene and 
tissue specific methylation during development (Bernstein et al., 2007; Bird, 2002; 
Strichman-Almashanu et al., 2002).  
2.7.2 Oxidative stress and DNA methylation 
     Recent studies have suggested interactions between oxidative stress and DNA methylation 
(Andreazza et al., 2012). Oxidative stress induces glutathione S-transferase (GST) production 
to prevent oxidative damage. The production of GST requires the utilization of homocysteine 
which subsequently decrease the availability of a methyl donor, S-adenosylmethionine 
(SAM), leading to hypomethylation of DNA (Lertratanangkoon et al., 2007).  
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     ROS also induce the hydroxylation of 5-methylcytosine (5mc) in a catalyzed reaction by 
ten-eleven-translocation (TET) oxygenase to 5-hydroxymethylcytosine (5hmc) (Matarese et 
al., 2011). The TET proteins were newly identified oxoglutarate- and iron-dependent 
dioxygenases in this enzyme superfamily (cupin superfamily) (Lyer et al., 2008; Lyer et al., 
2009). Activation of TET correlates to the high oxygen concentration and requires alpha-
ketoglutarate – a product of both the citric acid cycle and urea cycle (Chia et al., 2011).  
     Hydroxylation of 5mC to 5hmC could induce passive demethylation by preventing 
DNMT1 binding at hydroxymethylated CpGs during DNA replication (Reik et al., 2012). 
Also, the presence of 5hmC may attenuate the silencing effect of 5mc by preventing binding 
of methyl-binding proteins at 5mC (Valinluck et al., 2004). 
     However, whether there is a correlation between promoter 5hmC and gene transcription is 
not consistent among studies. Some analyses have found 5hmC and 5mC often co-exist in the 
genome (Ficz et al., 2011; William et al., 2011), and that 5mC within promoter regions 
causes transcriptional repression. In TET1 knockdown ESCs with a potential reduced 
activating role of 5hmC, several genes are downregulated; however, surprisingly a large 
number of genes are repressed (William et al., 2011, Wu et al., 2011; Xu et al., 2011). Many 
of these repressed genes are polycomb repressive complex (PRC2) target genes (Wu et al., 
2011). In ESCs, such genes are often associated with histone bivalent domains with the active 
mark of trimethylation at histone H3 lysine 4 (H3K4me3) and the repressive mark 
(H3K27me3). Genes enriched with bivalent domains are generally transcriptionally ‘poised’ 
so that they can be rapidly activated or silenced depending on the specific differentiation 
pathway (Reik et al., 2012).  
2.7.3 Epigenetic regulation of Hox genes during development  
2.7.3.1 PcG and trxG proteins  
     The discovery of polycomb group (PcG) and trithorax (trxG) group is an important 
milestone in developmental biology. Over the last 60 years, studies of their role in epigenetic 
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regulation of Drosophila homeotic genes have provided invaluable information for exploring 
their functions (Schuettengruber et al., 2007) . 
     PcG proteins involve three different complexes (reviewed previously in 5.2.4.1b). The 
SET domain-containing E(z) subunit trimethylates lysine 27 of histone H3 (H3K27me3)(Cao 
and Zhang, 2004). This histone mark can be specifically recognized by the chromodomain of 
Pc (Cao and Zhang, 2004), a subunit of PRC1 type complex. Recently, a third complex, 
PhoRC, has been identified and is also involved in homeotic gene silencing (Klymenko et al., 
2006). The dRing subunit of PRC1 and the mammalian homologs Ring1A and Ring1B, are 
E3 ubiquitin ligases that ubiquitinate H2AK119, a modification that is essential for silencing 
of Hox genes (Wang et al., 2004a). In mammals there is evidence that Yin Yang-1 (YY1) 
recruits PRC2, as knockdown of YY1 with RNA interference (RNAi) leads to loss of E(Z)H2 
and H3K27 trimethylation (Caretti et al., 2004).  
     TrxG proteins are heterogeneous protein group. One class of trxG members is composed 
of SET domain factors like Drosophila Trx and Ash1 and vertebrate MLL, as well as their 
associated proteins. A second class of trxG factors consists of components from ATP-
dependent chromatin remodeling complexes such as the SWI/SNF or the NURF complexes 
(Schuettengruber et al., 2007). 
      PcG and trxG proteins also bind near transcription start sites, suggesting a role in 
regulation of transcription. The trxG proteins are crucial for more than one phase of 
transcription. H3K4 methylation is highest near promoters and is required for transcriptional 
initiation and promoter clearance, as well as early transcriptional elongation (Petruk et al., 
2006; Smith et al., 2004).  However, promoter clearance, marked by the synthesis of a short 
strand of RNA and melting of the DNA ahead of RNA Pol II, did not occur, suggesting the 
PcG proteins prevent it (Beck et al., 2010).  
     Disruption of DNMT1 causes improper recruitment of polycomb ring finger oncogene B 
lymphoma Mo-MLV insertion region 1 homolog (Bmi1) and RING finger protein member of 
Polycomb group (Ring1B) to PcG bodies (Hernandez-Munoz et al., 2005). During in vitro ES 
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cell differentiation, 21% of genes that lose H3K4me2 and maintain H3K27me3 are de novo 
DNA methylated and PRC2 targets are more likely nonPRC2 targets to be de novo 
methylated (Mohn et al., 2008). An acceptable hypothesis is that PRC1 together with the 
maintenance DNA methyltransferase at the replication fork  promote transcriptional silencing 
of newly synthesized daughter strands. Thus, DNA methylation may serve as a memory mark 
and simply stabilize gene silencing in which other mechanisms are involved.  (Bird, 2002).  
     It is yet to be determined what regulates whether PcG or trxG proteins are recruited to a 
particular locus by sequence specific factors (Beck et al., 2010).  
2.7.3.2 Hox and Hoxa2 genes 
     Homeobox genes encode transcription factors which act as regulators of downstream gene 
activity and are characterized by the presence of a highly conserved 180-base pair sequence 
known as the homeobox. The homeobox encodes a 60-amino acid helix-turn-helix DNA 
binding motif within the transcription factor. Hox genes are homologous to homeobox genes 
of Drosophila, which map to the Antennapedia and Bithorax complex (Akin and Nazarali, 
2005). They are organized into a single chromosomal cluster in invertebrates, in contrast to 
higher vertebrates such as the mouse which have 39 Hox genes, organized into four distinct 
chromosomal clusters (Hoxa-Hoxd) (McGinnis and Krumlauf, 1992) (Fig.2.5). The most 
significant feature of the organized expression of Hox gene family members is the spatial and 
temporal colinearity, which confers positional information along the body axis (Dolle et al., 
1989; Donaldson et al., 2011; Duboule and Dolle, 1989; Kessel and Gruss, 1991; McGinnis 
and Krumlauf, 1992;Durston, 2012). Hox gene collinearity is crucial in embryogenesis and 
features the important interrelated properties -- functional collinearity and spatial and 
temporal collinearity. Functional collinearity describes the order in which Hox genes act 
along a body axis; spatial and temporal collinearity refers to the spatial order and the time 
sequence in which the Hox genes are expressed (Durston, 2012).  Hox genes located nearer to 
the 3' end of the chromosomal cluster are expressed earlier during development and more 
anteriorly than those located nearer the 5' end, such that Hox genes exhibit nested domains of 
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expression along the anterior-posterior (A-P) axis along the neural tube and, each gene has a 
characteristic segmental limit of expression at its anterior boundary (Hunt et al., 1991; 
Durston et al., 2011;Pick and Heffer, 2012).  Hox genes are key controllers of rostrocaudal 
patterning in the head, including hindbrain segmentation and rhombomere identity (Cordes, 
2001; Lumsden, 2004; Durston et al., 2011; Pick and Heffer, 2012). Hox genes are expressed 
in neural crest cells, which migrate predominantly from even-numbered rhombomeres into 
the branchial arches, generating skeletal tissues and cranial ganglia (Graham et al., 1991; 
Kontges and Lumsden, 1996; Durston et al., 2011; Pick and Heffer, 2012).  
 
Fig. 2.5 The 39 mouse Hox genes are organized in four clusters on four separate 
chromosomes. They are derived from a single ancestral cluster from which the single HOM-C 
complex in Drosophila is also derived. HOM-C consists of two regions: Antennapedia and 
Bithorax. Cluster duplication during evolution has led to the concept of paralogous groups of 
Hox genes. Groups of up to four genes derived from a common ancestral gene can be 
identified based upon sequence homology. The paralogues show similar expression domains 
along the anterior-posterior axis of the embryo leading to the concept of functional 
redundancy between genes [Adapted from Cobourne, 2000].  
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     Hoxa2 belongs to the HoxA cluster of the Hox gene family and is the most anteriorly 
expressed Hox gene. Hoxa2 shows a rostral limit of expression at the border between 
rhombomere 1 (r1) and r2 in the E8 mouse hindbrain. During development Hoxa2 is 
expressed in several tissues, including the neural tube and the neural crest-derived 
mesenchyme of the branchial area (Gavalas et al., 1997; Krumlauf, 1993; Prince and 
Lumsden, 1994;Donaldson et al., 2011). In mouse, disruption of the Hoxa2 gene affects 
second branchial arch development. Second arch skeletal elements (stapes, styloid process, 
lesser horn of the hyoid bone) are transformed into first arch-specific skeletal elements (incus, 
malleus and tympanic ring). They are arranged in a mirror image disposition to their first arch 
counterparts. (Barrow and Capecchi, 1999; Gendron-Maguire et al., 1993; Rijli et al., 1993). 
A recent study from our lab was the first to demonstrate a direct role of Hoxa2 in palate 
development (Smith et al., 2009). Hoxa2 mRNA and protein were detected in the developing 
palate in mice between E12.5 and E15.5. Hoxa2 plays intrinsic roles in regulating both cell 
proliferation and gene expression during palatogenesis (Smith et al., 2009). More recent 
studies using Hoxa2 ChIP-sequencing reveals that Hoxa2 has large genome coverage and 
potentially regulates thousands of genes in developmental stage (E11.5). In this study, a 
significant amount of genes involved in the Wnt-signaling pathway associated with Hoxa2-
bound regions were identified. The tissue- and stage-specific activation of the Wnt–-catenin 
pathway in the second branchial arch was observed, which is undetectable in Hoxa2 mutant 
embryos. These data describe where Hoxa2 localizes in the genome while functioning to 
direct embryonic development. This study presents one of the first global maps of the in vivo 
interactions between a Hox gene and chromatin during embryogenesis (Donaldson et al., 
2011). 
2.7.3.3 Genome-wide histone methylation of Hox genes 
     Hox genes play key roles in embryonic spatial segmental identity along the AP axis during 
development (Ringrose, 2007). The activation of Hox genes is referred to as spatial 
collinearity. Genes at anterior extremity of the cluster are activated in anterior parts of the 
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developing embryo, whereas genes located at the posterior end are transcribed in more 
posterior areas (Schwartz and Pirrotta, 2007). Hox gene promoters therefore demonstrate an 
organized AP polarity. The role of PcG and TrxG is to preserve appropriate Hox expression 
domains during development (Schwartz and Pirrotta, 2007). The PcG proteins act on Hox 
genes as silencers, maintaining previously established states of gene expression over cell 
generations; while the TrxG genes act to conteract PcG silencing and maintain Hox genes 
active wherever necessary (Klymenko and Muller, 2004; Muller and Kassis, 2006; 
Schuettengruber et al., 2007; Schwartz and Pirrotta, 2007; Simon et al., 1992). Both groups 
act through the same DNA elements – the Polycomb/Trithorax response elements (or 
PRE/TREs) (Ringrose, 2007). These are known as ‘memory’ elements of genes as the 
elements preserve gene transcriptional activity - active or silent. Regulation of PcG and TrxG 
proteins on Hox genes are conserved from flies to vertebrates, although PRE/TRE elements 
have only been identified in Drosophila (Pires-daSilva and Sommer, 2003; Ringrose and 
Paro, 2004; Schubert et al., 2005).    
     Major progress has recently been made in understanding mechanisms of epigenetic 
regulation of Hox genes during embryonic development. Faithful expression patterns of Hox 
genes are critical for the normal homeostasis of adult tissues and organs. Mis-regulation of 
Hox genes can readily lead to diseases such as cancer (Maroulakou and Spyropoulos, 2003; 
McGonigle et al., 2008). 
      To mediate long-term repression of Hox genes, Ezh2 of PRC2 tri-methylates H3 on K27 
(Rea et al., 2000), and recruitment of PRC1 members to H3K27me3 and subsequently forms 
a heterochromatin structure (Fischle et al., 2003). Ubiquitination of H2A at K119, a 
modification that interferes with RNA polymerase II activity (Nakagawa et al., 2008; Stock et 
al., 2007; Zhou et al., 2008), is essential in this process and facilitates PRC1 member binding 
to H3K27me3 (Cao et al., 2005; de Napoles et al., 2004; Wang et al., 2004a).  
     Genome-wide studies in ES cells recently revealed the components of PRC1 and PRC2 
are associated with promoters of many transcription factors (Boyer et al., 2006; Bracken et al., 
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2006; Lee et al., 2006b; Ringrose et al., 2003; Schwartz et al., 2006; Tolhuis et al., 2006). 
The PRC2 and trimethylation of H3K27 were distributed along approx. 100 kb domains 
within all four Hox gene clusters (Lee et al., 2006b; Schwartz et al., 2006). Mutations in PcG 
genes can lead to ectopic Hox gene expression and posterior homeotic transformations in 
both Drosophila and vertebrates (van der Lugt et al., 1994). Analyses of PRC2 mutants have 
further demonstrated that PRC2-dependent methylation of H3K27 is required for silencing 
Hox genes in ES cells (Lee et al., 2006b). TrxG/MLL proteins complexes catalyze the 
trimethylation of H3K4, which is generally related to active transcription (Schuettengruber et 
al., 2007; Schwartz and Pirrotta, 2007). H3K4me3-modified nucleosomes are specifically 
enriched at the promoter region of active genes (Barski et al., 2007; Bernstein et al., 2002; 
Bernstein et al., 2005; Bernstein et al., 2006; Schubeler et al., 2004; Barski et al., 2007; Beck 
et al., 2010; Bernstein et al., 2002; Bernstein et al., 2005; Bernstein et al., 2006; Schubeler et 
al., 2004). In Drosophila trx or Mll mutants, Hox genes are properly expressed but cannot be 
faithfully maintained (Glaser et al., 2006; Schwartz and Pirrotta, 2007; Terranova et al., 
2006). Further analysis of Drosophila trxG/PcG double mutants indicates that the activity of 
TrxG/MLL complexes is required to prevent PcG-mediated silencing of transcribed Hox 
genes (Klymenko and Muller, 2004). Interestingly, in ES cells, Hox gene promoters often 
display both H3K4me3 and H3K27me3 marks, which are referred to as ‘bivalent domains’. 
Bivalent marks are mostly enriched at GC-rich promoters (Mikkelsen et al., 2007) where they 
may prevent DNA methylation and silencing, at least in stem cells (Mohn et al., 2008). The 
function of bivalent domains remains elusive, and this equilibrium between active and 
repressive marks may maintain genes in a poised state, ready for rapid activation during cell 
differentiation (Azuara et al., 2006; Bernstein et al., 2006).  
     Presently, the most popular explanation for temporal and spatial collinearity suggests that 
these phenomena are rate-limited transcription via a progressive opening of the chromatin at 
Hox complexes from 3 ends towards 5 ends (Duboule, 1994; Spitz et al., 2003; Duboule, 
1994; Kmita and Duboule, 2003). During early mouse development, temporally collinear 
expression of the Hoxd complex correlates with the progressive 3–5 modification of its 
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chromatin from a repressing to an activating state (Soshnikova and Duboule, 2009b). 
Furthermore, elegant experiments showed that transposing a 3 Hox gene to a 5 position in 
the Hoxd complex caused later and more posterior expression (Kmita et al., 2000; van der 
Hoeven et al., 1996). In ES cells when retinoic acid is used to induce temporally collinear 
Hoxb gene expression, looping out of genes from their chromosome territory (a correlate of 
chromatin activation) occurs from 3 to 5 in coordination with Hox gene expression 
(Bickmore et al., 2004). 
     Hox genes are activated in a time dependent sequence. This is referred to as “temporal 
collinearity”.  In some species, the activation of Hox genes in a time dependent sequence 
reflects their position in the gene cluster (Kmita and Duboule, 2003). More recently, the 
sequential epigenetic activation of Hoxd cluster in developing murine tail buds was 
investigated by ChIP combined with hybridization on tiling array (ChIP-on-chip). A highly 
dynamic equilibrium was identified where demethylation of H3K27 paralleled an increase in 
trimethylation of H3K4, along with progressive gene activation. The region of transition 
between these two chromatin states corresponds to the areas where Hoxd genes become 
transcriptionally active, and this expression region of Hoxd genes shifts from one end of the 
cluster to the other during gastrulation (Soshnikova and Duboule, 2009a). For example, at 
E8.5, H3K4me3 marks drastically increased and covered the telomeric part of the cluster up 
to both Hoxd10 and Hoxd11, which remain silenced at this time point. However, at E9.5, 
elevated levels of H3K4 trimethylation over the Hoxd11 and Hoxd12 loci was observed to 
correspond to their robust transcriptional activation. The results suggest that temporal 
collinearity of Hoxd gene cluster in tail buds corresponds to chromatin dynamics, which 
involves the removal of H3K27me3 marks, enrichment of the methylation of H3K4, and the 
acetylation of H3, a distance of about 100 kilobases over less than two days (Soshnikova and 
Duboule, 2009a). The observation also indicates the transcriptional activation occurs along 
gene cluster with transition between H3K27me3 and H3K4me3 during mouse tail bud 
development (Soshnikova and Duboule, 2009b).   
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     Specific analysis of HOXA cluster in human embryonal carcinoma (EC) cells showed the 
presence of H3K4 trimethylation and dimethylation associated with cell differentiation. 
H3K4 trimethylation and dimethylation span the region from HOXA4 to HOXA11 with 
enrichment at the 3' end of HOXA4 and HOXA9, and the 5' end of HOXA10 during 
pluripotent cell differentiation (Atkinson et al., 2008). At the same time, acetylation of 
histones H3 and H4 is restricted to the same region from HOXA4 to HOXA11. In 
undifferentiated EC cells, trimethylation of H3K9 is enriched at HOXA3 and the intergenic 
region between HOXA6 and HOXA7. These differential locations of epigenetic modifications 
in EC cells demonstrate that epigenetic modifications not only regulate the expression of 
HOXA genes in pluripotent cells, but also maintain the collinear activation of these genes 
during cell differentiation (Atkinson et al., 2008; Snowden et al., 2002).  
     Epigenetic modifications are also associated with Hox genes in cancer cell development. 
CpG methylation of Hox genes is sporadically observed during breast tumorigenesis, 
including methylation of HOXB13 gene (Rodriguez et al., 2008), and members of the HOXA 
cluster genes (Novak et al., 2006; Raman et al., 2000). Hypermethylation of the HOXB13 
gene is a late-stage event in breast tumorigenesis (Rodriguez et al., 2008). Inappropriate 
silencing of HOXA gene cluster in breast tumors is widely seen both in vivo and in vitro, and 
is closely connected to the presence of hypoacetylation of H3 and H4 at CpG islands in 
HOXA gene cluster (Novak et al., 2006; Tommasi et al., 2009). A large number of homeobox 
genes were found methylated in lung tumors including adenocarcinomas and squamous cell 
carcinomas (Rauch et al., 2007). Therefore, it seems that all four HOX gene clusters are 
preferential targets for DNA methylation in cancer cell lines and the early stage lung tumors 
(Ohm et al., 2007; Pfeifer and Rauch, 2009).  
     Methylation profile of extrahepatic cholangiocarcinoma (CCA) was identified with 
MeDIP (Methylated DNA immunoprecipitation) microarray with respect to different gene 
functions and signaling pathways. The results showed that 97 genes with hypermethylated 
CpG islands in the promoter region were homeobox genes. The top 5 hypermethylated 
homeobox genes validated by BSP were HOXA2 (94.29%), HOXA5 (95.38%), HOXA11 
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(91.67%), HOXB4 (90.56%) and HOXD13 (94.38%). Expression of these genes was 
reactivated with 5’-aza-2’-deoxycytidine. Significant expression differences were found 
between normal bile duct cancer and extrahepatic CCA tissues (Shu et al., 2011). However, 
currently no other information exists on epigenetic regulation of Hoxa2 gene. Hence the 
subject of my investigations described in this thesis was to identify if epigenetic regulation 
(DNA methylation and histone methylation) played a role in transcriptional control of Hoxa2 
in the developing embryo and whether VPA impacted Hoxa2 gene expression through 
epigenetic modulation. 
  
60 
 
CHAPTER 3: MATERIALS AND METHODS 
 
3.1  Chemicals 
     Valproic acid (2-propylpentanoic acid, P6273, ≥ 98% pure), L-ascorbic acid (sodium salt, 
A4034, ≥ 98% pure), L-buthionine-S, R-sulfoximine (BSO) and penicillin-streptomycin 
solutions (50 ×, Cat.#  P4458) were obtained from Sigma (St. Louis, MO,   USA). 2-
vinylpyridine (Cat.# 132292, 97% pure), metaphosphoric acid (M 6288, ≥ 33.5% pure) and 
triethanolamine (T1377, ≥ 98% pure) were obtained from Sigma-Aldrich Inc., (St. Louis, MO, 
USA). Isoflurane (100% v/v) was purchased from Baxter Corporation (CA2L9107, 100% 
pure, Toronto, ON, CAN). Minimal essential medium (MEM) with Earle’s salt was 
purchased from GIBCO (Cat.# 11095-080, NY, USA). 
3.2  Animals and preparation of culture serum 
     The University Committee on Animal Care and Supply at the University of Saskatchewan 
approved all animal protocols. Timed-pregnant CD-1 mice at gestation day (GD) 8 were 
obtained from the Animal Resources Center at the University of Saskatchewan. Female CD-1 
mice were mated overnight; mating was confirmed the following morning by the presence of 
a vaginal plug; this was considered gestation day GD 0. On GD 8.5, the pregnant dams were 
anesthetized with isoflurane and euthanized by cervical dislocation; uteri were then removed 
to prepare embryos for culture.  
     Retired male Sprague Dawley breeder rats weighing 400-450 g were used for serum 
preparation. The rats were anesthetized with isoflurane, and the serum was prepared from 
blood collected from the dorsal aorta of the animal.  After collection, the blood was 
centrifuged immediately at 2,000 rpm for 5 min to separate the cells from the plasma. A 
fibrin clot was formed during centrifugation, and serum was obtained by squeezing the clot, 
followed by a second round of centrifugation at 3,000 rpm for 10 min. The supernatant 
plasma was then isolated.  The serum was filtered using a 0.45 um filter, aliquoted and stored 
at -20 °C and used within two weeks.  On the day of culturing, the serum was heat-
inactivated at 56 °C for 30 min immediately prior to use (Zhang et al, 2010).  
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3.3  Mouse whole embryo culture and experimental design 
     Embryos were explanted and cultured as previously described (Freeman and Steele, 1986; 
New, 1978). After removal of deciduas and Reichert’s membrane, embryos with 6 to 8 
somites [E8.5], an intact visceral yolk sac and ectoplacental cone were placed randomly in 
sealed culture bottles (3 embryos/bottle) containing 4 mL culture medium (MEM culture 
media ratio to rat serum [1:3]). The culture media was supplemented at the initiation of 
culture with penicillin and streptomycin with final concentrations of 100 IU/mL and 100 
g/mL, respectively. Cultures were incubated at 37 °C in rolling culture bottles (rotation 
speed at 23 rpm) for 48 h. Culture bottles were saturated for 3 min on 3 occasions: initially 
with a gas mixture of 5% O2:5% CO2:90% N2; after 18 h with a gas mixture of 20% O2:5% 
CO2:75% N2; and after 25 h with a gas mixture of 40% O2:5% CO2:55% N2. Embryos were 
taken from different pregnant dams.  
3.4  VPA, L-Buthionine-sulfoximine (BSO) and antioxidant treatment in the mouse 
whole embryo culture 
     The culture media was supplemented at the initiation of culture with VPA completely 
dissolved in Hanks solution with final concentrations of 0, 50 g/mL [0.35 mM], 100 g/mL 
[0.7mM], 200 g/mL [1.4mM], or 400 g/mL [2.8mM]; and embryos (E8.5) were examined 
and evaluated after 48 h at E10.5 (Fig. 3.1). 
      In this earlier study on the toxicity-concentration relationship it was found that 400 
g/mL VPA produced maximal toxicity. Therefore, for the subsequent culture treatment of 
VPA in the presence of antioxidant, VPA was added at a concentration of 400 g/mL 1 h 
after starting the embryo cultures. In order to determine the effects of an antioxidant, 1000 
g/mL [5mM] L-ascorbic acid (St. Louis, MO, USA) was added to the media just prior to 
addition of VPA and embryos harvested at 48 h. Control for this experiment was treated with 
L-ascorbic acid without VPA. 
     To examine the effect of a decrease in GSH content on Hoxa2 gene expression in embryos, 
cultures were treated with BSO to block GSH synthesis. BSO dissolved in HBSS solution 
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was added to the culture media at a concentration of 225 g/mL [1 mM] from time 0, and 
embryos were collected after 48 h to measure the total GSH level.  
3.5  Morphological assessment 
     After 48 h of incubation, mouse embryos were harvested and examined under a dissecting 
microscope (Model 312684-122, Bausch & Lomb, Rochester, NY) for the presence of yolk 
sac circulation and heart beat (viability). The magnifications used to carry out morphological 
assessments were in the range of 2.5 × to 3.0 ×.  Only live embryos were further evaluated 
according to the morphologic scoring system of Van Maele-Fabry et al. (1990). Diameters of 
the yolk sac, crown-rump length and head length of each viable embryo were determined by 
ocular micrometer. Seventeen morphological items were assessed including yolk sac 
circulation, allantois, embryonic flexion, heart, neural tube, cerebral vesicles (forebrain, 
midbrain and hindbrain), otic, optic and olfactory vesicle, branchial arch, maxillary, mandible, 
limb buds (forelimb bud and hind limb bud), and somites. Morphological assessments were 
made by the observer who was blinded to each VPA treatment group.  
 
Fig. 3.1 Schematic diagram of procedures used in whole mouse embryo culture  
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3.6 Drug administration for animal in vivo study 
     Time pregnant CD-1 mice at E8 (30 – 40g) received a subcutaneous (s.c) injection of VPA 
at the dose of 400 mg/kg/day (Nau et al., 1981) or intraperitoneal (i.p) injection of ascorbic 
acid (vitamin C) at the dose of 250 mg/kg/day (Stojiljkovic, et al., 2010) followed by s.c 
injection of VPA. VPA and ascorbic acid were dissolved in saline and mice were 
administered VPA and/or ascorbic acid once daily in the morning (at 10 a.m.) at E8, E9 and 
E10, respectively. After 5-6 h following the last injection of VPA and/or ascorbic acid, E10.5 
embryos were dissected from the uteri for DNA, RNA and protein isolation or chromatin 
immunoprecipitation assay.  N=5-6 for each assay.  
3.7 Cell lines and culture conditions 
     The mouse embryonic fibroblast cell line NIH3T3 and mouse T lymphocyte cell line EG7 
were used for in vitro studies (NIH3T3 cell line (ATCC): A hypertriploid mouse cell line. 
The modal chromosome number was 68 occurring in 30% of cells. The rate of cells with 
higher ploidies was 2.4%; EG7 cell line (ATCC): E.G7-OVA derivative of EL4. The EL4 
cells were transfected by electroporation with the plasmid pAc-neo-OVA which carries a 
complete copy of chicken ovalbumin (OVA) mRNA and the neomycin (G418) resistance 
gene). NIH3T3 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Invitrogen) with 10% (v/v) bovine calf serum (BCS, Invitrogen). EG7 cells were cultured in 
DMEM containing 110 mg/L sodium pyruvate supplemented with 10% (v/v) fetal bovine 
serum (FBS, Invitrogen). All cultures contained 1% antibiotic-antimycotic solution (Ab/Am, 
Sigma) and were maintained at 37° C, 5% CO2 and 100% relative humidity. Cells were 
incubated with VPA for 24 h. EG7 cells were incubated with 5 -Aza for 48 h. NIH3T3 cell 
line was treated with VPA at the concentration of 0, 6.25 µg/mL [0.04 mM], 12.5 µg/mL 
[0.09 mM], 25 µg/mL [0.18 mM], 50 µg/mL [0.35 mM] or 100 µg/mL [0.70 mM], or BSO of 
10 µM. EG7 cells were treated with VPA at doses of 0, 20 µg/mL [0.14 mM], 40 µg/mL 
[0.28 mM], 80 µg/mL [0.56 mM], 100 µg/mL [0.70 mM] or 200 µg/mL [1.4 mM]. NIH3T3 
cells were treated with VPA (same doses as indicated above) or BSO (same doses as 
indicated above) in the presence of ascorbic acid at a concentration of 5 µg/mL [25 μM].  A 
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pre-trial with three ascorbic acid concentrations (5 µM, 25 µM and 100 µM) was used to treat 
NIH3T3 cells and 25 µM was identified as the highest dose that exhibited no cell death. EG7 
cells were incubated with 5-Aza at the concentration of 0, 0.23 µg/mL [1 µM], 0.46 µg/mL [2 
µM], 0.92 µg/mL [4 µM], 1.84 µg/mL [8 µM] or 2.3 µg/mL [10 µM], N=3-4. 
3.8 Glutathione assay 
     Embryos isolated were stored immediately on dry ice and kept at -80 C for analysis at a 
later time. Each individual embryo was analyzed. Embryos and NIH3T3 cells were 
homogenized respectively, in 200 L of cold PBS buffer (50 mM phosphate, 1 mM EDTA, 
pH 6.3); 20 L of the homogenized sample was removed for protein measurement using the 
Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA). The remainder of the 
sample was divided into two aliquots and immediately stored at -80 °C; one aliquot was used 
to measure total glutathione (GSSG+GSH) and the other for GSSG. Total glutathione and 
GSSG contents in embryos were measured spectrophotometrically by a Glutathione Assay 
Kit (Cayman Chemical Company, Ann Arbor, MI, USA). This kit utilized a carefully 
optimized enzymatic-recycling assay for the quantification of GSH based on glutathione 
reductase (Baker et al., 1990; Eyer and Podhradsky, 1986; Tietze, 1969). The sulfhydryl 
group of GSH reacts with DTNB (5,5’-dithiobis-2-nitrobenzoic acid) and produces a yellow-
colour 5-thio-2-nitrobenzoic acid (TNB). Quantification of GSSG, exclusive of GSH, was 
accomplished by first derivatizing GSH with 2-vinylpyridine (Griffith, 1980). GSH content 
was estimated by subtracting the amount of GSSG from the total glutathione. A standard 
curve with concentrations of 0 to16 µM of GSH and 0 to 8.0 µM of GSSG was run 
simultaneously with each set of sample, respectively.  
3.9 Isolation of DNA 
     Genomic DNA was isolated from cells and embryos using the PureLink genomic DNA 
kits (Invitrogen) according to manufacturer’s instructions. It yielded approximately 15-20 μg 
of DNA per embryo at E10.5 or 5 × 10
6
 starting cells. The samples were stored at -20 °C.
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3.10  Isolation of total RNA 
    Total RNA was prepared with TRI Reagent (Sigma, St. Louis, MO) or RNeasy mini kit 
(Qiagen). For embryos using TRI Reagent extraction, 10-20 mg tissues were placed in 1.5 
mL microcentrifuge tube with 250 µL of TRI Reagent and homogenized. The homogenate 
was stored for 15 min at room temperature, and extracted with 150 µL of 1-bromo-3-
chloropropane (BCP) (Sigma, St. Louis, MO). The aqueous phase was combined with an 
equal volume (150 µL) of isopropanol (EMD, Gibbstown, NJ) to precipitate total RNA. The 
precipitate was centrifuged to form a pellet, subsequently washed with 75% ethanol and air-
dried. The isolated total RNA was then re-dissolved in RNase free water (Sigma, St. Louis, 
MO).  
Total RNA isolation from cells or embryos using RNeasy mini kit (Qiagen) followed the 
manufacturer’s instruction. The kit yielded 10 μg of RNA per 1 × 106 starting cells, and ~ 20
μg of RNA per embryo between E8 to E10. The isolated total RNA was then dissolved in 
RNase free water. The purity of RNA was determined by the ratio of A260/A280 
spectrophotometrical reading. Total RNA concentration was determined at OD260 using an 
Ultraspec 3100 pro Spectrophotometer (Biochrom Ltd. Cambridge, England). RNA samples 
were stored at -80°C. For quantitative real time PCR, total RNA solutions were diluted to 
concentrations of 50 ng/µL. An aliquot of 1.6 L was taken for reverse transcription (RT) 
reaction. 
3.11  Reverse transcription PCR (RT-PCR) 
     RT-PCR was used to measure gene expression in NIH3T3 cells, EG7 cells and developing 
embryos. Total RNA was used as a template for the synthesis of cDNA using SuperScript 
cDNA kit (Invitrogen, Carlsbad, CA) according to manufacturer’s specification. Briefly, 80 
ng of total RNA was mixed with 4.0 l of 5 X first-strand reaction mix, 1.0 l of dNTP (10 
mM each), 2.0 l of 0.1 M DTT, 1.0 l of random primer (100 M) and 1 l of SuperScript 
II reverse transcriptase in a total volume of 20 l. Synthesis of cDNA was completed by 
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incubation at 65°C for 5 min, 37 °C for 2 min, and 25°C for 10 min followed by 50 min at 
37°C and 15 min at 85°C. Samples were stored at -20 °C or used immediately.  
     Polymerase chain reaction (PCR) was performed in a total volume of 50 l containing 1-2 
l of cDNA, 1X PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 0.5 M of each primer and 2.5 
units of Taq polymerase. The PCR program consisted of an initial step at 95°C for 2 min 
followed by 35 cycles of 95°C for 30 sec, annealing temperature (55°C-60°C depending on 
the primer), 72°C for 1 min and a final incubation of 72°C for 2 min.  
3.12  Chromatin immunoprecipitation (ChIP) 
Cells: ChIP experiments were carried out by using ChIP assay kit and protocol (Upstate). An 
aliquote of 135 µl of 37% formaldehyde (final 1% formaldehyde) was added to ~ 5×10
5
 cells
in a 100 mm culture dish containing 5 mL of growth media to crosslink protein and DNA at 
37 °C for 15 min. After three washes in cold PBS containing protease inhibitor (1mM 
PMSF/1ug/ml aprotinin/1ug/ml pepstatin), the cells were resuspended in 200 μl of SDS lysis 
buffer. The lysates were sonicated (40% output) for 10s on ice and sonication repeated 4 
times to obtain DNA in size range of 200 to 1000 bp. An aliquot (40 to 50 μl) of the 
sonicated lysate without the antibody was used as input DNA to quantitate the total amount 
of DNA present in different sample extracts before immunoprecipitation. The remaining 
sonicated lysate was diluted 10-fold in ChIP dilution buffer. The antibodies including anti-
H3K27me3 (Abcam), anti-H3K4me3 (Abcam), anti-Ezh2 (Evx-1, Santa Cruz) and anti-
Dnmt1 (Abcam) were used for immunoprecipitation at 4°C overnight. Immune complexes 
were then precipitated with protein A agarose provided in the kit, and washed sequentially 
with low salt, high salt immune complex wash, LiCl immune complex wash and TE buffer. 
The immune complex was then eluted from agarose beads with elution buffer (1% SDS, 
0.1M NaHCO3). At the end of the ChIP procedure, both the input DNA and the protein/DNA 
cross-linked chromatin complex immunoprecipitated with specific antibodies were reversed 
cross-linked with 5M NaCl at a final concentration of 200 mM at 65 °C for 8-12 h. Samples 
were then treated with proteinase K. Protein-free DNA was extracted in phenol/chloroform, 
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precipitated and washed in ethanol. The DNA extract was used for detection and 
quantification of regulator at Hoxa2 gene promoter region with real-time PCR. N=3-4. 
Tissue: About 10 mg of embryo tissue was used for this ChIP procedure. Tissue was first 
rinsed in cold PBS and cut into pieces. Tissue pieces were then incubated with 400 µl of PBS 
containing 1% formaldehyde at 37 °C for 15 min. After three washes with cold PBS 
containing protease inhibitors (1mM PMSF/1ug/ml aprotinin/1ug/ml pepstatin), tissue was 
homogenized in 200 to 400 µl of SDS lysis buffer. The ChIP procedure was then carried out 
by using the ChIP assay kit (Upstate) and protocol using the same procedures as described 
above for cells (Dong et al., 2008). N=3-4.     
     PCR primers for evaluating ChIP assays were designed to amplify 150-200 bp fragments 
from the region near the transcription start site at the Hoxa2 gene promoter.  For ChIP 
experiments, real-time PCR was performed in a final volume of 25 μl containing 50 ng of 
ChIP DNA or 50 ng of input DNA as template, 400 ng of each primer, and 12.5 μl of SYBR 
green PCR master mix (Applied Biosystems). The amplification consisted of 10 min at 95°C 
followed by 35 cycles of 95°C for 30 s, 60°C for 1min, and 72°C for 30 s in 7300 ABI 
detection system. The fold enrichment of each protein at the Hoxa2 gene promoter was 
determined by the 2
(-∆∆Ct)
 method described in the Applied Biosystems User Bulletin (ABI
PRISM 7700 Sequence Detection System, Applied Biosystems, 2001). Evaluations were 
determined from three independent ChIP assays, and each assay was evaluated in duplicate 
by real-time PCR (Fig. 3.2).  
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Fig. 3.2 Schematic diagram of ChIP assay 
3.13  Quantitative real time PCR analysis 
      Quantitative Real-time PCR with TaqMan primers (Applied Biosystems, Foster City, CA) 
was used to quantify Hoxa2. For relative quantification, the amplification was performed in a 
Cepheid Smart Cycler
®
 System (Roche Molecular System, Inc., Alameda, CA). Two L of
the RT reaction was amplified in a 20 µL PCR mixture, containing 1X Universal PCR master 
mix (Applied Biosystems, Foster City, CA) and 900 nM of PCR primers and probes designed 
by Applied Biosystems. The transcript of the -actin housekeeping gene was amplified as an 
endogenous control. Four samples were analyzed at each dose treatment group. The real-time 
PCR conditions were 50°C/2 min (for optimal AmpErase uracil-N-glycosylase [UNG] 
activity), 95°C/12 min followed by 95°C/15 sec and 60°C/1 min for 45 cycles. The Smart 
Cycler
®
 System established the threshold cycle (CT) values needed to reveal the minimal
amount of amplified material of the target transcript. The values of the total Hoxa2 and -
actin transcript were calculated with the averaged CT values of each sample, and extrapolated 
from standard curves. The normalized value of Hoxa2 was established by dividing the 
average Hoxa2 value with the average -actin value for each sample. For comparative 
quantitation of gene expression, real time RT-PCR was employed using TaqMan
®
 primers
and labeled probe system and the ABI 7300 (Applied Biosystems).  The reaction was 
Crosslinking of protein and DNA 
and shearing of DNA 
Immunoprecipitation with an 
antibody to the protein 
Reversal of crosslinking, purification of 
immunoprecipitated DNA  
qPCR detection with primers designed at 
the Hoxa2 gene promoter 
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performed using the TaqMan
®
 Universal Master Mix (2X), FAM-labeled TaqMan
®
 Gene
Expression assays for gene of interest (Hoxa2), VIC-labeled Taqman
®
 Endogenous Control
-actin, and 36 ng of cDNA.  All reactions were run in replicates of 4, and an n=3-4 was used 
for each group.  Thermocycling parameters were as follows: 2 min. at 50
o
C, 10 min. at 95
o
C,
40 cycles of 15s at 95
o
C followed by 70s at 60
o
C.
3.14 Western blot analysis of Hoxa2 protein 
     Protein from the cultured mouse embryos was extracted with 10 µL of 1% SDS and 5 µL 
of 2X loading buffer. Individual embryos were analyzed. The protein samples were then 
denatured at 90 °C for 10 min. A 12% SDS-PAGE gel was used to separate proteins 
according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA) with 50 g of total 
protein supernatant loaded onto the gel. The protein was transferred and immobilized onto a 
PVDF transfer membrane (PolyScreen, PerkinElmer, Boston, MA) using Xcell II Blot 
Module (Invitrogen, Carlsbad, CA) for wet transfer in 1 X transfer buffer containing 12 mM 
Tris, 96 mM glycine and 20% methanol, for 2 h at 30V/200 mAmp. Blocking of the 
membrane was carried out in 3% skim milk (in PBS) at 4 °C overnight. For detection of the 
Hoxa2 protein, the membrane was incubated for 2 h at 4 °C with the rabbit anti-Hoxa2 
antiserum (Hao et al., 1999) at a dilution of 1:5000 in 3% skim milk. The membrane was then 
washed 3 x 20 min with 0.08% Tween-20 in PBS (Sigma, St. Louis, MO) and incubated for 2 
h at room temperature with horse radish peroxidase (HRP) conjugated secondary goat anti-
rabbit IgG (Bio-Rad, Hercules, CA), diluted 1:3000 in 3% skim milk. After visualization of 
Hoxa2 protein, the membrane was again blocked in 3% skim milk at 4 °C overnight for 
detection of the beta-actin protein. A 1:800 dilution of the mouse anti-actin (JLA20 
monoclonal antibody, Developmental Studies Hybridoma Bank, Iowa City, IA) in 3% skim 
milk was used as the primary antibody. The membrane was incubated for 1 h at room 
temperature. After washing for 3 x 20 min with 0.08% Tween-20 in PBS, a 1:3000 dilution of 
HRP conjugated goat anti-mouse IgM was used as the secondary antibody, then the 
membrane washed 3 x 20 min in 0.08% Tween-20 in PBS. Visualization of proteins was 
performed by a Western Lightening Kit (PerkinElmer Life Sciences, Inc., Boston, MA) as per 
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manufacture’s instructions, followed by exposure of the membrane to Kodak Scientific 
Imaging Film (X-OMAT Blue XB-1, Kodak, Rochester, NY) for 3 to 10 sec. Two replicates 
were run for each sample, and 8 samples were run in total for each dose of VPA.  
3.15 DNA methylation analysis 
3.15.1 Sodium bisulfite modification 
     Genomic DNA was modified with bisulfite reagent for DNA methylation analysis by 
using the EpiTect bisulfite kit (Qiagen) or EZ DNA methylation kit (Zymo Research, USA). 
Genomic DNA (2 μg) was modified per sample according to the manufacturer’s instructions. 
The concentration and purity of bisulfite treated DNA samples were determined by NanoVue 
UV/visible Spectrophotometer (GE Healthcare Life Sciences). Bisulfite treated DNA samples 
were stored at -20°C.  
3.15.2. Bisulfite specific PCR (BSP) and methylation specific PCR (MSP) 
     DNA methylation within promoter associated CpG islands was determined by BSP 
sequencing after sodium bisulfite modification of genomic DNA as described above (Fig. 
3.3). BSP primers were designed using the online ‘MethPrimer’ 
(http://www.urogene.org//methprimer/) (Li and Dahiya, 2002). For BSP sequencing, three 
sets of primers were designed within 1688 bp region near the transcription start site at the 
Hoxa2 gene promoter. PCR was carried out in a final volume of 50 μl containing 100-200 ng 
of bisulfite-modified DNA, 1 × HotStar Taq master mix, 2.5 mM MgCl2, 200 μM of each 
dNTP, 500 nM of each primer, and 2.5 units of HotStar Taq DNA polymerase (Qiagen). The 
amplification consisted of a Taq activation step at 95°C for 15 min, 35 cycles of 94°C for 
1min, 55°C for 1min, and 72°C for 2 min, and a final incubation at 72°C for 10 min. Mouse 
embryos were from E6.5, E8.5 and E10.5. E6.5 mouse embryos were taken with 
ectoplacental cone.  
     MSP primers also designed using online ‘MethPrimer’ software (Li and Dahiya, 2002). 
PCR amplification conditions were the same as described above for BSP.  
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3.15.3 Sub-cloning and sequencing 
     Bisulfite PCR products were subcloned into pGEM-T easy vector (Promega) according to 
manufacturer’s protocol. Two clones were randomly selected on each plate. The clones were 
purified with PureLink HQ mini plasmid DNA purification kit (Invitrogen). The purified 
DNA was sent for sequencing using the vector primer M13F or M13R.  
     For sequencing DNA samples isolated from drug treated cells and embryos, the bisulfite 
primers near the transcription start site (Bsp_kx5 and kx6) were used to generate PCR 
products. The PCR products were confirmed by visualizing following agarose gel 
electrophoresis (1.5% agarose gel). Samples were then purified with PCR purification kit 
(Qiagen) and sent to National Research Council laboratories, Saskatoon, SK for DNA 
sequencing. Modified EG7 DNA served as the methylated positive control while modified 
NIH3T3 DNA served as the unmethylated positive control. (However, neither 5-mC nor 5-
hmC undergo C-to-T transitions after bisulfite treatment) (Huang, et al., 2010).  
 
 
 
 
 
 
 
 
 
Fig. 3.3 Bisulfite determination of DNA methylation 
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3.16 Determining DNA methylation using Pyrosequencing assay 
     Pyrosequencing is a real-time sequencing that allows us to quantify methylation at 
multiple CpG sites individually (Colella et al., 2003; Rietschel et al., 2008; Ronaghi, 2003). 
Genomic DNA was extracted from NIH3T3 cells or mouse embryos using DNeasy Blood & 
Tissue Kit (Qiagen). DNA sample (200 ng to 2 µg) was bisulfite treated using Zymo DNA 
Methylation Kit (Zymo research, Orange, CA). The bisulfite treated DNA was eluted in 10 µl 
volume and used for PCR amplification with the primers designed and supplied by EpigenDx 
(Worcester, MA). The PCR was performed in a PCR reaction mix containing 1 µl of 
bisulfite-converted DNA sample or internal controls, 10 × PCR buffer, 3.0 mM MgCl2, 200 
µM of each dNTP, 0.2 µM forward primer, 0.02 µM reverse primer tailed, 0.18 µM universal 
primer, and 0.75 U of HotStar DNA polymerase (Qiagen Inc, Valencia, CA).  The PCR 
conditions were as follows: 15 min at 95 °C, 35 cycles of 30s at 95 °C, 30s at 55 °C, and 30s 
at 72 °C, followed by a final extension step for 5 min at 72 °C. Samples subsequently were 
sent to EpigenDx for commercial pyrosequencing. The PCR products (each 10 µl) were 
sequenced by Pyrosequencing
 
PSQ96 HS System (Qiagen Pyrosequencing) following the 
manufacturer’s instructions (Qiagen Pyrosequencing).  The methylation status of each locus 
was analyzed individually by EpigenDx as a T/C SNP using QCpG software (Qiagen 
Pyrosequencing). The extent of methylation at each CpG site was automatically calculated 
and is sensitive enough to detect 5% changes in methylation levels (EpigenDx) n=3. 
3.17  Quantitative telomerase activity assay 
     The assay was performed using Quantitative Telomerase Detection Kit (Allied Biotech, 
Inc) which is determined through its ability to synthesize telomeric repeats onto an 
oligonucleotide substrate. The resultant extended product is subsequently amplified by SYBR 
real-time PCR. NIH3T3 cells (10
5
-10
6
 cells) or mouse embryos (40 to 100 mg) were 
homogenized and incubated in 200 µl 1 X lysis buffer (added with protease inhibitor) on ice 
for 30 min. The lysate were then centrifuged at 10,000 x g for 15 min at 4 °C. The 
supernatant was removed and stored at -80 °C until use. The protein concentration was 
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determined with Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA). For each 
assay the samples were diluted to 0.5 µg/uL. The PCR reaction mix contains 1 µl of diluted 
sample and 1x Quantitative Telomerase Premix. The telomerase reaction was carried out at 
25 °C for 30 min. followed by PCR conditions: 10 min at 95 °C, 40 cycles of 30s at 95 °C, 
35s at 60 °C and 30s at 72 °C. A standard curve was generated from dilutions of TSR control 
which is an oligonucleotide with a sequence similar to telomerase extended product (TSR is 
ratio of telomere repeat copy number to single gene copy number). The amount of the 
telomerase extended product of each sample was extrapolated from the standard curve. The 
relative value for each sample was established by dividing with the control value, 
representing the relative activity of telomerase of each sample. 
3.18  Telomere length measurement by real-time PCR 
     Genomic DNA was extracted from NIH3T3 cells and mouse embryos using DNeasy 
Blood & Tissue Kit (Qiagen). Relative average telomere length was assessed by a modified 
version of real-time PCR-based method, in which the telomere repeat copy number to single 
gene copy number (β-globin) ratio (T/S) was determined (Cawthon, 2002; McGrath et al., 
2007). Both telomere and β-globin PCR reaction mixture consisted of 1x SYBR green master 
mix (Qiagen) and 5 ng genomic DNA. For telomere PCR reaction contained 100 nM of 
telomere forward primer and 900 nM of telomere reverse primer. PCR reaction proceeded at 
95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s, and 54 °C for 1 min. β-globin PCR 
reaction contained 300 nM of globin forward primer and 700 nM of globin reverse primer. 
The reaction proceeded at 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s, 58 °C 
for 20 s, and 72 °C for 28 s. In addition to the samples, a standard curve from 0.0625 ng to 
12.5 ng using genomic DNA was generated to assess the PCR efficiency. The slope of the 
standard curve for both the telomere and β -globin reactions ranged from -3.30 to -3.70. The 
T/S ratio (-dCt) for each sample was calculated by subtracting the β -globin Ct value from the 
telomere Ct value. The relative T/S ratio (-ddCt) was determined by subtracting the T/S ratio 
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of the 5 ng standard curve point from the T/S ratio previously calculated from each sample 
(Cawthon, 2002; McGrath et al., 2007). 
3.19 Statistical analysis 
     All statistical analyses concerning morphologic scoring parameters, embryonic growth 
parameters, glutathione status, Hoxa2 gene expression at mRNA level, ChIP real-time PCR 
results, pyrosequencing analysis of DNA methylation, telomere length and telomerase 
activity in treatment and control groups were compared using one-way ANOVA with 
Tukey’s HSD (Honestly Significant Differences) as the post-hoc test, or were analyzed by 
independent-samples t test to compare. A probability of less than 0.05 was assumed to denote 
significant difference. The incidence of the embryonic malformation in treatment and control 
groups was compared using chi-square (x
2
)
 
test. The level of significance was P≤0.05.  
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Table 3.1 Sequences of primers used in this study 
Name 
 
Sequence 
 
Hoxa2 gene 
Forward: 5’ CTGGATGAAGGAGAAGAAGGC 
Reverse: 5’ CGGTTCTGAAACCACACTTTC 
 
GAPDH gene 
Forward: 5’ ACCACAGTCCATGCCATCAC 
Reverse: 5’ TCCACCACCCTGTTGCTGTA 
 
 
ChIP-PCR primers at 
Hoxa2 gene promoter 
 
Fragment 1: 
Forward: 5’ GTTGTCTTTTGAATCCTTCAGCC (A2-1)  
Reverse: 5’ GGCACTCTGGGTTTCATACC (A2-2) 
Fragment 2: 
Forward: 5’ TATGAATCGGTTCTGAGAACTG (A2-3)  
Reverse: 5’ GCCACTGTCTGTTTGATTGATCC (A2-4)  
 
ChIP quantitative  
real-time PCR 
(both for H3K4me3 and 
H3K27me3) 
Forward: 5’ CCAGGGAGCACACTAGATCC (Klx 3) 
Reverse: 5’ AGTCAGAAAGGAACGCCTCA (Klx 3-1) 
 
 
 
Bisulfite specific PCR 
 
Bsp_kx1: 5’ GGAAAGAGGGATTAAGAAATAAGAGTT 
Bsp_kx2: 5’ ACATATACCAAAAAAAACAACAACC 
Bsp_kx3: 5’ GGTTGTTGTTTTTTTTGGTATATGT 
Bsp_kx4: 5’ TCCAAAATCAATTCTCAAAAC 
Bsp_kx5: 5’ GTTAGGTTGAGGTGTTTAAAT 
Bsp_kx6: 5’ ACCACTATCTATTTAATTAATCC 
 
 
 
 
 
 
Methylation specific PCR 
 
 
 
 
 
Msp-kx1-MF: 5’ TTTTTGGAAGTCGGAAATATTTATC 
Msp-kx1-MR: 5’ AATCCCCGTAACCTAAACGAC 
Msp-kx1-UF: 5’ TTTTGGAAGTTGGAAATATTTATTGT 
Msp-kx1-UR: 5’ CAAATCCCCATAACCTAAACAAC 
Msp-kx2-MF: 5’ TAGTTATTTTTGAGAAGTTGATGGC 
Msp-kx2-MR: 5’ TATCCAACCCGAAACCTACG 
Msp-kx2-UF: 5’ GTTATTTTTGAGAAGTTGATGGTGA 
Msp-kx2-UR: 5’ TTAATATCCAACCCAAAACCTACAC 
Msp-kx3-MF: 5’ TTTTCGATAGTTTTAAATAATGCGC 
Msp-kx3-MR: 5’ TAAATAACAATACCCCGAAAATACG 
 
Sequence 
 Msp-kx3-UF: 5’ TTTGATAGTTTTAAATAATGTGTGG 
Msp-kx3-UR: 5’ AATAACAATACCCCAAAAATACATA 
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CHAPTER 4: RESULTS 
4.1  VPA-induced dysmorphogenesis in mouse embryo  
4.1.1  Effect of VPA on embryonic differentiation and growth 
     To investigate the pattern of VPA-induced teratogenesis, E8.5 CD-1 mouse embryos with 
6-8 somites were exposed to 0, 50, 100, 200, and 400 µg/mL VPA in vitro for 48 h. We 
observed a dose-dependent decrease in various parameters of embryonic growth (Table 4.1.1) 
and morphological score (Table 4.1.2), and an increase in the frequency of embryonic 
malformations (Table 4.1.3). Embryos exposed to 50 µg/mL VPA showed obvious inhibition 
of embryonic head development. At VPA concentrations ≥200 µg/mL, overall embryonic 
growth was affected, as represented by reduced yolk sac diameter, crown-rump length, head 
length, and decreased number of somites (Table 4.1.1).  
     As for embryonic differentiation, total morphological score (Table 4.1.2) decreased 
significantly at a VPA concentration of 50µg/mL, as did scoring parameters such as yolk sac 
circulation, allantois, caudal neural tube, hindbrain, forebrain, and branchial arch. At VPA 
concentrations ≥200 µg/mL, almost all scoring parameters except hind limb notably 
decreased (Table 4.1.2).  
     VPA concentrations of 50, 100, 200, and 400µg/mL increased the incidence of abnormal 
embryos by 11.8%, 35.3%, 47.1% and 88.2%, respectively (Table 4.1.3). VPA concentrations 
≥200 µg/mL caused an obvious increase in the incidence of dead embryos. Embryo 
malformations included neural tube defects (NTDs), abnormal flexion, yolk sac circulation 
defects, somite defects, and craniofacial deformities such as fusion of maxillary and 
mandibular branchial arches (Fig. 4.1.1).  
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Fig. 4.1.1 Embryos treated with VPA. Control (A), 50 µg/mL (B, E), and 200 µg/mL (C, D). 
The types of malformations observed included open neural tube (B, C and E), somite defects 
(C), and craniofacial malformations such as fusion of first and second arch (C, D). D is the 
same embryo as C magnified to show the fusion of the first and second arches (arrow). E, 
Dorsal view of the embryo in (B), arrows exhibiting an open neural tube. 
Table 4.1.1 Effect of VPA on mouse embryonic growth in vitro (Mean± SD) 
Parameter Concentrations of VPA (µg/mL) 
0 (n=17) 50.0 
(n=17) 
100.0 
(n=17) 
200.0 
(n=15) 
400.0 
(n=15) 
Yolk sac diameter 
(mm) 
Crown-rump length 
(mm) 
Head-length (mm) 
Somite number 
4.70±0.37 
4.27±0.33 
2.53±0.57 
31.3±1.41 
4.26±0.20 
4.04±0.23 
2.17±0.12
a
29.76±1.39 
4.15±0.36
a
3.96±0.29 
2.09±0.35
a
28.11±2.11 
4.01±0.41
a
3.50±0.25
a
1.70±0.27
b
25.0±2.36
a
3.83±0.37
b
2.56±0.15
b
1.28±0.29
b
22.5±2.77
a
a: p ≤ 0.05 vs. control 
b: p ≤  0.01 vs. control 
78 
 
Table 4.1.2 Effect of VPA on mouse embryonic differentiation in vitro (Mean± SD) 
Morphologica
l score
* 
Concentrations of VPA (µg/mL) 
 
0.0 
(n=17) 
 
50.0 
(n=17) 
 
100.0 (n=17) 
 
200.0 (n=15) 
 
400.0 
(n=15) 
Yolk sac 
circulation 
4.58±0.50 3.76±0.43
a
 3.35±0.49
a
 2.67±0.62
b
 1.86±0.35
b
 
Allantois 3.88±0.33 2.76±0.43
a
 2.59±0.50
a
 2.13±0.52
b
 2.06±0.26
b
 
Flexion 5.00±0.00 4.76±0.42 4.44±0.78 3.06±0.95
a
 3.06±0.25
a
 
Heart 4.35±0.60 3.94±0.42 3.64±0.60
a
 2.71±0.46
b
 2.13±0.35
b
 
Candal neural 
tube 
5.00±0.00 4.53±0.51
a
 3.73±1.25
b
 1.80±0.94
b
 1.33±0.48
b
 
Hindbrain 4.88±0.33 4.29±0.58
a
 3.29±0.97
a
 2.00±0.77
b
 1.80±0.41
b
 
Midbrain 5.00±0.00 4.53±0.51 3.29±0.77
b
 2.40±0.63
b
 1.80±0.41
b
 
Forebrain 5.11±0.33 4.53±0.51
a
 3.29±0.84
b
 2.60±0.73
b
 1.20±0.56
b
 
Otic system 5.23±0.43 4.71±0.46 4.00±0.50
a
 3.20±0.41
b
 1.53±0.51
b
 
Optic system 4.59±0.51 4.47±0.51 4.05±0.42 2.47±0.63
a
 1.86±0.83
b
 
Olfactory 
system 
3.00±0.00 2.76±0.41 2.711±0.33 2.66±0.48
a
 2.07±0.26
b
 
Branchial bar 3.54±0.62 2.82±0.39
a
 2.71±0.46
a
 2.60±0.50
b
 2.00±0.00
b
 
Maxillary 
process 
3.00±0.00 2.76±0.41 2.59±0.50 2.53±0.51
a
 2.06±0.26
a
 
Mandibular 
process 
3.35±0.49 3.23±0.43 3.14±0.78 2.27±0.45
b
 2.06±0.26
b
 
Fore limb 3.00±0.00 2.71±0.46 2.62±0.39 2.33±0.48
a
 2.13±0.35
a
 
Hind limb 1.06±0.24 0.76±0.43 0.64±0.49 0.60±0.50 0.33±0.48
a
 
Somites 
(score) 
5.00±0.00 5.00±0.00 4.88±0.33 4.33±0.48
a
 3.80±0.56
b
 
Total score 68.29±2.51 62.53±1.81
a
 
54.94±5.72
a
 42.00±4.09
b
 33.07±2.77
b
 
*as per Van Maele-Fabry et al. (1990) 
a: p ≤ 0.05 vs. control 
b: p ≤ 0.01 vs. control 
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Table 4.1.3 Incidence of dysmorphogenesis in mouse embryos in vitro 
a: p ≤ 0.05 vs. control; b: p ≤ 0.01 vs. control 
 
4.1.2  Effect of ascorbic acid on developing embryos treated with VPA 
     Mouse whole embryo cultures treated with VPA (100 µg/mL) exhibited abnormal 
differentiation in areas such as the hindbrain, midbrain, forebrain and the optic system (time- 
pregnant mice were administered a dose of VPA (100 µg/ml, s.c) at E8.5 and embryos 
harvested for culture after 48 h). There was a significant decrease in the morphological score 
(Van Maele-Fabry et al., 1990) of hindbrain, midbrain and forebrain in VPA treated embryos 
compared to untreated cultured embryos. Exposure to VPA (100 µg/mL) also induced 
embryonic malformations in 6 out 17 embryos with incidence rate of 35.3%.  Exposure to 
ascorbic acid (5 mM, 1000 µg/mL) alone had no significant effect on embryonic growth 
whereas co-treatment with ascorbic acid significantly reduced the impact of VPA on the 
developing mouse brain (Table 4.1.4).   Interestingly, treatment with ascorbic acid decreased 
the incidence of malformed embryos following VPA exposure (Table 4.1.5).  
  
 Concentrations of VPA (µg/mL)  
0.0 50.0 100.0 200.0 400.0 
Embryos, n 
Normal form, n 
Malformations, n (%) 
Death, n (%) 
17 
17 
0 
0 
17 
15 
2 (11.76) 
a
 
0 
17 
11 
6 (35.3) 
a
 
0 
17 
7 
8 (47.1) 
b
 
2 (11.76) 
a
 
17 
0 
15 (88.2) 
b
 
2 (11.76) 
a
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Table 4.1.4 Ascorbic acid protects embryos from abnormal brain differentiation 
Morphological 
Score 
VPA (µg/mL) 
Ascorbic 
acid 
VPA (100 
µg/ml) 
+ Ascorbic acid      
0 
 (n=17) 
100 
(n=17) 
1000 µg/ml 
 (n=17) 
1000 µg/ml 
(n=15) 
Hindbrain 
Midbrain 
Forebrain 
Optic system 
4.88±0.33 
5.00±0.00 
5.11±0.33 
4.59±0.51 
3.29±0.97
a
3.29±0.77
b
3.29±0.84
b
4.05±0.42 
4.69±0.34 
4.92±0.10 
4.97±0.13 
4.72±0.10 
4.43±0.12 
4.67±0.29 
4.83±0.58 
4.67±0.29 
(
a
, p < 0.05; 
b
, p < 0.01 compared to control)
Table 4.1.5 Ascorbic acid reduces the incidence of malformations induced by VPA    
VPA (µg/mL) Ascorbic 
acid 
VPA (100 
µg/ml) 
+ Ascorbic acid      
0 
 (n=17) 
100 
(n=17) 
1000 µg/ml 
 (n=4) 
1000 µg/ml 
(n=15) 
Embryos (n) 
Normal form (n) 
Malformations 
(n, %) 
17 
17 
0 
17 
11 
6 (35.3%) 
4 
4 
0 
18 
18 
0 
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4.1.3  Effect of VPA on mouse embryonic oxidative status  
     The oxidative status of cultured mice embryos was assessed by determining total 
glutathione and the GSSG/GSH ratio after exposure to 0, 50, 100, 200, and 400 g/mL VPA. 
A significant decrease in total glutathione in embryos only occurred at a VPA dose of 400 
g/mL; a decreasing trend was evident as VPA doses increased from 0 to 400 g/mL (Fig. 
4.1.2a).  The oxidative status of mice embryos using the GSSG/GSH ratio was also evaluated 
as this method accounts for possible compensatory increases in glutathione biosynthesis that 
may occur in response to redox changes (Ozolinš and Hales, 1997). A dose-dependent 
increase in embryonic GSSG/GSH ratio was observed; the GSSG/GSH ratio was 
significantly affected at VPA exposure doses ≥100 μg/mL (Fig. 4.1.2b). 
 
Fig. 4.1.2 Effect of VPA on total glutathione content (A) and on GSSG/GSH ratio (B) in 
mice embryos in vitro (n=8). GSSG glutathione disulfide, GSH reduced glutathione. * p ≤ 
0.05 and **  p ≤ 0.01 between bars indicated by brackets            
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4.1.4  Effect of VPA on Hoxa2 gene expression in mice embryos 
     The level of Hoxa2 gene expression in embryos in culture was measured at the protein 
level by Western blot analysis (Fig. 4.1.3) and at the gene expression level by quantitative 
real-time RT-PCR (Table 4.1.6). Western blot results show that VPA causes a dose-
dependent decrease in Hoxa2 protein expression in developing mice embryos in culture. A 
dose-dependent decrease in Hoxa2 mRNA expression was also observed. Total Hoxa2 
mRNA content in embryos and Hoxa2 gene expression normalized to β-actin decreased with 
increasing exposure to VPA. Significant decreases in Hoxa2 gene expression occurred in 
every experimental group (VPA  50 µg/mL) after VPA exposure.  
 
Fig. 4.1.3 Western blot analysis of Hoxa2 in embryos treated with VPA. 
Lane 1: untreated control embryos; Lanes 2-5: embryos treated with dose of 50 µg/mL [0.35 
mM], 100 µg/mL [0.7 mM], 200 µg/mL [1.4 mM] and 400 µg/mL [2.8 mM] VPA, 
respectively.    
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Table 4.1.6 Effect of VPA on Hoxa2 gene expression in cultured mice embryos 
(Mean ± SD), n=4 
Concentrations of 
VPA (µg/mL) 
Hoxa2  
ng Total RNA 
β-actin  
ng Total RNA 
Hoxa2 normalized 
to β-actin 
0  3.55±0.66 1.61±0.35 2.20±0.09 
50 1.17±0.30
a
1.37±0.79 0.85±0.14
 a
100 1.11±0.78
a
1.73±0.10 0.64±0.19
 b
200 0.82±0.30
b
1.79±0.29 0.46±0.04
 b
400 0.04±0.02
b
1.57±0.38 0.03±0.03
 b
a: p≤0.05 vs. control 
b
: p≤0.01 vs. control
4.1.5  Antioxidant status of Hoxa2-/- embryos and wild-type embryos treated with BSO 
To determine if a relationship exists between GSH content and Hoxa2 gene expression, 
BSO (Buthionine sulphoximine) was added to mouse embryo cultures (starting at E8.5 for 
48h to E10.5) to block the biosynthesis of glutathione. However, results indicate that BSO 
was unable to significantly reduce GSH content or to cause an increase in the GSSG/GSH 
ratio in cultured wild-type mice embryos (Fig.4.1.4).  The antioxidant status of untreated 
Hoxa2-/- embryos at E10.5 was also investigated. Significant changes in GSH content or in 
GSSG/GSH ratio were not observed in the Hoxa2-/- mice embryos compared to matched 
control or BSO treated wild-type embryos (Fig. 4.1.4). Results indicate embryonic 
antioxidant status does not change with loss of Hoxa2 gene function.  
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Fig. 4.1.4 GSH content (A) and GSSG:GSH ratio (B) in control untreated wild-type mice 
embryos in culture (control), wild-type embryos treated with BSO at a concentration of 225 
g/mL (1 mM) for 48 h in culture (BSO), and in Hoxa2 -/- mice embryos (E10.5) (n=4-5 
embryos). Bars represents mean ± SD.  
 
4.1.6  Ascorbic acid maintains glutathione homeostasis in VPA-treated NIH3T3 cells 
and in VPA-treated embryos 
     To determine the effect of ascorbic acid (5g/mL, 25 M) on glutathione homeostasis, 
NIH3T3 fibroblast cells (1×10
5
 cells/cm
2
) were treated with VPA at doses of 6.25 g/mL to 
100 g/mL for 24 h. The total glutathione content in VPA treated cultures at doses of 6.25 
g/mL to 50 g/mL did not change from control untreated cells. However, a significant 
decrease in total glutathione occurred at VPA dose of 100 g/mL; a decreasing trend was 
evident as VPA doses increased from 25 to 100 g/mL (Fig. 4.1.5). The presence of 5 g/mL 
[25 M] ascorbic acid reversed the decline in total glutathione content (Fig. 4.1.5) in cells 
treated with VPA at 12.5 g/mL and 25 g/mL, however supplemental ascorbic acid had no 
effect at the highest VPA doses of 50 g/mL and 100 g/mL.  
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     The effect of ascorbic acid on glutathione level and GSSG/GSH ratios in developing mice 
embryos in culture was also investigated.  Embryos in culture were treated with L-ascorbic 
acid 1000 g/mL [5 mM] just prior to exposure to the highest dose of VPA (400 µg/ml) and 
embryos harvested after 48 h. Pilot experiments with 400 g/mL [2 mM] VPA and 1000 
g/ml [5 mM] ascorbic acid revealed 1000 g/ml to be optimal for embryo protection. 
Results indicate that ascorbic acid was able to counter effects of VPA and reversed the 
depletion of total glutathione (Fig. 4.1.6a) and normalized the GSSG/GSH ratio in cultured 
embryos (Fig. 4.1.6b). Ascorbic acid alone had no significant effect on total glutathione 
levels in cultured embryos (Fig. 4.1.6a) but did have an inhibitory effect on the GSSG/GSH 
ratio (Fig. 4.1.6b) indicating its potent antioxidant property. 
 
 Fig. 4.1.5 Total glutathione in NIH3T3 cell cultures treated with VPA (6.25 to 100 g/mL) 
[0.04 to 0.70 mM] and VPA in the presence of 5 g/mL [25 M] ascorbic acid for 24 h (A). 
Cells were harvested at 5×10
5
 cells/cm
2
. Bars represents mean ± SD.  * represents a 
significance p ≤ 0.05 and ** represents a significance p ≤ 0.01 between bars indicated by 
brackets. GSH: reduced glutathione. Statistical analysis: one-way ANOVA with Tukey’s 
HSD as post-hoc analysis N=3-4.  
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Fig. 4.1.6 Effect of ascorbic acid on total glutathione content (A) and on GSSG/GSH ratio (B) 
in cultured embryos treated with VPA. Control: AA, treated with 1000 μg/mL [5 mM] L-
ascorbic acid; VPA, treated with 400 μg/mL [2.8 mM] of valproic acid; VPA+AA, treated 
with 1000 μg/mL L-ascorbic acid prior to addition of 400 μg/mL of valproic acid. Embryos 
were cultured for 48 h. Bars represents mean ± SD, n = 4-5.  * represents a significance p ≤ 
0.05 and ** represents a significance p ≤ 0.01 between bars indicated by brackets. GSSG: 
glutathione disulfide, GSH: reduced glutathione 
 
4.1.7  Ascorbic acid prevents the VPA-induced inhibition of Hoxa2 
     In a separate set of mouse embryo cultures, the effect of ascorbic acid on VPA-induced 
inhibition of Hoxa2 was measured using quantitative real-time RT-PCR. Mouse embryos in 
culture were pretreated with L-ascorbic acid 1000 μg/mL just prior to exposure to the highest 
dose of VPA (400 µg/ml) and embryos harvested 48 h later for analysis. Results indicate that 
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the relative quantity of Hoxa2 gene expression was significantly decreased after VPA 
exposure but that this inhibition was prevented from occurring after pretreatment with 
ascorbic acid, with Hoxa2 levels remaining higher than both control and VPA-treated 
embryos (Fig. 4.1.7a). Western blot analysis for protein expression also showed similar 
results (Fig. 4.1.7b). VPA-induced inhibition of Hoxa2 is downstream from VPA-induced 
oxidative stress since Hoxa2 null mice did not exhibit a change in total glutathione levels 
compared to wild-type embryos (Fig. 4.1.4a). 
 
 
Fig. 4.1.7 Relative quantitative expression of Hoxa2 in cultured mouse embryos as 
determined by quantitative real-time RT-PCR using TaqMan primers and probes (A). 
Western blot analysis of Hoxa2 protein in cultured embryos (B). Control; AA, treated with 
1000 µg/mL [5 mM] L-ascorbic acid; VPA, treated with 400 µg/mL [2.8 mM] of valproic 
acid; VPA + AA, pretreated with 1000 µg/mL L-ascorbic acid prior to addition of 400 µg/ml 
of valproic acid. Embryos were cultured for 48 h. Bars represents mean ± SD, N = 3–4. ** 
Represents a significance P < 0.01 between bars indicated by brackets. 
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4.1.8  Effect of VPA on telomerase activity and telomere length in vitro and in vivo 
     Since it is known that telomerase activity is impacted by oxidative stress (Borras et al, 
2004), we then determined the telomerase activity in VPA treated samples (NIH3T3 
fibroblast cells and mouse embryos). A real-time PCR based quantitative telomerase 
detection kit (Allied Biotech, Inc.) was used to measure telomerase activity. Values for 1/Ct 
(Ct: real-time PCR cycle threshold) obtained are directly proportional to telomerase activity, 
hence an increase in 1/Ct corresponds to an increase in telomerase activity (Wege, 2003; 
Lanca, 2009).  NIH3T3 cells (5 x 10
4
 cells/cm
2
) treated with VPA (6.25 to 100 µg/mL) for
24h showed no difference in telomerase activity compared to respective untreated control or 
to cells pre-treated with ascorbic acid (5g/mL) (Fig. 4.1.8a).   
In time-pregnant mice administered 400mg/Kg VPA, s.c once daily at E8, E9 and E10, and 
embryos harvested at E10.5 for analyses there was a significant decrease in 1/Ct value 
indicating a decrease in telomerase activity (Fig.4.1.8b). Time-pregnant mice pretreated with 
L-ascorbic acid 250mg/Kg, i.p. just prior to administration of VPA (400 mg/Kg, s.c. at E8, 
E9 and E10 and embryos harvested after E10.5) also exhibited a significant decrease in 1/Ct 
values indicating a significant decrease in telomerase activity. Thus, the inhibitory effect of 
VPA on telomerase activity appeared to be augmented by ascorbic acid.   
Administration of ascorbic acid alone (i.p. injected with L-ascorbic acid 250 mg/kg/day) did 
not significantly change telomerase activity compared to untreated wild-type control embryos 
(Fig.4.1.8b).  
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Fig.4.1.8 (a) Effect of VPA and ascorbic acid on telomerase activity (1/Ct) in protein extracts 
from NIH3T3 cells (1×10
5
 cells/cm
2
); (b) Effect of VPA and ascorbic acid on telomerase
activity in developing embryos. NIH3T3 cells were treated with 0 to 100 µg/mL VPA alone, 
or pretreated with 5 µg/mL ascorbic acid followed by 0 to 100 µg/mL VPA for 24 h. Time-
pregnant CD-1 mice (beginning at E8 till E10) received once daily s.c. dose of 400mg/Kg 
VPA, or i.p. dose of ascorbic acid (250 mg/Kg), or i.p. dose of ascorbic acid followed by the 
daily s.c dose of VPA at E8.0 to E10. After 6h following the last administration of VPA, 
E10.5 embryos were dissected from the uteri for further analyses. 1/Ct was used as Y-axis to 
represent telomerase activity. Bars represents mean ± SD.  * represents a significance p ≤ 
0.05 and ** represents a significance p ≤ 0.01 between bars indicated by brackets. Statistical 
analysis: one-way ANOVA with Tukey’s HSD as post-hoc analysis (*, p<0.05, **, p<0.01 
compared to untreated control cultures) N=3-4. 
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     To assess the impact of VPA on telomere length in NIH3T3 cells and the developing 
embryos, quantitative real time PCR (SYBR green) was used. Telomere length is presented 
as relative telomere length, which is the ratio of number of telomere gene copies (quantity) to 
single copy gene (β-globin) quantity (Cawthon, 2002; McGrath et al., 2007).  
     Results showed no significant alteration in the mean telomere length in NIH3T3 cells 
treated with VPA at doses 6.25 to 100 µg/mL (Fig. 4.1.9a). NIH3T3 cells (5 x 10
4
 cells/cm
2
)
treated with 5 µg/mL ascorbic acid prior to VPA treatment (doses12.5 to 100 µg/mL) for 24 h, 
however, exhibited a significant increase in telomere length compared to cells treated with 
VPA alone (Fig. 4.1.9a).  Administration of VPA alone (s.c. injection of 400mg/Kg, (daily 
from E8.0 to E10) to time-pregnant mice decreased telomere length whereas administration 
of ascorbic acid alone (i.p. injection of 250mg/Kg daily from E8.0 to E10) exhibited an 
increase in telomere length. However, administration of ascorbic acid followed by VPA did 
not reverse the effect of VPA on telomere length (Fig.4.1.9b).  
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Fig.4.1.9 (a) Effect of VPA and ascorbic acid on telomere length in DNA extracts from 
NIH3T3 cell cultures; (b) Effect of VPA and ascorbic acid on telomere length in DNA 
extracts from developing embryos (T/S: the ratio of telomere repeat copy number to single 
gene β-globin copy number). NIH3T3 cells were treated with 0 to 100 µg/mL VPA alone, or 
treated with 5 µg/mL ascorbic acid followed by 100 µg/mL VPA for 24 h. Time pregnant 
CD-1 mice (beginning at E8 till E10) received once daily s.c. dose of 400mg/Kg VPA, or i.p. 
dose of ascorbic acid (250 mg/Kg), or i.p. dose of ascorbic acid followed by the s.c dose of 
VPA at E8.0 to E10. After 6h following the last administration of VPA, E10.5 embryos were 
dissected from the uteri for further analyses. Statistical analysis: one-way ANOVA with 
Tukey’s HSD as post-hoc analysis (a, p<0.05 compared to untreated control; b, p<0.01 
compared to VPA and VPA+AA), N=3-4. 
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4.1.9  Effect of VPA on telomerase gene expression in NIH3T3 cell cultures and in E10.5 
mouse embryos 
      Telomerase gene expression in NIH3T3 cells and developing mouse embryos treated with 
VPA was quantified using qRT-PCR (Fig. 4.2.0a,b). Initially, NIH3T3 cell cultures incubated 
with VPA showed a significant decline in telomerase gene expression at the lower 
concentration of 6.25 µg/mL. However, this significance did not hold for VPA doses between 
12.5 µg/mL and 50 µg/mL reaching significance only at 100 µg/mL where telomerase gene 
expression was higher than untreated NIH3T3 cells. Treatment with ascorbic acid (5 mM) 
followed by treatment with VPA (6.25 to 25 µg/mL), did not alter telomerase gene 
expression when compared with VPA treatment alone. However, at VPA doses of 50 and 100 
µg/mL, pre-treatment with ascorbic acid significantly inhibited telomerase gene expression in 
NIH3T3 cells (Fig. 4.2.0a).  For the in vivo study, time-pregnant CD-1 mice (E8 to E10) 
received once daily s.c. dose of 400mg/Kg VPA or pre-treatment with an i.p dose of ascorbic 
acid (250 mg/Kg) followed by the s.c dose of VPA (400mg/Kg once daily E8 to E10). After 
6h following the last administration of VPA and/or ascorbic acid, E10.5 embryos were 
dissected from the uteri for qRT-PCR analyses of telomerase gene expression. Treatment 
with VPA alone increased telomerase gene expression in mouse embryos compared to saline 
treated control embryos (Fig. 4.2.0b).  However, treatment with ascorbic acid followed by 
VPA administration, significantly reduced the telomerase gene expression (Fig. 4.2.0b).  
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Fig.4.2.0  (a) Telomerase expression in control wild-type NIH3T3 cells or in NIH3T3 cells 
treated with VPA (6.25 to 100µg/mL); Telomerase expression in NIH3T3 cells treated with 
5µg/mL [25 µM] ascorbic acid (AA), followed by VPA (6.25 to 100µg/mL). NIH3T3 cells 
were cultured for 24 h before harvesting for analyses (1× 10
5
 cells/cm
2
). (b) Telomerase
expression in developing embryos. Time-pregnant CD-1 mice (beginning at E8 till E10) 
received once daily s.c. dose of 400mg/Kg VPA or i.p dose of ascorbic acid (250 mg/Kg) 
followed by the s.c dose of VPA at E8.0 to E10, once daily. After 6h following the last 
administration of VPA and/or ascorbic acid, E10.5 embryos were dissected from the uteri for 
telomerase expression analysis. Statistical analysis: one-way ANOVA with Tukey’s HSD as 
post-hoc analysis (a, p<0.01 compared to untreated control, b, p<0.05 compared to VPA 
treated in the same group; *, p<0.05, **, p<0.01 compared to untreated control cultures), 
n=3-6.  
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4.2 Effect of VPA on epigenetic regulation at the Hoxa2 gene promoter 
4.2.1 DNA methylation status at Hoxa2 gene promoter in NIH3T3 and EG7 cells 
     Hoxa2 gene expression in NIH3T3 and EG7 cells was determined by RT-PCR (Fig.4.2.1). 
Results indicate presence of Hoxa2 expression in NIH3T3 cells but not in in EG7 cells. Based 
on these finding, NIH3T3 cells with activated Hoxa2 expression and EG7 cells with silenced 
Hoxa2 expression were chosen as in vitro model cell lines in this epigenetic study.  
     To determine DNA methylation status at the Hoxa2 promoter in NIH3T3 and EG7 cells, 
bisulfite specific PCR (BSP) sequencing and methylation specific PCR (MSP) were 
performed. For both assays, genomic DNA was isolated from the cells and subjected to 
bisulfite modification, which results in conversion of unmethylated cytosine to uracil, and 
subsequently to thymidine following PCR amplification (Fig. 3.3). BSP primers were 
designed outside CpG regions at the selected promoter region. Three pairs of primers were 
designed for the 3 CpG regions and sequences amplified from -1301 bp to -1176 bp, -1133 bp 
to -919 bp and -620 bp to -277 bp (Fig. 4.2.2a).  Amplification using MSP was performed 
using two sets of primers, one set for unmethylated DNA and the other for methylated DNA. 
Results show that DNA at the three CpG islands (CpG islands 1 to 3) of Hoxa2 promoter in 
EG7 cells is methylated, and same regions in NIH3T3 cells is primarily unmethylated (Fig. 
4.2.2b). This was further confirmed by BSP sequencing (Fig. 4.2.3 and schematic Fig. 4.2.4). 
The highly unmethylated and methylated DNA at Hoxa2 promoter correlates with the level of 
Hoxa2 gene expression in the two cell lines. As shown in Fig. 4.2.1, Hoxa2 gene is expressed 
in NIH3T3 cells, whereas Hoxa2 mRNA transcript level is not detectable in EG7 cells. 
Fig.4.2.1. RT-PCR detection of Hoxa2 gene expression in E10.5 embryo (positive control), 
NIH3T3 cells and EG7 cells. Hoxa2 expression is not detectable in EG7 cells. 
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Fig.4.2.2 DNA methylation analysis at the Hoxa2 gene promoter in NIH3T3 and EG7 cells 
(cells were harvested at 1× 10
5
 cells/cm
2
). (A) Schematic diagram of CpG islands at Hoxa2
gene promoter; (B) Methylation specific PCR at the Hoxa2 gene promoter region (CpG 
islands 1-3) in NIH3T3 cells show unmethylated (U) DNA and in EG7 cells show methylated 
(M) DNA. Primers Msp-kx3-MF, Msp-kx3-MR, Msp-kx3-UF, Msp-kx3-UR were used for 
PCR amplification within CpG island 1; Primers Msp-kx2-MF, Msp-kx2-MR, Msp-kx2-UF, 
Msp-kx2-UR were used for PCR amplification within CpG island 2; Primers Msp-kx1-MF, 
Msp-kx1-MR, Msp-kx1-UF, Msp-kx1-UR were used for PCR amplification within CpG 
island 3 (see Methods section Table 5.1 for primer sequence). 
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(A) CpG island 1 
NIH 3T3 cells 
TGTTAGGTTGAGGTGTTTAAATGATTTG
TGAGGTGTGAGGTGTTTTTTTGATAGTT
TTAAATAATGTGTGGAGTGTGTGGGGGA
GGTAGAGGGTAGTTATTGGTGGGATGGT
AGTAGGGTTTATATGTATATACTTATAT
ATATACTTTAGGGAGTATATTAGATTTT
TGTAGATTAGGAGGTAAATAGGTATTTT
TGTTTTTTACGTATTTTTGGGGTATTGT
TATTTATATTTATATATATGTATTTTTG
TTTTGAAAAAAAGTGTAAATAAAGTTTT
GATGGTTTTTAATGAGGTG 
EG7 cells 
TGTTAGGTTGAGGTGTTTAAATGATTTG
TGAGGTGCGAGGCGTTTTTTCGATAGTT
TTAAATAATGCGCGGAGTGTGCGGGGGA
GGTAGAGGGTAGTTATTGGCGGGACGGT
AGTAGGGTTTATACGTATATATTTATAT
ATATATTTTAGGGAGTATATTAGATTTT
TGTAGATTAGGAGGTAAATAGGTATTTT
CGTTTTTTACGTATTTTCGGGGTATTGT
TATTTATATTTATATATATGTATTTTTG
TTTTGAAAAAAAGTGTAAATAAAGTTTC
GATGGTTTTTAATGAGGCG 
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(B) CpG island 2 
NIH 3T3 cells 
TGAAGGAAGATTAGTAGGTTTTGAGAGT
TGTTTTTTGTTTTTTGTTGTTTGTAGGA
GTTAGATGTAAAGTTGTTGTGGAAAAGT
TGGTTAATAATGGGTTAGGGGTGTAGGT
TTTGGGTTGGATATTAAGAGGAGGTGAG
AGGTTGGGGGGGAGGAGAAGGGGATAGG
ATAGAGTGGGGTGGGGGAAGGAGAGAGG
AAAAAAGGAAAGGAGAATGGAAAGGAGA
GAGGGAGGGAGTG 
EG7 cells 
CGAAGGAAGATTAGTAGGTTTCGAGAGT
CGTTTTTCGTTTTTCGTTGTTCGTAGGA
GTTAGATGTAAAGTTGTCGTGGAAAAGT
CGGTTAATAATGGGTTAGGGGCGTAGGT
TTCGGGTTGGATATTAAGAGGAGGCGAG
AGGTTGGGGGGGAGGAGAAGGGGATAGG
ATAGAGTGGGGTGGGGGAAGGAGAGAGG
AAAAAAGGAAAGGAGAAAGGAGAGGAGA
GAGGGAGGGAGCG  
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(C) CpG island 3 
NIH 3T3 cells 
TGGAAATATTTATTGTATTTGAGTTTTA
TGGGTATGAAATTTAGAGTGTTAGGAGT
TGTATGAGTTTGTTTGGGATGGTATTGT
TTTGGTTGGTTGTTGTTTAGGTTATG 
EG7 cells 
CGGAAATATTTATCGTATTCGAGTTTTA
CGGGTATGAAATTTAGAGTGTTAGGAGT
TGTACGAGTTTGTTCGGGACGGTATTGT
TTTGGTTGGTCGTCGTTTAGGTTACG 
Fig. 4.2.3 DNA sequencing following bisulfite specific PCR at the Hoxa2 gene promoter 
region in NIH3T3 cells and EG7 cells (see Appendix for original DNA sequencing 
chromatograms). Cells were harvested at 1× 10
5
 cells/cm
2
. (A) CpG island 1, (B) CpG island
2, and (C) CpG island 3. Primers Bsp_kx5 and Bsp_kx6 were used for PCR amplification 
within CpG island 1; Primers Bsp_kx3 and Bsp_kx4 were used for PCR amplification within 
CpG island 2; Primers Bsp_kx1 and Bsp_kx2 were used for PCR amplification within CpG 
island 3 (see Methods Section, Table 5.1 for primer sequence).  
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Fig.4.2.4 Schematic diagram of DNA methylation status at the three CpG islands of the 
Hoxa2 gene promoter in NIH3T3 and EG7 cells after BSP sequencing (see DNA sequence 
above in Fig. 4.2.3) 
4.2.2 Effect of VPA on Hoxa2 gene expression and DNA methylation status at the Hoxa2 
promoter in NIH3T3 cells 
     Real-time RT-PCR was used to determine the effect of VPA on Hoxa2 gene expression in 
NIH3T3 cells (Fig. 4.2.5). Hoxa2 expression was measured at VPA doses (6.25, 12.5, 25, 50 
and 100 µg/mL) in NIH3T3 cell cultures and were within VPA’s therapeutic range (50-100 
µg/mL) [0.35-0.70 mM] (Duenas-Gonzalez et al., 2008). Hoxa2 expression decreased in a 
dose dependent manner in NIH3T3 cells with increasing doses of VPA. A significant 
decrease in Hoxa2 gene expression was observed starting at VPA concentration of 12.5 
µg/mL.  
     Exposure to VPA in NIH3T3 cells induced an increasing number of CpG sites to be 
methylated at Hoxa2 promoter on CpG island 1, a region closest to the transcription start site 
(Fig. 4.2.6a). Differential DNA methylation level was subsequently measured at all ten CpG 
sites within CpG island 1 at Hoxa2 gene promoter: CpG
-617
, CpG
-582
, CpG
-577
, CpG
-569
, CpG
-
551
, CpG
-553
, CpG
-540
, CpG
-514
, CpG
-509
 and CpG
-492
. Pyrosequencing data (Fig. 4.2.7) showed
100 
VPA increased the percent of DNA methylation at CpG
-551
, CpG
-553
, CpG
-540
, CpG
-509
 and
CpG
-492
 (see Fig. 4.2.14 for comparison of pyrosequencing data in embryos).
Fig. 4.2.5 Real-time RT-PCR of Hoxa2 gene expression in NIH3T3 cells treated with VPA 
(6.25 µg/mL to 100 µg/mL) for 24 h. Cells were harvested at 1×10
5
 cells/cm
2
 (*, p<0.05; **,
p<0.01 compared to control).  
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(A) CpG island 1 of Hoxa2 promoter 
NIH 3T3 cells (wild-type control) 
TGTTAGGTTGAGGTGTTTAAATGATTTGTGA
GGTGTGAGGTGTTTTTTTGATAGTTTTAAAT
AATGTGTGGAGTGTGTGGGGGAGGTAGAGGG
TAGTTATTGGTGGGATGGTAGTAGGGTTTAT
ATG 
NIH 3T3 cells (treated with 100 g/mL VPA) 
GGTTAGGTTGAGGTGTTTAAATGATTTGTGA
GGTGTGAGGTGTTTTTTTGATAGTTTTAAAT
AATGCGCGGAGTGTGCGGGGGAGGTAGAGGG
TAGTTATTGGTGGGACGGTAGTAGGGTTTAT
ACG 
 (B) 
Fig. 4.2.6 (A) DNA sequence of CpG island 1 of Hoxa2 promoter in wild-type NIH 3T3 cells 
and in NIH3T3 cells treated with VPA (100µg/mL) for 24 h. Cells were harvested at 1×10
5
cells/cm
2
. (B) A schematic diagram of DNA methylation sites on CpG island 1 at the Hoxa2
gene promoter in wild-type control NIH 3T3 cells and in cells treated with VPA following 
BSP sequencing (see Appendix for original DNA sequencing chromatograms).  
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NIH3T3 cells (control) 
NIH3T3 cells (VPA) 
Fig. 4.2.7 Pyrosequencing analysis of DNA methylation on CpG island 1 of the Hoxa2 
promoter in wild-type control NIH3T3 cells and in NIH3T3 cells treated with VPA (100 
µg/mL) for 24 h. Cell were harvested at 1×10
5
 cells/cm
2
. Statistical analysis: one-way
ANOVA with Tukey’s HSD as post-hoc analysis, n=3-4.  Gray shaded boxes show CpG sites. 
Within the gray shaded boxes C denotes signal from methylated cytosines and T denotes 
signal from unmethylated cytosines.  
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4.2.3 Treatment of EG7 cells with VPA or 5-Aza did not induce Hoxa2 gene expression 
     To determine if VPA or 5-Aza (5-Aza-2'-deoxycytidine), will inhibit DNA methylation 
(Christman, 2002) and have an effect on Hoxa2 gene expression in EG7 cells, VPA at doses 
of 80 µg/mL and 200 µg/mL, and 5-Aza at doses of 0.23 µg/mL [1 µM], 0.46 µg/mL [2 µM], 
0.92 µg/mL [4 µM], 1.84 µg/mL [8 µM] and 2.3 µg/mL [10 µM] were added to EG7 cells. 
Hoxa2 gene expression was not detectable in treated cells using RT-PCR (Fig. 4.2.8a). In 
addition, pyrosequencing analysis of the Hoxa2 gene promoter (CpG island 1) of EG7 cells 
treated with VPA or 5-Aza showed no change in DNA methylation status compared to 
control wild-type EG7 cells (Fig. 4.2.8b).   
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EG7 cells (control) 
EG7 cells (VPA) 
EG7 cells (5-AZA) 
Fig. 4.2.8 (A) Hoxa2 gene expression was not detected following RT-PCR in EG7 
cells treated with VPA (80 and 200 µg/mL for 24 h) and 5-Aza (dose, 0.23 µg/mL [1 
µM] to 2.3 µg/mL [10 µM] for 48 h). (B) Pyrosequence analysis of DNA methylation 
status at Hoxa2 gene promoter (CpG island 1) in control wild-type EG7 cells and in 
EG7 cells treated with 200 µg/mL VPA and 2.3 µg/mL [10 µM] 5-Aza, respectively. 
Cells were harvested at 1× 10
5
/cm
2
. Statistical analysis: one-way ANOVA with
Tukey’s HSD as post-hoc analysis, n=2-3.  
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4.2.4 DNA methylation status at Hoxa2 gene promoter in developing mice 
embryos (E6.5-E10.5) 
Hoxa2 gene expression was not detected in E6.5 embryos but was expressed 
in developing mice embryos at E8.5 and E10.5 (Fig. 4.2.9). This matches with the fact 
that during embryonic development Hoxa2 gene is initially expressed in the hindbrain 
at E8.0 in mice (Prince and Lumsden, 1994b).  Bisulfite sequencing of the 3 CpG 
islands in E6.5 and E8.5 mouse embryos was performed to characterize Hoxa2 
promoter DNA methylation status. Results indicate Hoxa2 promoter (CpG islands 1-3) 
in E8.5 embryos remained primarily unmethylated (Fig. 4.2.10), as did CpG islands 2 
and 3 in E6.5 embryos. Interestingly, in E6.5 embryos the CpG island 1 (-620 to -277 
bp) closest to transcription start site on the Hoxa2 gene promoter is only partially 
methylated DNA and primarily at CpG sites -551 bp, -553 bp, -540 bp, -509 bp and -
492 bp (Fig. 4.2.11). Subsequent quantification of DNA methylation following 
pyrosequencing indicated that percent of DNA methylation at the CpG island 1 at all 
ten CpG sites (-617 bp to -492 bp) in E6.5 and E8.5 embryos are higher than those in 
E10.5 embryo (Fig. 4.2.12). Since Hoxa2 gene expression is not detected at E6.5, and 
is only initially expressed at E8.5 (Fig. 4.2.9), the significantly higher level of DNA 
methylation of the Hoxa2 promoter in E6.5 embryos may reflect repression of Hoxa2 
gene expression at this stage in the developing mouse embryo. 
Fig.4.2.9 Hoxa2 gene expression in developing embryos (E6.5 to E10.5). 
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(A) CpG island 1 
E10.5 
GGTTAGGTTGAGGTGTTTAAATGATTTG
TGAGGTGTGAGGTGTTTTTTTGATAGTT
TTAAATAATGTGTGGAGTGTGTGGGGGA
GGTAGAGGGTAGTTATTGGTGGGACGGT
AGTAGGGTTTATACGTATATATTTATAT
ATATATTTTAGGGAGTATATTAGATTTT
TGTAGATTAGGAGGTAAATAGGTATTTT
TGTTTTTTATGTATTTTTGGGGTATTGT
TATTTATATTTATATATATGTATTTTTG
TTTTGAAAAAAAGCCTGACAGAACTGTT
TACCCCAGGATG 
E8.5 
TGTTAGGTTGAGGTGTTTAAATGATTTG
TGAGGTGTGAGGTGTTTTTTTGATAGTT
TTAAATAATGTGTGGAGTGTGTGGGGGA
GGTAGAGGGTAGTTATTGGTGGGATGGT
AGTAGGGTTTATATGTATATATTTATAT
ATATATTTTAGGGAGTATATTAGATTTT
TGTAGATTAGGAGGTAAATAGGTATTTT
TGTTTTTTATGTATTTTTGGGGTATTGT
TATTTATATTTATATATATGTATTTTTG
TTTTGAAAAAAAGTGTAAATAAAGTTTT
GATGGTTTTTAATGAGGTG 
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E6.5 
TGTTAGGTTGAGGTGTTTAAATGATTTG
TGAGGTGTGAGGTGTTTTTTTGATAGTT
TTAAATAATGCGCGGAGTGTGCGGGGGA
GGTAGAGGGTAGTTATTGGTGGGACGGT
AGTAGGGTTTATACGTATATATTTATAT
ATATATTTTAGGGAGTATATTAGATTTT
TGTAGATTAGGAGGTAAATAGGTATTTT
TGTTTTTTATGTATTTTTGGGGTATTGT
TATTTATATTTATATATATGTATTTTTG
TTTTGAAAAAAAGTGTAAATAAAGTTTT
GATGGTTTTTAATGAGGTG 
(B) CpG island 2 
E8.5 
TGAAGGAAGATTAGCAGGTTTTGAGA
GTTGTTTTTTGTTTTTTGTTGTTTGT
AGGAGTTAGATGTAAAGTTGTTGTGG
AAAAGTTGGTTAATAATGGGTTAGGG
GTGTAGGTTTTGGGTTGGATATTAAG
AGGAGGTGAGAGGTTGGGGGGGAGGA
GAAGGGGATAGGATAGAGTGGGGTGG
GGGAAGGAGAGAGGAAAAAAGGAAAG
GAGAAAGGAGAGGAGAGAGGGAGGGA
GTG 
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E6.5 
TGAAGGAAGATTAGTAGGTTTTGAGA
GTTGTTTTTTGTTTTTTGTTGTTTGT
AGGAGTTAGATGTAAAGTTGTTGTGG
AAAAGTTGGTTAATAATGGGTTAGGG
GTGTAGGCTTTGGGTTGGATATTAAG
AGGAGGTGAGAGGTTGGGGGGGAGGA
GAAGGGGATAGGATAGAGTGGGGTGG
GGGAAGGAGAGAGGAAAAAAGGAAAG
GAGAAAGGAGAGGAGAGAGGGAGGGA
GTG 
(C) CpG island 3 
E8.5 
TGGAAATATTTATTGTATTTGAGTTTTA
TGGGTATGAAATCTAGAGTGCCAGGAGT
TGTATGAGTTTGTTTGGGATGGTATTGT
TTTGGTTGGTTGTTGTTTAGGTTATG 
E6.5 
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TGGAAATATTTATTGTATTTGAGTTTTAT
GGGTATGAAATTTAGAGTGTTAGGAGTTG
TATGAGTTTGTTTGGGATGGTATTGTTTT
GGTTGGTTGTTGTTTAGGTTATG 
Fig. 4.2.10 DNA methylation status of Hoxa2 gene promoter (CpG islands 1-3) in 
E6.5, E8.5 and E10.5 embryos. (A) CpG island 1, (B) CpG island 2, and (C) CpG 
island 3. The primers used in embryos were the same BSP primers used in NIH 3T3 
cells (see Methods Section, Table 5.1 for primer sequence). 
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Fig. 4.2.11 Schematic diagram of DNA methylation status at Hoxa2 gene promoter in embryos at 
E6.5, E8.5 and E10.5  
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Fig.4.2.12 Pyrosequence analysis of DNA methylation on CpG island 1 of the Hoxa2 gene promoter 
in developing embryos (E6.5, E8.5 and E10.5) (statistical analysis: one-way ANOVA with Tukey’s 
HSD as post-hoc analysis, N=3) 
 
 
4.2.5 Effect of VPA on DNA methylation at the Hoxa2 promoter in E10.5 mouse 
embryos   
     Hoxa2 gene expression is down regulated in mouse embryos cultured in vitro after 
treatment with VPA (Table 4.1.4). Bisulfite specific PCR sequencing results reveal that in 
developing embryos treated with VPA, increased DNA methylation at the Hoxa2 gene 
promoter within CpG island 1 was observed at some CpG sites (Fig. 4.2.13a).  Interestingly, 
the VPA-induced methylation on CpG sites at CpG
-551
, CpG
-553
, and CpG
-540 
were among 
those found methylated in developing mouse embryos at E6.5 (Fig. 4.2.13b). These results 
demonstrate that the inhibition of Hoxa2 gene expression in embryos treated with VPA could 
be due to increased DNA methylation at Hoxa2 gene promoter.  Similarly, pyrosequencing 
data also revealed an increase in percent of DNA methylation in embryos treated with VPA 
in all CpG sites within CpG island 1 (Fig. 4.2.14).   
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(A) CpG island 1 of Hoxa2 promoter 
E10.5 (control)  
GGTTAGGTTGAGGTGTTTAAATGATTTGTGA
GGTGTGAGGTGTTTTTTTGATAGTTTTAAAT
AATGTGTGGAGTGTGTGGGGGAGGTAGAGGG
TAGTTATTGGTGGGACGGTAGTAGGGTTTAT
ACG 
 
 
 
E10.5 (VPA treated) 
GGTTTAAATGATTTGTGAGGTGTGAGGT
GTTTTTTTGATAGTTTTAAATAATGCGC
GGAGTGTGCGGGGGAGGTAGAGGGTAGT
TATTGGTGGGACGGTAGTAGGGTTTATA
CG 
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(B) 
Fig. 
4.2.13 
(A) DNA sequence of CpG island 1 indicating the CpG sites in wild-type E10.5 embryo and in 
E10.5 embryos treated with VPA. Time-pregnant mice were administered s.c 400 mg/kg VPA 
once daily between E8 and E10 and embryos isolated for DNA sequence analysis at E10.5. (B) 
Schematic diagram of DNA methylation status at Hoxa2 gene promoter (CpG island 1) in wild-
type E10.5 developing embryo and in E10.5 embryo treated with VPA. 
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E10.5 (Control) 
117 
E10.5 (VPA) 
Fig. 4.2.14 Pyrosequence analysis of DNA methylation at Hoxa2 gene promoter (CpG island 1) 
in a wild-type control E10.5 embryo and in a E10.5 embryo treated with VPA. Time-pregnant
mice were administered s.c. 400 mg/kg VPA once daily between E8 and E10 and the embryos 
analyzed at E10.5 (Statistical analysis: one-way ANOVA with Tukey’s HSD as post-hoc 
analysis, N=3-4).  
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4.2.6 Effect of VPA on DNA methyltransferase binding capacity at Hoxa2 promoter in 
NIH3T3 cells and in E10.5 mouse embryos 
     DNA methyltransferase 1 (Dnmt1) binding on Hoxa2 gene promoter (CpG island 1) was 
evaluated in NIH3T3 cells and in E10.5 embryos using Quantitative Chromatin 
Immunoprecipitation PCR (qChIP-PCR) (Fig. 4.2.15). Treatment with VPA (50 µg/mL and 100 
µg/mL) resulted in higher level of Dnmt1 occupied at the Hoxa2 gene promoter (CpG island 1) 
compared to wild-type untreated NIH3T3 cells (Fig. 4.2.15a). Results also reveal higher 
enrichment of Dnmt1 at the Hoxa2 promoter (CpG island 1) in embryos treated with VPA at 
E10.5 (Fig. 4.2.15b). The increased binding capacity of Dnmt1 protein at the Hoxa2 promoter 
region (CpG island 1) corresponds with increased DNA methylation at the Hoxa2 gene promoter 
(Fig. 4.2.6 and Fig. 4.2.13).  
Fig. 4.2.15 qChIP-PCR assay of Dnmt1 binding at the Hoxa2 gene promoter (CpG island 1) in NIH 3T3 
cells and E10.5 mouse embryos treated with VPA. NIH 3T3 cells were exposed to VPA (50 and 100 
µg/mL) for 24 h. Cells were harvested at 1×10
5
 cells/cm
2
. Time-pregnant mice were administered a daily 
of dose of VPA (s.c. 400 mg/kg) between E8 and E10 and the embryos were isolated for analyses at 
E10.5. Primers Klx 3 and Klx 3-1 (see Methods section, Table 5.1 for primer sequence) were used for 
qChIP-PCR of Dnmt1 within the CpG island 1 of the Hoxa2 promoter (*, p<0.05; **, p<0.01). 
4.2.7 Ascorbic acid decreased DNA methylation at Hoxa2 gene promoter in NIH3T3 cells 
treated with VPA 
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     Differential DNA methylation was measured at all ten CpG sites within the CpG island 1 
close to transcription start site at the Hoxa2 gene promoter: CpG
-617
, CpG
-582
, CpG
-577
, CpG
-569
,
CpG
-551
, CpG
-553
, CpG
-540
, CpG
-514
, CpG
-509
, CpG
-492
. VPA significantly increased DNA
methylation at CpG
-551
, CpG
-553
, CpG
-540
, CpG
-509
, CpG
-492 
in NIH 3T3 cells (Fig. 4.2.6).
Pretreatment with ascorbic acid, however, reversed the higher level of DNA methylation status at 
these CpG sites induced by VPA (Fig. 4.2.16). 
Fig. 4.2.16 Pyrosequence analysis of DNA methylation at Hoxa2 gene promoter (CpG island 1) 
in wild-type untreated NIH3T3 cells, NIH3T3 cells treated with 100 µg/mL VPA alone, or 5 
µg/mL [25 µM ascorbic acid alone or 5 µg/mL ascorbic acid followed by 100 µg/mL VPA for 24 
h. Cells were harvested at 1× 105/cm2. Statistical analysis: one-way ANOVA with Tukey’s HSD
as post-hoc analysis. N=2-4 
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4.2.8 Effect of ascorbic acid on DNA methyltransferase binding capacity on Hoxa2 
promoter in NIH3T3 cells treated with VPA 
     DNA methyltransferase 1 (Dnmt1) binding on Hoxa2 gene promoter (CpG island 1) was 
evaluated in NIH3T3 cells treated with VPA (50 µg/mL and 100 µg/mL) or with VPA (50 
µg/mL and 100 µg/mL) following treatment with ascorbic acid (25 µM). VPA treatment resulted 
in higher level of Dnmt1 occupied at the Hoxa2 gene promoter (CpG island 1) compared to wild-
type untreated NIH3T3 cells (Fig. 4.2.17b). Cells treated with ascorbic acid alone, however 
decreased higher enrichment of Dnmt1 at Hoxa2 promoter (Fig. 4.2.17a). As a result, when NIH 
3T3 cells were treated with VPA in the presence of ascorbic acid (25 µM), the binding capacity 
of Dnmt1 protein at Hoxa2 promoter region (CpG island 1) was significantly reduced (Fig. 
4.2.17b). These results correspond with the decreased DNA methylation at the Hoxa2 gene 
promoter (Fig. 4.2.16) in ascorbic acid treated NIH3T3 cells exposed to VPA.  
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Fig. 4.2.17 qChIP-PCR assay of Dnmt1 binding at the Hoxa2 gene promoter (CpG island 1) in 
NIH3T3 cells treated with ascorbic acid (5 µg/mL, 25 µM) (A), in NIH3T3 cells treated with 
ascorbic acid (25 µM) followed by VPA (50 and 100 µg/mL) for 24 h (B). Cells were harvested 
at 1×10
5
 cells/cm
2
. Primers Klx 3 and Klx 3-1 (see Methods section, Table 5.1 for primer
sequence) were used for qChIP-PCR of Dnmt1 within the CpG island 1 of the Hoxa2 promoter. 
Statistical analysis: one-way ANOVA with Tukey’s HSD as post-hoc analysis (**, p<0.01), N=3. 
123 
4.2.9  Histone methylation is associated with Hoxa2 gene promoter 
     To identify potential mechanisms that lead to transcriptional silencing of Hoxa2 gene 
expression after VPA treatment, bivalent domains of active histone modification H3K4me3 and 
inactive histone modification H3K27me3 were characterized within 1688 bp of the Hoxa2 gene 
promoter (Fig.6.2.18a). ChIP-PCR assay with the primers designed for the Hoxa2 gene promoter 
showed that trimethylation of H3K27 and H3K4 were simultaneously associated at the Hoxa2 
promoter (Fig.6.2.18b). Results demonstrate that the two histone methylation marks (H3K27 and 
H3K4) are enriched near the transcription start site at the Hoxa2 gene promoter, indicating the 
intermingled presence of active and inactive histone methylation marks (a bivalent domain) that 
is associated with Hoxa2 gene activity.  
Fig. 4.2.18 (A) Schematic diagram of the Hoxa2 gene showing the two regions (fragment 1 and 
fragment 2) of the promoter that were used for the ChIP-PCR assay using primers A2-1 and A2-
2 for fragment 1 and primers A2-3 and A2-4 for fragment 2 (see Methods section, Table 5.1 for 
primer sequence). (B) PCR detection of H3K27me3 and H3K4me3 at Hoxa2 gene promoter 
following chromatin immunoprecipitation (ChIP) in NIH3T3 cells. Enrichment of both 
H3K27me3 and H3K4me3 was only present in fragment 2 near the transcription start site of the 
Hoxa2 gene. Cells were harvested at 1× 10
5
/cm
2
.
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4.2.10 VPA increased H3K27me3 and decreased H3K4me3 enrichment at the Hoxa2 gene 
promoter in NIH3T3 cells  
     To determine what effect VPA has on histone modification domain status, qChIP-PCR was 
used to quantify the enrichment of H3K27me3 and H3K4me3 at the Hoxa2 gene promoter in 
NIH3T3 cells treated with VPA (Fig. 4.2.19). Results indicate that the enrichment of the 
repressive histone modification mark, H3K27me3, was enhanced at the Hoxa2 gene promoter 
and was significant even at the lowest VPA concentration used (6.25 µg/mL) compared to 
control untreated group (Fig.4.2.19b). In contrast, the enrichment of the active histone 
modification mark, H3K4me3, was significantly reduced at all VPA doses relative to the control 
untreated group (Fig.4.2.19c). Generally, for chromatin domains over a gene promoter, an active 
domain mark (e.g H3K4me3) is defined by potential for high transcriptional rates, whereas a 
repressive chromatin domain mark (e.g. H3K27me3) is characterized by low transcriptional rates 
(Rodriguez et al., 2008b). The observed increased enrichment of H3K27me3 and a 
corresponding decreased enrichment of H3K4me4 in the same region of Hoxa2 gene promoter 
near the transcription start site may explain lower Hoxa2 expression in NIH3T3 cells treated with 
VPA.  
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Fig. 4.2.19 Schematic diagram of the Hoxa2 gene promoter (A). Primers Klx 3 and Klx 3-1 (see 
Methods section, Table 5.1 for sequence) were used for qChIP-PCR of both H3K27me3 and 
H3K4me3 within the CpG island 1 close to the transcription start site. VPA induced increased 
enrichment of H3K27me3 (B) and a decreased enrichment of H3K4me3 (C) at the Hoxa2 gene 
promoter in NIH3T3 cells treated with VPA (dose, 6.25-100 µg/mL) for 24 h (*, p<0.05; **, 
p<0.01 compared to control). Cells were harvested at 1× 10
5
/cm
2
. Statistical analysis: one-way
ANOVA with Tukey’s HSD as post-hoc analysis (**, p<0.01), N=3. 
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4.2.11 Dynamic change in bivalent domain status induced by VPA is only associated with 
active Hoxa2 gene expression when Hoxa2 promoter is unmethylated 
     Hoxa2 gene is silenced in EG7 cells where the promoter region is highly methylated (Figs. 
4.2.3 and Fig. 4.2.4). To determine if the methylation status of the Hoxa2 gene promoter 
influenced the dynamic change in the histone bivalent domain, qChIP-PCR assays for the two 
histone modification marks, H3K27me3 and H3K4me3, were carried out in control untreated and 
VPA treated (200 µg/mL) EG7 cells (Fig. 4.2.20). VPA treatment did not significantly change 
enrichment of H3K27me3 or of H3K4me3 (Fig. 4.2.20) at Hoxa2 gene promoter in EG7 cells. 
These findings indicate that significant dynamic change of these bivalent domains (H3K27me3 
and H3K4me3) is specific to NIH 3T3 cells where the Hoxa2 gene promoter is primarily 
unmethylated DNA with an active Hoxa2 gene expression. 
Fig. 4.2.20 Bivalent domains (H3K27me3 and H3K4me3) status at the Hoxa2 gene promoter in 
wild-type untreated control EG7 cells and in EG7 cells treated with 200 µg/mL VPA for 24 h. 
No significant change in enrichment of H3K27me3 (A) or of H3K4me3 (B) at the Hoxa2 gene 
promoter in wild-type control EG7 cells compared to EG7 cells treated with VPA was observed. 
Cells were harvested at 1× 10
5
/cm
2
. Statistical analysis: one-way ANOVA with Tukey’s HSD as
post-hoc analysis, N=3. 
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4.2.12 Ascorbic acid decreased H3K27me3 and increased H3K4me3 enrichment at Hoxa2 
gene promoter in NIH 3T3 cells treated with VPA 
     Hoxa2 gene expression is down regulated in both NIH3T3 cells and in whole mouse embryo 
cultures treated with VPA (Fig. 4.1.3, Table 4.1.4, and Fig. 4.2.5). Treatment with ascorbic acid 
(1000 µg/mL in embryos or 5 µg/mL in NIH 3T3 cells) blocked the effects of VPA on Hoxa2 
gene expression in both whole mouse embryo cultures (Fig. 4.1.7) and in NIH3T3 cells 
(Fig.4.2.21).  
Indeed, treatment with ascorbic acid significantly decreased the enrichment of H3K27me3 at the 
Hoxa2 promoter in VPA treated (25 µg/mL, 50 µg/mL or 100 µg/mL) NIH3T3 cells (Fig. 
4.2.22a). In contrast, ascorbic acid induced higher enrichment of H3K4me3 at the Hoxa2 
promoter in VPA treated NIH3T3 cells compared to the untreated NIH3T3 cells. A significant 
enrichment of H3K4me3 was observed at VPA doses of 25 µg/mL and 100 µg/mL in NIH3T3 
cells treated with ascorbic acid (Fig. 4.2.22b). Results demonstrate that ascorbic acid blocked the 
effect of VPA on the enrichment of bivalent domains, H3K27me3 and H3K4me3, at Hoxa2 gene 
promoter. 
Fig. 4.2.21 Hoxa2 gene expression in NIH3T3 cells treated with VPA (12.5 to 100 µg/mL) and 
VPA in the presence of 5µg/mL [25 µM] ascorbic acid for 24 h. Cells were harvested at 1× 
10
5
/cm
2
. Statistical analysis: one-way ANOVA with Tukey’s HSD as post-hoc analysis (**, p <
0.01 compared to control), N=3.  
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Fig. 4.2.22 H3K27me3 (A) and H3K4me3 (B) Binding capacity (at CpG island 1) in NIH3T3 
cells treated with VPA (dose, 6.25 to 100 µg/mL) and VPA in the presence of 5 µg/mL [25 µM] 
ascorbic acid for 24 h (*, p<0.05; **, p<0.01 compared to control in each group). Cells were 
harvested at 1× 10
5
/cm
2
. Statistical analysis: one-way ANOVA with Tukey’s HSD as post-hoc 
analysis , N=3. 
 
4.2.13. Ascorbic acid decreased the enrichment of Ezh2 at Hoxa2 gene promoter in NIH 
3T3 cells treated with VPA 
     The histone methyltransferase Ezh2 was subsequently evaluated in NIH3T3 cells treated with 
ascorbic acid alone or following VPA treatment. Ascorbic acid alone reduced the association of 
Ezh2 at the Hoxa2 promoter (Fig.4.2.23a).  As a result, the total effect of ascorbic acid was to 
induce a decrease in enrichment of Ezh2 at the Hoxa2 gene promoter in NIH3T3 cells treated 
with VPA (Fig.4.2.23b). These significant changes were observed at VPA concentrations of 12.5 
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to 100 µg/mL. A decline in enrichment of Ezh2 induced by ascorbic acid following VPA 
exposure is in concordance with the dissociation of H3K27me3 mark that was found at the 
Hoxa2 gene promoter in NIH3T3 cells treated with VPA (Fig. 4.2.22a).  
 
Fig. 4.2.23 Relative occupancy of Ezh2 in wild-type NIH3T3 cells or in NIH 3T3 cells treated 
with 5 µg/mL [25 µM] ascorbic acid (A) and in NIH3T3 cells treated with VPA (dose, 6.25 to 
100 µg/mL) or VPA (dose, 6.25 to 100 µg/mL) following pretreatment with 5 µg/mL [25 µM] 
ascorbic acid (B) (all cell treatments were for 24 h) (*, p<0.05; **, p<0.01 compared to control 
of each group). Cells were harvested at 1× 10
5
/cm
2
. Primers of Klx 3 and Klx 3-1 were used for 
qChIP-PCR.  Statistical analysis: one-way ANOVA with Tukey’s HSD as post-hoc analysis, 
N=3 
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4.2.14 Dynamic changes of histone bivalent domains at the Hoxa2 gene promoter in 
developing embryos (E6.5 – E10.5) 
     To gain further insight into the mechanism(s) that lead to transcriptional silencing of Hoxa2 
in mouse embryos treated with VPA, we first profiled active and inactive histone modification 
bivalent domains, H3K27me3 and H3K4me3, at the Hoxa2 promoter region in the developing 
mouse embryo from E6.5 to E10.5 (Fig. 4.2.24). The chromatin profiling in the developing 
embryo revealed the coexistence of active H3K4me3 and inactive domains H3K27me3 at the 
Hoxa2 gene promoter. Interestingly, the enrichment of H3K27me3 at the Hoxa2 gene promoter 
in E8.5 and in E10.5 was significantly lower than in E6.5 embryos (Fig. 4.2.24a). In contrast, 
enrichment of H3K4me3 was significantly higher at same region of Hoxa2 promoter in E8.5 and 
E10.5 compared to the E6.5 embryos (Fig. 4.2.24b).  This enrichment trend of trimethylation of 
H3K27 and H3K4 at the Hoxa2 gene promoter, together with DNA methylation status at the 
Hoxa2 gene promoter (Fig. 4.2.10, Fig. 4.2.11), appears to be associated with the epigenetic 
regulation of Hoxa2 gene in developing embryos.  
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Fig. 4.2.24 Dynamic changes in H3K27me3 and H3K4me3 enrichment at the Hoxa2 gene 
promoter in developing mouse embryos. There is a significant change in enrichment of 
H3K27me3 (A) and of H3K4me3 (B) at the Hoxa2 gene promoter in E8.5 and E10.5 embryos 
compared to E6.5 embryos (**, p<0.01 compared to E6.5 embryos). Statistical analysis: one-way 
ANOVA with Tukey’s HSD as post-hoc analysis, N=3. 
 
4.2.15 VPA increases H3K27me3 and decreases H3K4me3 enrichment at the Hoxa2 
promoter in E10.5 mouse embryos  
     To determine VPA’s effect on the bivalent domains at the Hoxa2 gene promoter in 
developing mouse embryos, VPA was administered (s.c. 400 mg/kg, once daily) to time-
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pregnant mice between E8 and E10. Mice receiving s.c. dose of 400 mg/kg VPA daily between 
gestational days 7 and 15 reportedly attain therapeutic plasma concentrations (50-100 µg/mL) 
after 3 to 4h of dosing (Nau et al., 1981). This is due to the short half-life and high plasma 
clearance rate of VPA in the mouse (Nau et al., 1981). In our study, VPA treatment induced a 
significant increase in enrichment of H3K27me3 (Fig. 4.2.25a) and a significant decrease in 
enrichment of H3K4me3 (Fig. 4.2.25b) at the Hoxa2 gene promoter in E10.5 embryos which 
correlates with a switch in transcription from “on” to “off” as reduction in Hoxa2 expression is 
evident (Fig. 4.1.3, Table 4.1.4). Similar change in the bivalent domains was also observed in 
VPA treated NIH 3T3 cells when Hoxa2 mRNA is down-regulated (Fig. 4.2.19). 
 
Fig. 4.2.25 VPA induced increased enrichment of H3K27me3 (A) and decreased enrichment of 
H3K4me3 (B) at the Hoxa2 gene promoter in E10.5 embryos following once daily dose of s.c. 
400 mg/kg VPA in timed-pregnant mice from E8 to E10 (**, p<0.01 compared to control saline 
treated mice). Statistical analysis: one-way ANOVA with Tukey’s HSD as post-hoc analysis , 
N=3. 
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4.2.16 A component of the polycomb repressor complex is enriched at the Hoxa2 promoter 
in NIH3T3 cells and in E10.5 mouse embryos after VPA treatment  
     An increased enrichment of H3K27me3 at the Hoxa2 gene promoter suggested that 
components of the polycomb protein groups may be mediating, at least in part, the silencing of 
Hoxa2 gene expression following VPA treatment. A polycomb repressor complex (PRC) protein, 
Enhancer of Zeste Homolog 2 (Ezh2), is known to be responsible for catalyzing the deposition of 
the H3K27me3 mark (Ringrose and Paro, 2004). To determine if Ezh2 is associated with Hoxa2 
gene promoter, qChIP-PCR assay for Ezh2 was performed in NIH 3T3 cells and in E10.5 
embryos exposed to VPA (Fig. 4.2.26). Results show Ezh2 is enriched near the transcription start 
site at the Hoxa2 gene promoter where high levels of the H3K27me3 mark is also detected 
(Fig.4.2.19b, Fig.4.2.25a). A significant increase in Ezh2 enrichment at Hoxa2 gene promoter is 
observed in both NIH3T3 cells (Fig. 4.2.26a) and in E10.5 embryos (Fig. 4.2.26b) exposed to 
VPA. 
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Fig. 4.2.26 Enrichment of Ezh2 at the Hoxa2 gene promoter in VPA treated NIH3T3 cells (dose, 
6.25 µg/mL to 100 µg/mL) for 24 h (A); and in E10.5 embryos following once daily dose of s.c. 
400 mg/kg VPA in timed-pregnant mice from E8  to E10 (B). Primers Klx 3 and Klx 3-1 (see 
Methods section, Table 5.1 for sequence) were used for qChIP-PCR of Ezh2 within the CpG 
island 1 (*p<0.05; ** p<0.01 compared to control saline treatment). Statistical analysis: one-way 
ANOVA with Tukey’s HSD as post-hoc analysis, N=3. 
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CHAPTER 5: DISCUSSION 
 
5.1  Effect of VPA on embryonic differentiation and growth 
     Results indicate that VPA can inhibit embryonic organ differentiation and development in 
vitro. Total morphological score decreases significantly at VPA concentrations as low as 50 
g/mL [0.35 mM]. Embryonic head development is also inhibited at this concentration. Scoring 
parameters such as yolk sac circulation, allantois, caudal neural tube, forebrain, and branchial 
arch also decrease, indicating these embryonic organs may be particularly sensitive to VPA 
insult. The reduced overall embryonic growth and increased incidence of abnormal embryos at 
higher VPA concentrations observed are in agreement with previous reports (Bruckner et al., 
1983). Embryonic deformities such as fusion of the first and second branchial arches are of 
particular interest especially since these structures are implicated in the development of 
craniofacial skeletal components such as the mandibular bone, incus, and malleus, which 
originate from the first branchial arch, and the hyoid bone and stapes, which originate from the 
second branchial arch (Mahmood et al., 1996; Menegola et al., 2000). Fusion of the first and 
second arches probably produces a spectrum of mandibular, hyoid, ear, and cranial malformation. 
This result of the culture experiment correlates well with in vivo VPA-induced teratogenicity 
data in mice and humans where cranial abnormalities including small nose and mouth, low-set 
ears, craniosynostosis, and cleft palate are reported  (Faiella et al., 2000; Polifka and Friedman, 
2002).  
5.2  Effect of VPA on embryonic antioxidant status 
Glutathione (GSH), a major component of overall antioxidant defense, is synthesized within 
virtually every cell from glycine, cysteine, and glutamate in a series of reactions catalyzed by γ-
glutamylcysteine synthetase and glutathione synthetase (Pallardo et al., 2009). During oxidative 
stress, GSH can neutralize free radicals through its oxidation into glutathione disulfide (GSSG); 
GSSG can then be reduced back to GSH enzymatically via glutathione disulfide reductase to 
regulate a normal cellular GSH/GSSG ratio (Bannai and Tateishi, 1986). During embryonic 
development, maintenance of proper redox status is essential, because these processes play 
important roles in cell proliferation, apoptosis, and differentiation. Redox changes can result in 
transcription factor activation or inhibition, depending on the type of redox potential shift 
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(Pallardo et al., 2009). Depletion of GSH or the generation of GSSG increases the GSSG/GSH 
ratio, reflecting an increase in oxidative stress, which can lead to abnormal proliferation, altered 
differentiation, and/or apoptosis resulting in teratogenesis (Allen, 1991; Hamza and Amin, 2007; 
Hutter et al., 1997; Ozolins and Hales, 1997; Sen and Packer, 1996). Our study demonstrated that 
total glutathione content in embryos only decreased significantly at the highest VPA dose (400 
g/mL). However, VPA altered the glutathione homeostasis of mice embryos by causing an 
increase in the embryonic GSSG/GSH ratio at doses ≥ 100 g/mL (0.7 mM). The normal 
therapeutic dose of VPA in humans is in the range from 50 to 100 g/mL (0.35 mM to 0.7 mM) 
plasma (Ornoy, 2006; Samaei et al., 2009). These results suggest alteration of the embryonic 
antioxidant status plays a very important role in VPA-induced teratogenesis. Interestingly, mouse 
embryos pretreated with 5 mM L-ascorbic acid had a protective effect and prevented the VPA-
induced glutathione depletion at the highest VPA dose and normalized the GSSG/GSH ratio.  
5.3   Effect of VPA on the Hoxa2 gene expression in mouse embryos  
     Results of Western blot analysis and quantitative real-time RT-PCR show that VPA can 
inhibit Hoxa2 expression in cultured mice embryos both at the protein and mRNA levels. Hoxa2 
gene is  the only Hox gene expressed at the level of hindbrain in rhombomere 2 (r2) in the 
neuroectoderm, but not in neural crest cells that migrate from this region (Prince and Lumsden, 
1994b). Hoxa2 gene is also expressed in both r4 neuroectoderm and neural crest cells migrating 
into the second arch, and also in more posterior branchial arches (Maconochie et al., 1999; 
Prince and Lumsden, 1994b). Hoxa2 plays a key role as a selector gene in determining second 
arch fate and imposes the unique identity of second arch structures (Santagati et al., 2005; 
Trainor and Krumlauf, 2001). Hoxa2 knockout mice exhibit the defects in structures of neural 
crest origin, including the skeletal elements of the second branchial arch and the external ear 
pinna (Gendron-Maguire et al., 1993a; Rijli et al., 1993b). Exposure to VPA can induce a 
characteristic facial phenotype manifested as midfacial hypoplasia, epicanthal folds, down-
slanting palpebral fissure, telecanthus, a broad low nasal bridge, and IUGR (Clayton-Smith and 
Donnai, 1995). The facial features of FVS are suggestive of neural crest involvement in the 
pathogenetic mechanism. Neural crest cell cultures exposed to VPA can substantially decrease 
the proportion of cells migrating individually, instead promoting migration as epithelial sheets 
(Fuller et al., 2002). Further, Padmanabhan and Ahmed (1996) reported a delay in the migration 
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of the neural crest and increased cell death in crest-derived craniofacial tissue, in the optic cup, 
otic vesicle, and trigeminal and otic ganglia in response to VPA treatment. Inhibition of Hoxa2 
gene expression likely affects pattern formation in the branchial region (Santagati et al., 2005). 
Our results suggest VPA-induced inhibition of Hoxa2 expression may play an important role in 
its teratogenicity, especially in VPA-induced embryonic craniofacial malformations.  
5.4   Ascorbic acid prevents VPA-induced inhibition of Hoxa2 and maintains glutathione 
homeostasis in mouse embryos in culture 
     Treatment with ascorbic acid just prior to VPA exposure prevented VPA-induced 
downregulation of Hoxa2 gene expression in concert with enhanced glutathione status, indicating 
a protective effect on embryos. Indeed, the incidence of dysmorphogenesis and death was 
substantially reduced in embryos treated with ascorbic acid prior to VPA exposure. To further 
delineate whether a relationship existed between VPA, oxidative stress and Hoxa2, total 
glutathione levels were measured in Hoxa2 null mutant embryos. Findings demonstrate that 
glutathione levels are not altered in Hoxa2-/- embryos and indicate VPA specific depletion of 
glutathione. This prompted further investigations on whether VPA had a direct effect as an 
epigenetic modulator of Hoxa2 gene promoter to regulate gene expression (Fig. 5.1). 
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Fig. 5.1 Schematic diagram showing the relationship between VPA, glutathione, and Hoxa2 gene 
expression. A VPA-induced oxidative stress leads to a decline in glutathione levels which in turn 
induces a downregulation of Hoxa2 gene expression. VPA’s inhibition of glutathione and 
glutathione’s effect on Hoxa2 may be direct or via several intermediary factors. The arrow with 
a cross indicates that the response is in one direction only since Hoxa2-/- mice do not display 
altered glutathione levels. The broken arrow indicates VPA could directly affect Hoxa2. A 
combination of reduced glutathione levels and downregulation of Hoxa2 may trigger a 
teratogenic response. B Pretreatment with 5 mM L-ascorbic acid prior to VPA exposure prevents 
VPA-induced decline in glutathione and Hoxa2 gene expression, protecting embryos from a 
teratogenic insult.  
 
5.5   Protective effect of ascorbic acid on VPA-induced teratogenicity   
      Treatment with  pro-vitamin C (tetra-isopalmitoyl ascorbic acid) is known to reduce levels of 
reactive oxygen species (ROS) (Yokoo et al., 2004). In addition, prolongation of life-span has 
been attributed to a decrease in ROS as a result of a caloric restricted diet (Dhahbi et al., 1998; 
Lipman et al., 1998) fed to mice, and in vitro cell lifespan increased in cell cultures after 
treatment with vitamin E (Yu et al., 1998), although this has not been conclusively proven. The 
ROS-induced DNA damage within a cell can also be prevented by ascorbic acid or its derivatives 
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(Kanatate et al., 1995). In this thesis, I report that cultured embryos treated with VPA (0.7mM) 
developed abnormal differentiation in brain areas such as hindbrain, midbrain, forebrain and 
optical system. A significant lower score was observed in the embryos of hindbrain, midbrain 
and forebrain compared to cultured embryos without drug treatment. The addition of ascorbic 
acid (5 mM) in cultured embryos reduced defects in VPA-target areas in the mouse developing 
brain. Additionally, the optic system of embryos after ascorbic acid treatment showed a better 
morphological score compared to VPA treatment alone. Ascorbic acid has a significant 
protective effect on embryos exposed to VPA (Fig. 5.2).  
Fig. 5.2 Schematic diagram showing the relationship between VPA, glutathione, epigenetic 
changes and Hoxa2 gene expression. A VPA increased DNA methylation and induced bivalent 
domain changes at Hoxa2 promoter (increased enrichment of H3K27me3 and decreased 
enrichment of H3K4me3); B Ascorbic acid reversed DNA methylation and alteration of bivalent 
domain induced by VPA at the Hoxa2 gene promoter. 
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HDAC inhibitors and generation of ROS 
     The mechanisms of how HDAC inhibitors induce oxidative stress are not well understood. 
Two prominent mechanisms have been suggested. One involves regulating antioxidants levels 
and the other implicates mitochondrial damage (Miller et al., 2011).  
    Cellular exposure to HDAC inhibitors leads to accumulation of ROS. This relates to the 
intracellular thioredoxin reduction-oxidation system (Duncan et al., 2011).  Thioredoxin (Trx) is 
a hydrogen donor that is required for activation of many proteins, including ribonucleotide 
reductase that is essential for DNA synthesis (Lilig and Holmgren, 2007). Thioredoxin responds 
to the stressful stimuli that cause ROS to increase (Ungerstedt et al., 2005). Moreover, HDAC 
inhibitors upregulate the expression of Trx binding protein (TBP2) (Butler et al., 2002; Xu et al., 
2006), which bind to and inhibit Trx activity in transformed cells (Butler et al., 2002; Nishiyama 
et al., 1999; Ungerstedt et al., 2005). Trx acts as an inhibitor of apoptosis signal regulating kinase 
1 (ASK 1) (Saitoh et al., 1998). Inhibition of Trx by TBP2 activates ASK1. Furthermore, HDAC 
inhibitors increase the expression of ASK1. These effects act together to induce apoptosis. ROS 
accumulation may also be a consequence of apoptosis (Xu et al., 2007).  
     Vorinostat, the hydroxamic acid, has also been reported to be associated with ROS production 
(Chandra 2009). Vorinostat (SAHA) promotes expression of the proapoptotic B-cell lymphoma 2 
(Bcl-2) family member, BH3 interacting-domain death agonist (Bid) (Ruefli et al., 2001). Bid 
induces ROS by translocation to mitochondria and subsequent disruption of mitochondria (Ruefli 
et al., 2001). 
Oxidative stress in embryo vs. cell line 
i) Sensitivity
An oxidation event early in G1 phase is a critical regulatory step in the progression to S phase, 
and this initiates the redox cycle within the cell cycle. The transient change of ROS could modify 
the redox state of cell regulatory proteins through critical cysteine residues (Markovic et al. 
2009). The sensitivity to oxidative impacts may vary depending on cell types and experimental 
conditions (Guo et al., 2010). Embryonic stem cells (ESC) proliferation and viability show 
comparable sensitivity to hydrogen peroxide (H2O2) as do fibroblasts and vascular cells (Guo et 
al., 2010). The shifts in the redox potential determine the redox sensitive signaling and 
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regulatory pathways (Attene-Ramos et al., 2005; Imhoff and Hansen 2011; Jones et al., 2004; 
Nkabyo et al., 2002; Schafer and Buettner, 2001). The mechanisms are particularly important 
and relevant to developing embryos because the precise coordination of proliferation, 
differentiation, apoptosis, and necrosis are required for the temporal and spatial body formation 
and function (Harris and Hansen, 2012).  
ii) Timing in cell cycle
Glutathione (GSH) is generally recruited into the nucleus in early phases of cell proliferation 
when cells are in an active division state (Markovic et al., 2010). It later redistributes uniformly 
between the nucleus and cytoplasm when cells reach confluence (Markovic, et al., 2007). In my 
studies, NIH3T3 cells were incubated with VPA for 24 h and the doubling time for NIH3T3 cells 
is 18 h (ATCC, Specifications for 3T3-Swiss albino). Within 24 h when NIH3T3 cells were 
proliferating, GSH  is primarily accumulated in the nuclei, hence GSH was not significantly 
reduced in NIH3T3 cells treated with VPA at low concentration from 25 to 50 µg/mL. This 
finding demonstrated that short-term oxidative stress induced by VPA does not impact NIH3T3 
cells. It has been suggested that the reduced intracellular environment as cells progress from 
quiescence to proliferation may protect genomic DNA from oxidative damage upon breakdown 
during mitosis (Conour et al., 2004).  
iii) Function
Appropriate ROS levels generated within the cells may act as signaling molecules that trigger a 
wide range of cellular processes such as cellular defense (Yoon et al., 2002), and vascular 
functions (Rhee et al., 2005; Taniyama and Griendling 2003), differentiation, and proliferation 
(Kim et al., 2001; Sauer and Wartenberg 2005; Stouffs et al., 2006) depending on cell types. In 
normal embryonic development, energy production is generally achieved by a few metabolic 
pathways involved with O2 utilization (Takahashi, 2012). ROS levels are highly related to 
cellular function and signal transduction. Therefore, the cellular redox balance is very important 
for providing suitable environments for metabolic pathways and gene expression in developing 
embryos (Takahashi, 2012).  
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However, in cells when the level of oxidative stress is beyond the capacity of cells to manage, 
apoptosis may be the best means to avoid transmission of mutation or other damages to the 
descendant cells (Guo et al., 2010). Oxidative status is usually used as a way to estimate the 
oxidative damage and associated dysfunctions in developing embryos (Takahashi, 2012). 
Thiol-based biomolecules, as antioxidants, are one of the central and important cellular 
substances used to determine embryotoxicity (Harris and Hansen, 2012). It has been reported 
that the embryotoxicity caused by several classes of teratogens were altered significantly as a 
function of GSH status within cells and embryonic tissues (Harris 1993; Harris et al., 1995; 
Harris et al., 1988; Harris et al., 2004; McNutt and Harris 1994; Ozolins et al., 2002). Spatial and 
temporal patterns of GSH activity also show highly selective patterns of synthesis, turnover, and 
disposition of GSH, depending on the availability of amino acid precursors and cofactors, and 
gene expression (Harris and Hansen, 2012). In my experimental system, the developing mouse 
embryos appeared to be more vulnerable to VPA exposure compared to NIH3T3 cells. The 
changes of GSH in embryos were more significant and demonstrated tissue and organ 
malformations. Moreover, the  impact of the antioxidant ascorbic acid on GSH status was also 
more significant in the embryos compared to NIH3T3 cells.   
5.6 Epigenetic regulation of Hoxa2 gene 
5.6.1  CpG methylation status of the Hoxa2 gene promoter in cell lines 
     A growing body of evidence has indicated that methylation of cytosines within CpG 
dinucleotides on genes is an important mechanism for differential regulation of gene 
transcription in mammalian cells (Frigola et al., 2006; Hitchins et al., 2007; Meissner et al., 2008; 
Mohn et al., 2008; Widschwendter et al., 2007). Three CpG islands on Hoxa2 gene promoter 
were predicted using the following website (http://www.urogene.org//methprimer/)(Li and 
Dahiya, 2002) and manually identified using bisulfite specific PCR (BSP) sequencing.  The three 
identified CpG islands on the Hoxa2 gene promoter are: CpG island 1 (-277 to -620 bp), CpG 
island 2 (-919 to -1133 bp), and CpG island 3 (-1176 to -1301 bp) (Fig. 5.3). It is known that de 
novo methylation of CpG islands is associated with the transcriptional silencing of genes in many 
cancers (Esteller, 2007; Jones and Baylin, 2007). Data from my study indicates that methylation 
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status of specific CpG sites on the Hoxa2 gene promoter in two different cell lines appears to 
correlate with the transcriptional activities of Hoxa2. Unmethylated CpG sites were found on the 
Hoxa2 gene promoter in NIH 3T3 cells when Hoxa2 gene is activated, whereas these same CpG 
sites were methylated in EG7 cells that do not express Hoxa2.   
Fig. 5.3 Three CpG islands on Hoxa2 gene promoter 
5.6.2    Effect of VPA on CpG methylation status of Hoxa2 gene promoter in cell lines 
VPA inhibits Hoxa2 gene expression in NIH3T3 cell lines (Fig. 4.2.5) and enhances the 
DNA methylation status of CpG island 1 closer to the Hoxa2 transcription start site (Fig. 4.2.6). 
Cells treated with 100 µg/mL [0.7 mM] VPA increased methylation at CpG
-617
, CpG
-582
, CpG
-577
,
CpG
-569
, CpG
-514
 sites by 3-9%, and enhanced methylation at CpG
-551
, CpG
-553
, CpG
-540
, CpG
-509
and CpG
-492
 sites by as much as 30-50%. The later five CpG sites that are closer to Hoxa2
transcription start site may be critical regions for DNA methylation in silencing Hoxa2 
expression. Although it is not known how methylation status of the Hoxa2 gene promoter affects 
the transcription of this gene, reduced Hoxa2 gene expression could be due to direct blocking of 
the binding of transcription factors to methylated CpG sites (Mohn et al., 2008). Alternatively, 
binding of methyl-CpG-binding proteins to methylated CpG sites (Widschwendter et al., 2007)  
on the gene promoter may block expression of the Hoxa2 gene.  
To investigate if DNA methylation played a general role in Hoxa2 regulation, EG7 cells 
were also tested. This cell line does not express Hoxa2 (Fig.4.2.1) and is highly methylated at all 
of the CpG sites on the Hoxa2 promoter (Fig. 4.2.2). It was reasoned that treatment with 5-Aza, a 
DNA demethylating agent (Lemaire et al., 2008), may block methylation on the Hoxa2 promoter 
and induce the cells to start expressing Hoxa2. However, exposure to VPA (200 µg/mL) or to 5-
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Aza (2.3 µg/mL [10 µM]) did not change the DNA methylation status in any of ten CpG sites 
(CpG
-617
, CpG
-582
, CpG
-577
, CpG
-569
, CpG
-551
, CpG
-553
, CpG
-540
, CpG
-514
, CpG
-509
, and CpG
-492
)
of CpG 1 island in EG7 cells (Fig.4.2.8). Since these CpG sites are already highly methylated it 
was expected that VPA would have little or no effect on DNA methylation but it was expected 
that 5 Aza would demethylate the CpG sites.  A higher concentration of 5 Aza were toxic to the 
EG7 cells and  2.3 µg/mL [10 µM] is highest dose that has been used (Lemaire et al., 2008). Not 
surprisingly, exposure to 5 Aza at doses 0.23 µg/mL [1 µM] to 2.3 µg/mL [10 µM] or to VPA 80 
µg/mL (0.56 mM) and 200 µg/mL (1.4 mM) also did not induce Hoxa2 expression (Fig.4.2.8). 
Unfortunately, since 5 Aza had no effect on the DNA methylation status of the CpG island and 
no effect on Hoxa2 expression it was difficult to conclude whether DNA methylation in general 
played a role in regulating Hoxa2 expression.  
5.6.3  CpG methylation status of the Hoxa2 gene promoter in developing embryos 
     Specific DNA methylation patterns are essential for early embryogenesis (Li et al., 1992). 
Since Hoxa2 gene expression begins in mice at E8 to E8.5 stage of development (Prince and 
Lumsden, 1994b), I wanted to examine the DNA methylation profile of the Hoxa2 gene 
promoter in mouse embryos at stages E6.5, E8.5 and E10.5.  Interestingly, all of the CpG sites on 
the three CpG islands [CpG island 1 (-277 to -620 bp); CpG island 2 (-919 to -1133 bp), and 
CpG island 3 (-1176 to -1301 bp)] of the Hoxa2 promoter remained unmethylated in E8.5 and 
E10.5 embryos when Hoxa2 gene expression is evident (Fig. 4.2.10, 4.2.11, 4.2.12 ). However in 
E6.5 embryos, the CpG island 1 that is closer to transcription start site revealed partially 
methylated CpG sites (methylated at CpG
-551
, CpG
-553
, CpG
-540
, CpG
-509
, and CpG
-492
)
 
while the
CpG sites on both CpG island 2 and 3 remained unmethylated. This finding implies that 
methylation of CpG sites on island 1 may play a more prominent role in Hoxa2 gene regulation.  
Pyrosequencing revealed percent methylation of all 10 CpG sites (CpG
-617
, CpG
-582
, CpG
-577
,
CpG
-569
, CpG
-551
, CpG
-553
, CpG
-540
, CpG
-514
, CpG
-509
, and CpG
-492
) on CpG island 1 in E6.5
embryos were higher than at E8.5 and E10.5. As CpG island 1 is closest to Hoxa2 transcription 
start site and the most affected, differential DNA methylation status at this site between E6.5 and 
E8.5/E10.5 suggest a potential role for DNA methylation of CpG island 1 in regulating Hoxa2 
gene expression during the mouse embryonic development. The methylated status of several 
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CpG sites (methylated at CpG
-551
, CpG
-553
, CpG
-540
, CpG
-509
, and CpG
-492
) on CpG island 1 in
embryos at E6.5, may be one mechanism for transcriptional silencing of Hoxa2 expression. 
5.6.4  Effect of VPA on CpG methylation status of Hoxa2 gene promoter in developing 
embryos 
Bisulfite sequencing of Hoxa2 gene promoter in E10.5 embryos exposed to VPA revealed 
methylation at CpG
-551
, CpG
-553
, CpG
-540
, CpG
-509
, and CpG
-492
 sites of CpG island 1 (Fig.
4.2.13). However, pyrosequencing data revealed increased percent DNA methylation at all 10 
CpG sites of CpG island 1 (from CpG
-492
 to CpG
-617
) although these only reached significance at
CpG
-617
, CpG
-582
, CpG
-577
, CpG
-569
, CpG
-551
, CpG
-553
, CpG
-540
 sites when compared to untreated
control embryos (Fig 4.2.14), ranging from 1-20%. VPA exposure also inhibits Hoxa2 
expression in these embryos (Fig.4.1.7), hence VPA induced methylation of the CpG sites on 
island 1 may be involved in the transcriptional silencing of Hoxa2.  Interestingly, similar DNA 
methylation profile at CpG island 1 in E6.5 embryos when Hoxa2 gene is not expressed does 
lend support to the suggestion that CpG island 1 may play a critical role in transcriptional 
silencing of Hoxa2 expression. Although VPA is well known for its HDAC inhibitory properties 
(Phiel et al., 2001) this is the first time it has been demonstrated to induce DNA methylation. 
Hence, VPA appears to have dual role as a HDAC inhibitor and induction of DNA methylation 
in regulating gene expression. 
5.6.5 Effect of VPA on enrichment of DNA methyltransferases in NIH3T3 cell line and in 
E10.5 mouse embryos 
     Since VPA induced methylation of specific CpG sites on the Hoxa2 promoter, it was 
interesting to find enrichment of the enzyme DNA methyltransferase 1(Dnmt1) at the CpG island 
1 of Hoxa2 promoter in both NIH3T3 cells exposed to VPA (Fig. 4.2.15a) and in E10.5 embryos 
treated with VPA (Fig. 4.2.15b). These findings in NIH3T3 cells and in the embryo, indicates 
that VPA induces hypermethylation by either directly or indirectly increasing the relative 
occupancy of Dnmt1 at the Hoxa2 gene promoter. Although VPA induced hypermethylation 
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appears to play an important role in suppressing Hoxa2 expression, the role of other transcription 
factors or the essential role of histone modifications cannot be excluded. 
5.6.6  Bivalent chromatin domains associated with Hoxa2 promoter in cell lines 
     To investigate if histone modifications had a role in regulating Hoxa2 gene expression, 
qChIP-PCR was used to determine whether histone bivalent domains (H3K4 and H3K27 
trimethylation) were enriched at the Hoxa2 gene promoter. H3K4 and H3K27 trimethylation 
possess both activating and repressive effects respectively, on developmental genes (Bernstein et 
al., 2005). H3K4 and H3K27 methylation are catalyzed, respectively, by trithorax- and 
polycomb-group proteins, which mediate mitotic inheritance of lineage-specific gene expression 
programs and have key developmental functions (Ringrose and Paro, 2004). The enrichment of 
bivalent domains is associated with low-level of gene expression (Bernstein et al., 2005). 
Previous study also suggests that the trithorax complexes that methylate histone 3 at Lys 4 are 
associated with CpG-rich DNA (Ayton et al., 2004; Lee and Skalnik, 2005). My data revealed 
the bivalent domains, H3K27me3 and H3K4me3, were simultaneously associated at the CpG-
rich DNA region of the Hoxa2 promoter (Fig. 4.2.18). H3K27me3 and H3K4me3 co-occupied at 
Hoxa2 gene promoter may provide an epigenetic mechanism that maintains expression or 
repression of Hoxa2. Hence it is possible that these bivalent domains together with DNA 
methylation play a role in regulation of Hoxa2 gene expression. This was further investigated in 
developing embryos and in cell lines treated with VPA (see below).  
5.6.7. VPA increased H3K27me3 and decreased H3K4me3 enrichment at the Hoxa2 gene 
promoter in the NIH3T3 cell lines 
NIH3T3 cells exposed to VPA had a differential effect on the H3K27me3 and H3K4me3 
bivalent domain marks. The histone modification mark, H3K27me3 which suppresses gene 
expression, is significantly enriched at the Hoxa2 gene promoter even at the lowest VPA 
concentration (Fig.4.2.19b). In contrast, the enrichment of the active histone modification mark, 
H3K4me3, was significantly reduced at all VPA doses relative to the control untreated group 
(Fig.4.2.19c). Interestingly, this dynamic change in bivalent domain marks appears to be 
dependent on the methylation status of the Hoxa2 promoter. In the EG7 cells where Hoxa2 
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promoter is highly methylated and Hoxa2 gene is not expressed (Figs. 4.2.1 and Fig. 4.2.3) there 
was no change in the H3K27me3 and H3K4me3 bivalent domain marks in wild type or VPA 
treated cells (Fig. 4.2.20). Generally, for chromatin domains over a gene promoter, an active 
domain mark (e.g H3K4me3) is defined by high transcriptional rates, whereas a repressive 
chromatin domain mark (e.g. H3K27me3) is characterized by low transcriptional rates 
(Rodriguez et al., 2008b). The observed increased enrichment of H3K27me3 and a 
corresponding decreased enrichment of H3K4me4 in the same region of Hoxa2 gene promoter 
near the transcription start site may explain lower Hoxa2 expression in NIH 3T3 cells treated 
with VPA. Hence this differential effect on the histone bivalent domain marks over the CpG 
island 1 of the Hoxa2 promoter could have a role in Hoxa2 gene regulation. 
5.6.8 A dynamic transition of bivalent domains is associated with Hoxa2 gene expression 
during the mouse development (E6.5-E10.5) 
     To gain further insights into the mechanism(s) that lead to initiation of Hoxa2 expression in 
the developing embryos or in the transcriptional silencing of Hoxa2 gene in mouse embryos 
treated with VPA, I first characterized bivalent domains of H3K27me3 and H3K4me3 at the 
Hoxa2 promoter between E6.5 and E10.5. The chromatin profiling revealed the coexistence of 
active H3K4me3 and inactive domains H3K27me3 at the Hoxa2 promoter. These results raise 
intriguing facts about the establishment and function of chromatin structure on Hoxa2 gene 
during development. The enrichment of H3K27me3 at the Hoxa2 gene promoter is significantly 
reduced in embryos at E8.5 and E10.5 compared to embryos at E6.5. In contrast, H3K4me3 is 
the significantly enriched at the same region of Hoxa2 promoter in E8.5 and E10.5 compared to 
embryos at E6.5. The data suggest the transcriptional activation of Hoxa2 gene occurs with 
change in transition of enrichment from H3K27me3 to H3K4me3 during mouse development 
from E6.5 to E10.5. Interestingly, a reverse change in transition following VPA treatment with a 
significantly higher relative occupancy of H3K27me3 (Fig. 4.2.25a) and a significantly lower 
relative occupancy of H3K4me3 (Fig. 4.2.25b) at the Hoxa2 gene promoter in E10.5 embryos is 
observed and correlates with a reduction in Hoxa2 expression (Fig. 4.1.7, Table 4.1.4). Similar 
change in the bivalent domains was also observed in VPA treated NIH3T3 cells when Hoxa2 
mRNA is down-regulated (Fig. 4.2.19). Hence the increased relative occupancy of H3K4me3 
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and a parallel relative decrease in H3K27me3 occupancy appear to be required for subsequent 
gene activation during development (Orlando et al., 1998; Schmitt et al., 2005). A similar 
observation also was observed in a recent study of the sequential epigenetic activation of Hoxd 
cluster in developing murine tail buds (Soshnikova and Duboule, 2009b). In this study, a highly 
dynamic equilibrium was identified where demethylation of H3K27 paralleled an increase in 
trimethylation of H3K4, along with progressive gene activation. The region of transition between 
these two chromatin states corresponds to the areas where Hoxd genes become transcriptionally 
active, and this expression region of Hoxd genes shifts from one end of the cluster to the other 
during gastrulation (Soshnikova and Duboule, 2009a; Soshnikova and Duboule, 2009b) .  
5.6.9 Changes in histone bivalent domain marks and DNA methylation status after 
exposure to VPA appear to be involved in transcriptional silencing of Hoxa2 gene 
     The gene regulatory mechanism is a complicated process that involves discriminatory actions 
of transcriptional factors as well as epigenetic modifications including DNA and histone 
modifications (Wilson et al., 2005). The bivalent domains of H3K4me3 and H3K27me3 were 
characterized at Hoxa2 gene promoter, indicating the intermingled presence of active and 
inactive histone methylation marks associated with Hoxa2 gene transcriptional activity.  
     For transcription-related chromatin modifications that occur at specific gene promoters, an 
active domain is defined by high transcriptional rates, whereas the repressive chromatin domain 
is characterized by low transcriptional rates (Rodriguez et al., 2008a). The CpG island 1 is where 
the bivalent domains were identified and may play a crucial role in epigenetic regulation of 
Hoxa2 gene expression. In the mouse embryos at E8.5 that have active Hoxa2 gene expression, 
the CpG island 1 is very likely associated with active chromatin domains, which is featured by 
active transcription of Hoxa2 mRNA, unmethylated CpG sites, high levels of transcriptional 
active histone modification H3K4me3 and low levels of transcriptional repressive histone 
modification H3K27me3. In contrast, the same region in embryos at E6.5 that has an inactive 
chromatin domain is defined by DNA hypermethylation, low enrichment of H3K4me3 and high 
levels of H3K27me3 enrichment leading to transcriptional silencing of Hoxa2 gene.  
     The VPA-dose-dependent increased enrichment of H3K27me3 at the Hoxa2 gene promoter 
suggested the components of the polycomb protein groups could be mediating, at least in part, 
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the silencing Hoxa2 gene expression following VPA treatment. The reduction in enrichment of 
H3K4me3 at the Hoxa2 gene was not as much affected in a VPA concentration dependent 
manner. Hence, transcriptional inhibition of Hoxa2 gene expression after VPA treatment could 
be the result of changes in enrichment of bivalent domains and DNA hypermethylation at the 
gene promoter. 
5.6.10 Enrichment of Ezh2 at the Hoxa2 gene promoter 
     The PcG protein Ezh2 is a histone methyltransferase and catalyses the formation of H3K27 
trimethylation (H3K27me3) (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; 
Muller et al., 2002), resulting in the subsequent recruitment of additional PcG proteins 
contributing to the formation of a repressive chromatin state (Cao et al., 2002; Czermin et al., 
2002; Kuzmichev et al., 2002). Treatment with VPA resulted in an increase in relative 
occupancy of Ezh2 at the Hoxa2 gene promoter in E10.5 embryos in vivo and in NIH3T3 cells in 
vitro, which is in concordance with the higher enrichment of the H3K27me3 mark at this region 
when Hoxa2 expression is downregulated. 
     In addition to Ezh2, DNMTs are also key epigenetic regulators involved in transcriptional 
repression by inducing promoter DNA methylation (Bachman et al., 2003; Fuks et al., 2000; 
Fuks et al., 2001). My data demonstrates that VPA induced increased binding capacity of Dnmt1, 
in agreement with the increased DNA methylation status at the Hoxa2 gene promoter.  
      EZH2 is reported to associate with both the amino-terminal and carboxy-terminal regions of 
DNMTs (Vire et al., 2006). In vivo immunoprecipitation experiment (Vire et al., 2006) showed 
endogenous EZH2 precipitated with endogenous DNMT1, DNMT3A and DNMT3B. These 
results suggest that EZH2 associates with DNA methyltransferase activity, and interacts with 
DNMTs in components of PRC2/3 complexes (Vire et al., 2006). To test whether silencing of 
Hoxa2 gene requires both Ezh2 and DNA methyltransferase, I performed chromatin 
immunoprecipitation assays. An increase in occupancy of Ezh2 and H3K27me3 at Hoxa2 
promoter after VPA coincided with a significant increase in DNMT1 binding to the Hoxa2 
promoter. Interestingly, VPA treatment in EG7 cells that have completely methylated CpG sites 
on the Hoxa2 promoter did not impact binding of H3K27me3 at Hoxa2 promoter. Taken together, 
it can be reasoned that the binding of Ezh2 may be necessary for binding of DNMT1 to the 
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unmethylated Hoxa2 promoter.  In contrast, in methylated Hoxa2 promoter (e.g EG7 cells) Ezh2 
or H3K27me3 binding is not required. 
     Next, I wanted to determine whether Ezh2 might influence DNA methylation status at the 
Hoxa2 gene promoter. A number of CpG sites (CpG
-551
, CpG
-553
, CpG
-540
, CpG
-509
, and CpG
-492
)
located within the CpG island 1 were significantly methylated in VPA treated groups where 
higher level of Ezh2 was induced. These results may imply that Ezh2 is needed for CpG 
methylation of Ezh2-target Hoxa2. Our data suggest that PcG protein Ezh2 may be important in 
regulating CpG methylation through perhaps direct contact with DNMT1.   
   We can further speculate that the alteration of Ezh2-mediated H3K27 trimethylation and 
DNMT1 binding status induced by VPA may work together as part of an epigenetic program 
integrating Hoxa2 gene-silencing.  Other similar studies have also revealed that silencing of 
MYT1 gene expression requires both EZH2 and DNA methyltransferases, and the association of 
EZH2 is necessary for binding of DNA methyltransferases to EZH2-target promoters (Vire et al., 
2006). VPA enriched to a high level the inactive chromatin domain mark H3K27me3 and 
increased CpG methylation at Hoxa2 promoter near transcription start site. This could inhibit the 
transcription regulator binding at the Hoxa2 promoter, as a consequence, repressing Hoxa2 gene 
transcription (Fig.5.4).  
Fig.5.4 Ezh2 may be needed for binding of DNA methyltransferase (Dnmt1) and facilitates CpG 
methylation of Ezh2-target Hoxa2 promoter through contact with Dnmt1 
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VPA acts to repress Hoxa2 expression 
i) Histone acetylation plays an important role in chromatin modification and regulate gene
transcription (Struhl, 1998). In general, histone acetylation by histone acetyltransferases loosens 
chromatin packaging and is associated with transcriptional activation, whereas histone 
deacetylation by HDACs is correlated with transcriptional repression (Struhl, 1998). Histone 
acetylation is a dynamic process and the acetylation level is determined by the balance of the 
activities between acetyltransferases and HDACs (Qiao et al., 2006). However, recent studies 
have indicated that histone deacetylation can also associate with transcriptional activation in 
certain genes (Nusinzon and Horvath 2005). VPA and other HDAC inhibitors generally increase 
histone acetylation by inhibiting HDAC activity. However, it has recently been reported that 
inhibition of HDAC activities also suppresses certain gene expression such as c-myc, 
interleukin-2 (IL-2), IL-8, and leucocyte-phosphotyrosine phosphatase (LC-pTP) (Gurvich and 
Klein 2002; Huang et al., 1997; Takahashi et al., 1996; Van Lint et al., 1996). HDAC inhibitors 
TSA or trapoxin could upregulate or downregulate gene expression (Van Lint et al., 1996). 
Therefore, HDAC inhibitors modulate gene transcription either positively or negatively in a 
gene-specific manner (Qiao et al., 2006).  
     VPA directly inhibits class I and II HDACs (Gottlicher et al., 2001; Gurvich et al., 2004; 
Phiel et al., 200;). Our study showed that VPA directly suppress Hoxa2 expression. However, 
further studies need to be carried out to determine whether VPA increases in acetylation of both 
histones H3 and H4, and activities of HDAC1 and polymerase II at the Hoxa2 locus change in 
response to VPA to investigate whether inhibition of HDAC activity is directly correlated with 
VPA-induced down-regulation of Hoxa2 expression in cells and developing embryos.   
ii) The general conclusion from our current study is that both active (H3K4me3) and repressive
(H3k27me3) epigenetic marks together dictates the levels of Hoxa2 mRNA expression in the 
developing embryo and cell line. DNA hypermethylation together with repressive histone 
modification (H3K27me3) dictate the silencing or extreme reduction in Hoxa2 expression in 
mouse developing embryos and NIH3T3 fibroblast cells treated with VPA. When VPA was 
applied to embryos and NIH3T3 cells, it changed the bivalent chromatin pattern at the Hoxa2 
promoter. Our results are consistent with a recent study that showed global expression levels of 
the HOXA cluster genes during H9hESC differentiation where lower gene expression correlates 
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with the poorer enrichment of histone modification marks generally associated with active gene 
transcription (H3K4 trimethylation, dimethylation, and H3/H4 acetylation) (Atkinson et al., 
2008). 
     The H3K27 trimethylation regulated by the PRC2 complex serves as a recruitment signal for 
the other polycomb complex, PRC1, whose core component (PC) recognizes H3K27me3 
through its chromodomain (Min et al., 2003). Although the transcriptionally repressive role for 
PcG is well established, the precise molecular mechanisms by which silencing are achieved at 
PcG-target genes are not fully understood (reviewed by Sparmann and van Lohuizen, 2006). The 
in vitro interactions between EZH2 and DNA methyltransferases 
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(Vire et al., 
2006), and between EED (another core component of the PRC2 complex) and HDACs (van der 
Vlag and Otte 1999) suggests that both DNA methylation and histone deacetylases have been 
associated with polycomb-mediated silencing (Garrick et al., 2008). Recent work has also linked 
PRC2 to DNA methylation in neuronal development and differentiation in mice (Mohn et al., 
2008; Schlesinger et al., 2007). In this study, I demonstrate that although the PRC2 complex (as 
indicated by Ezh2) and DNMT1 were increased in response to VPA in the developing embryos 
and NIH3T3 fibroblast cells, Ezh2 and DNMT1 proteins co-occupy the same promoter sites of 
Hoxa2, and transcription may be down-regulated via recruitments of both DNA 
methyltransferase and histone methyltransferase proteins. Moreover, this may indicate that 
epigenetic repressors (MBD and most likely others) form a large complex that cooperatively 
participates in regulation of Hoxa2 gene expression. However, the mechanisms of recruitment 
and their precise interactions between Ezh2 and DNMT needs further characterization. 
iii) Lastly, although the DNA sequence elements responsible for binding of PcG complex
(Polycomb response elements, PREs) have not yet been identified in mammals (Garrick et al., 
2008), the PRE elements are included within promoter CpG islands, and the associations 
between PREs and CpG islands have been reported by some studies (Roh et al., 2006; Tanay et 
al., 2007). Furthermore, bioinformatic analyses suggested that binding of PRC2 is partially 
influenced by the structural characteristics of the CpG islands (Garrick et al., 2008). It is more 
likely that genomic factors other than DNA sequence may also be associated with PcG 
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recruitment at Hoxa2 gene. It can also be hypothesized that VPA treatment may also alter signal 
pathway(s) or transcription factor(s) and thereby inhibit Hoxa2 gene transcription.  
5.6.11 Ascorbic acid decreased DNA methylation at Hoxa2 gene promoter in NIH 3T3 cells 
treated with VPA 
     It is possible that ascorbic acid may exert a protective effect through epigenetic modifications, 
particularly since treatment with ascorbic acid can restore Hoxa2 gene expression following 
VPA exposure. To test this possibility, we investigated the effect of ascorbic acid on DNA 
methylation status at the Hoxa2 gene promoter after treatment of NIH3T3 cell line with VPA. 
Interestingly, ascorbic acid significantly decreased DNA methylation by 30-47% at CpG
-551
,
CpG
-553
, CpG
-540
, CpG
-509
, and CpG
-492
 that were hypermethylated following VPA treatment
(Fig.4.2.7). 
     Fuso et al., (2005) analyzed levels of methylation of CpG islands on the promoter of the APP 
and the PSEN1 genes in human cell lines, observing that in conditions of folate and vitamin B-12 
deficiency, there was a variation in the methylation status of the PSEN1 promoter, with a 
subsequent deregulation of the production of PSEN1, BACE (the β-secretase) and APP proteins 
(Fuso et al., 2005). This study confirmed that some of the genes responsible for the production of 
Aβ fragments in Alzheimer’s disease (AD) can be regulated through an epigenetic mechanism 
depending on the cellular availability of folate and vitamin B-12, and affected the production of 
S-adenosyl methionine (SAM) and the status of methylation of CpG islands in the DNA (Fuso et 
al., 2005).  
     Furthermore, prenatal or early life dietary and environmental exposures can have a profound 
effect on our epigenome, resulting in birth defects and diseases developed later in life (Reamon-
Buettner and Borlak, 2007). Epigenetic changes in DNA methylation can impact both gene 
transcription and the ability to repair damaged DNA (Reamon-Buettner and Borlak, 2007). 
Similarly, my data demonstrate that VPA induces oxidative stress by reducing GSH content and 
increases DNA methylation at Hoxa2 promoter. Ascorbic acid reversed oxidative stress, 
maintaining GSH homeostasis, hence normalizing DNA methylation at the Hoxa2 gene promoter, 
preventing silencing of Hoxa2 gene expression.  
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5.6.12 Ascorbic acid decreased H3K27me3 and increased H3K4me3 enrichment at Hoxa2 
gene promoter in NIH3T3 cells treated with VPA 
     We also examined the effect of ascorbic acid on histone bivalent domains. Ascorbic acid also 
reduced the enrichment of H3K27me3, whereas it increased the relative occupancy of H3K4me3 
at the Hoxa2 gene promoter. Recently, Hitchler et al., (2006) proposed a link between epigenetic 
regulation and transcriptional silencing of genes important in determining ROS levels such as 
superoxide dismutase 2 (SOD2) (the antioxidant gene encoding manganese superoxide 
dismutase). An epigenetic perspective of the free radical theory of development was proposed 
(Hitchler and Domann, 2007) where increased GSH production influences epigenetic processes 
including DNA and histone methylation by limiting the availability of S-adenosylmethionine, an 
important cofactor utilized by DNA and histone methyltransferases during epigenetic control of 
gene expression (Hitchler and Domann, 2007).   
     VPA induces dysmorphogenesis and birth defects in mouse embryos possibly through altering 
the DNA methylation and the association of histone bivalent domains at the Hoxa2 gene 
promoter, and ascorbic acid reverses this epigenetic alteration and protects the embryos from 
VPA induced toxicity (Fig.5.4).  
5.7 Oxidative stress associated telomerase and telomere dysfunction 
5.7.1 Tert expression is deregulated by VPA 
     Although knowledge of telomeres from cultured human cells has expanded, less is known 
about the biology of telomeres in vivo. We have used a mouse cell line and mouse embryos to 
investigate the effects of oxidative stress induced by VPA on telomere length and telomerase 
activity, and the effect of altered telomere length and telomerase activity on embryonic growth. 
In general, there is a close correlation between expression of the telomerase catalytic subunit 
(TERT) and telomerase activity (Liu, 1999). Most differentiated human somatic cells do not 
have TERT expression and telomerase activity, whereas germ cells, some stem cells, and a 
majority of cancers demonstrate both telomerase activity and TERT expression. In contrast, many 
tissues of adult rodents show abundant Tert expression and telomerase activity (Golubovskaya et 
al., 1997; Martin-Rivera et al., 1998; Miura et al., 1998; Yamaguchi et al., 1998). We first 
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examined Tert expression and observed a low level of telomerase activity in NIH3T3 cells and 
the mouse embryos. However, the reduced telomerase activity in VPA treated cells and embryos 
were accompanied by an increase in the abundance of Tert mRNA, indicating that 
posttranscriptional mechanisms could be involved in the VPA-regulated Tert expression as VPA 
is known as a histone deacetylase inhibitor. The upregulation of Tert expression by VPA may be 
through epigenetic mechanisms of histone or DNA modifications.  
     Santos et al., (Santos et al., 2004, 2006) have reported that ectopically expressed TERT in 
human fibroblasts under acute oxidative stress results in increased mitochondrial DNA damage. 
However, one study pointed out cells that overexpress TERT showed evidence for improved 
mitochondrial function, specifically less mitochondrial superoxide production and lower levels 
of cellular ROS, improved mitochondrial coupling and suppressed retrograde response (Ahmed 
et al., 2008). Our data showed that VPA caused overexpression of Tert, at the same time, 
induced oxidative stress as the result of reduced total glutathione and elevated GSSG/GSH ratio 
both in vivo and in vitro.  
 
5.7.2 Oxidative stress-mediated telomerase and telomere dysfunction  
     It had been noted that increased oxidative stress accelerated telomere shortening even in 
telomerase-positive cells (Furumoto et al., 1998; von Zglinicki, 2002). Our results show that 
VPA induced oxidative stress interferes with telomere length and maintenance at two levels: 1) 
increases the rate of telomere shortening, and 2) prevents telomerase from counteracting 
telomere shortening by reducing telomerase activity.  
     Telomerase maintains a normal telomeric length after many cellular divisions and plays a key 
role in cellular homeostasis (Brown et al., 2007). We found VPA reduced telomerase activity, 
and also, depleted the total glutathione content and increased GSSG/GSH ratio.  This decrease in 
telomerase activity could result from VPA-induced alterations in glutathione and thiol 
metabolism. Some studies (Brown et al., 1998; Brown et al., 2003; Brown et al., 2007) have 
demonstrated an increase in telomerase activity observed in the iron-loaded livers is 
accompanied by elevated levels of cysteine, γ-glutamyl cysteine, and glutathione as well as 
increased activity of rate-limiting enzyme glutamate cysteine ligase. (Brown et al., 2007) 
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Moreover, in cultured fibroblasts, telomerase activity is enhanced by a high ratio of GSH/GSSG, 
whereas activity is decreased after treatment with buthionine sulfoximine, an inhibitor of 
glutathione synthesis (Borras et al., 2004; Hayakawa et al., 1999). Consistent with these data, 
VPA may decrease the availability of reduced thiols, resulting in reduced telomerase activity. 
Although the data indicate telomerase activity in VPA treated cells and embryos is sensitive to 
modulatation by thiol redox state, this does not exclude the possibility that other mechanisms 
contribute to the reduction of telomerase activity exposed to VPA. Phosphorylation of human 
TERT by Akt/protein kinase B and protein kinase C has been implicated in nuclear translocation 
of TERT via interactions with NF-κB (Akiyama et al., 2002; Akiyama et al., 2003). It is likely 
that the glutathione redox potential may be important for maintaining the cysteine residue in a 
reduced state. Our results here indicate that telomerase is regulated by changes in glutathione 
redox potential following exposure to VPA (Borras et al., 2004).  
     We next measured telomere length in cells and embryos treated with VPA using quantitative 
real-time PCR. The relative average telomere length was assessed by a modified version of real-
time PCR-based method, in which the telomere repeat copy number to single gene copy number 
(β-globin) ratio (T/S) was determined (Cawthon, 2002; McGrath et al., 2007). Treatment with 
VPA induced telomere length shortening in developing embryos compared to the untreated 
control. Moreover, the reduced telomerase activity can directly accelerate telomere shortening, 
which is a consequence of oxidative stress induced by VPA treatment. 
     Two major pathways have been proposed to lead to senescence, telomere shortening and 
oxidative stress-mediated cellular damage. Particularly,  in fibroblast cells it has been reported 
that oxidative stress could cause telomere shortening due to 1) the high and very susceptible 
guanine content of the telomeres, and 2) the deficiency of telomeric DNA in repairing of single-
stranded breaks (Erusalimsky and Kurz, 2005; Houben et al., 2008; Kawanishi and Oikawa, 
2004; Passos and Von Zglinicki, 2006; von Zglinicki, 2002). 
     In summary, we have shown that histone methyltransferase Ezh2 is a novel target showing 
increased binding capacity at Hoxa2 promoter induced by VPA, resulting in increased repression 
by histone mark H3K27me3 at Hoxa2 promoter. Two groups of proteins (TrxG and PcG) have 
been implicated with histone bivalent domains (H3K4me3 and H3K27me3) in maintaining 
chromatin structure (Mahmoudi and Verrijzer, 2001; Simon and Tamkun, 2002). The PcG 
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protein, EZH2, is implicated in chromosome remodeling (Jones et al., 1998; Sewalt et al., 1998). 
Methylation of the histone H3 N-terminal tail causes stable changes in chromatin that define the 
status of gene expression (Strahl and Allis, 2000; Kouzarides, 2002). In the absence of 
telomerase activity, telomeres gradually shorten because of the inability of the DNA replication 
machinery to completely duplicate chromosome ends (Friedman, 2011). A novel VPA-induced 
mechanism for teratogenecity is proposed through epigenetic-mediated Hoxa2 gene repression 
and VPA-induced oxidative stress. In addition, as telomerase activity is associated with 
senescence and oxidative stress, it can be speculated that decreased telomerase activity and 
telomere shortening may be involved in the regulation of VPA-induced developmental defects. 
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CHAPTER 6: CONCLUSION 
 
     Many anticonvulsant drugs are teratogenic to the embryo and fetus when exposed in-utero 
(Diav-Citrin et al., 2008; Kultima et al., 2004; Morrow et al., 2006; Ornoy, 2003). My results 
demonstrate that VPA, a clinically used anticonvulsant drug, inhibits embryonic organ 
differentiation and development in the whole mouse embryo culture system in the therapeutic 
dose range 50 to 100 g/mL (0.35 mM to 0.7 mM). The scoring parameters measured in the 
assessment of embryonic development including yolk sac circulation, allantois, caudal neural 
tube, forebrain, and branchial arches have shown lower scores in the embryos treated with VPA, 
indicating these embryonic organs are particularly sensitive to VPA insult.  Several mechanisms 
have been proposed for VPA induced teratogenicity including folic acid deficiency, oxidative 
stress, and inhibition of histone deacetylase (Tabatabaei and Abbott, 1999; Weber et al., 1991; 
Wegner and Nau, 1991, Wiltse, 2005). Our data from in vitro and in vivo studies suggests VPA 
induces depletion of GSH and increases the GSSG/GSH ratio, reflecting an increase in oxidative 
stress. In addition, a dose-dependent inhibition of Hoxa2 gene expression after VPA treatment 
was also observed. Hox genes are embryonic developmental genes encoding transcription factors. 
They are key controllers of rostrocaudal patterning in early embryogenesis, particularly of 
hindbrain segmentation and rhombomere identity (Cordes, 2001; Lumsden, 2004). Hoxa2 gene is 
the only Hox gene expressed at the level of hindbrain rhombomere 2 (r2) in the neuroectoderm. 
It plays a crucial role as a selector gene in determining second arch fates and imposes the unique 
identity of second arch structures (reviewed by Trainor and Krumlauf 2001; Santagati et al. 
2005). Moreover, children affected by VPA develop a typical “fetal valproate syndrome” (FVS). 
Features include intrauterine growth restriction (IUGR) and facial dysmorphism such as mid-
facial hypoplasia, short nose with a broad nasal bridge, cleft palate and cleft lips (Dean et al., 
2000; DiLiberti et al., 1984). These facial features of FVS are suggestive of neural crest 
involvement in the pathogenetic mechanism (Fuller et al. 2002). Inhibition of Hoxa2 gene likely 
affects pattern formation in the branchial arch region (Santagati et al. 2005). These evidences 
suggest that  VPA-induced inhibition of Hoxa2 gene expression may play an important role in its 
teratogenicity. To delineate a relationship between VPA, oxidative stress and Hoxa2, total 
glutathione levels were measured in Hoxa2-/- embryos. Results suggest that glutathione levels 
are not altered in Hoxa2-/- embryos. Interestingly, treatment with ascorbic acid just prior to VPA 
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exposure prevented VPA-induced downregulation of Hoxa2 gene expression in concert with 
enhanced glutathione status, indicating VPA-induced inhibition of Hoxa2 is downstream of the 
VPA-induced depletion of glutathione. Moreover, the telomerase activity and telomere length are 
both regulated by changes in glutathione redox potential induced by VPA. As a consequence of 
oxidative stress induced by VPA, the reduced telomerase activity can directly accelerate 
telomere shortening. Telomere and telomerase dysfunction can lead to cellular apoptosis and 
senescence. This could be one of the mechanisms of VPA induced developmental malformations 
in mouse embryos.  
     Next, to determine if VPA is a direct epigenetic modulator regulating Hoxa2 gene expression, 
the effect of VPA on dynamic changes of transcription-associated histone trimethylation bivalent 
domains (H3K4me3 and H3K27me3) and DNA methylation status at Hoxa2 gene promoter was 
investigated. It has been reported that in ES cells Hox gene promoters often display both 
H3K4me3 active and H3K27me3 repressive marks, which are referred to as ‘bivalent domains’. 
Bivalent marks are mostly enriched at GC-rich promoters (Mikkelsen et al., 2007) where they 
may prevent DNA methylation and silencing in stem cells (Mohn et al., 2008). This equilibrium 
of active and repressive marks may maintain genes in a poised state, ready for rapid activation 
during cell differentiation (Azuara et al., 2006; Bernstein et al., 2006).  
     Characterization of the DNA methylation and bivalent domain status at Hoxa2 gene promoter 
was undertaken in the developing mouse embryos at E6.5, E8.5 and E10.5. Results showed that 
the higher percentage of DNA methylation of Hoxa2 gene promoter occurs at E6.5 and E8.5 
compared to E10.5, which corresponds to the Hoxa2 transcription level since Hoxa2 gene 
expression initiates at E8.0 (Prince and Lumsden, 1994). The increased level of H3K27me3 and 
reduced H3K4me3 at Hoxa2 promoter are also associated with the transcription of Hoxa2 gene 
expression in the developing embryo between E6.5 and E10.5. 
     We next investigated whether VPA altered the status of these bivalent domains. I 
performed ChIP real-time PCR (qChIP-PCR) to quantitate the enrichment of H3K27me3 and 
H3K4me3 at the Hoxa2 promoter. Treatment of NIH3T3 cell line and mouse embryos with VPA 
induced a significant increased enrichment of H3K27me3 and a significantly decreased 
enrichment of H3K4me3 at the Hoxa2 promoter. The VPA-dose-dependent increased enrichment 
of H3K27me3 at the Hoxa2 gene promoter suggested the components of the polycomb protein 
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groups could be mediating, at least in part, the silencing Hoxa2 gene expression following VPA 
treatment. The reduction in enrichment of H3K4me3 at the Hoxa2 gene was not as much affected 
in a VPA concentration dependent manner.  Transcriptional inhibition of Hoxa2 gene expression 
after VPA treatment could be the result of changes in enrichment of bivalent domains and DNA 
hypermethylation at the gene promoter. 
     My study also shows direct changes in chromatin status at CG-rich Hoxa2 gene promoter 
both in vivo and in vitro after VPA treatment. Additionally, increased CpG methylation induced 
by VPA was found to be associated with dynamic changes of bivalent domains in the same 
Hoxa2 promoter region. Thus, it appears that alteration of histone bivalent domains and 
increased DNA methylation cooperate with each other, serving important roles in VPA 
transcriptional silencing of Hoxa2 gene. Interestingly, the presence of ascorbic acid prevented an 
increase in H3K27me3 and a decrease in H3K4me3 enrichment induced by VPA at Hoxa2 gene 
promoter, and reduced higher level of DNA methylation induced by VPA both in vivo and in 
vitro. Taken together, this is the first study to assess the effects of VPA on oxidative stress as 
indicated by GSSG/GSH ratio, histone bivalent domains and DNA methylation status at Hoxa2 
gene promoter. Our results suggest that responses of ascorbic acid involving upregulation of 
glutathione level as well as blocking the epigenetic events occurring at Hoxa2 gene promoter, 
normalizing Hoxa2 gene expression in the presence of VPA, may represent an important 
protective mechanism against VPA-induced teratogenicity in the mouse embryos.  
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CHAPTER 7: FUTURE DIRECTIONS 
     Epigenetics provides stability and diversity to the cellular phenotype through chromatin 
marks that affect local transcriptional activity.  Epigenetic marks are preserved or regenerated 
during cell division and embryonic development. The complex time/space patterns of gene 
expression necessary for normal development are likely to require multiple epigenetic signals 
(Bonasio et al., 2010).  
     We have demonstrated H3K27me3 and H3K4me3, the bivalent domain, were localized on 
Hoxa2 gene promoter and affect the transcriptional level of Hoxa2 gene. As H3K4me3 is 
associated with RNA Pol II, it is necessary to further investigate how H3K27me3 cooperates 
with H3K4me3 to regulate the initiation of gene transcription on Hox gene clusters. How are 
bivalent domains timely patterned on the gene promoter, and associated with RNA Pol II to exert 
the effect on gene expression during embryonic development?  
     H3K9 is a substrate for both acetylation and methylation. Acetylation of H3K9 correlates 
with activation of gene expression (Agalioti et al., 2002). In contrast, methylation of H3K9 can 
lead to the recruitment of silencing proteins (Bannister et al., 2001; Lachner et al., 2001) and is 
directly linked to DNA methylation in a number of human cell lines (Esteve et al., 2006). Since 
the acetylation of H3K9 precludes methylation, it would be interesting to investigate the effect of 
VPA on modification status of H3K9 associated with bivalent domains. In this case, the action of 
TrxG protein MLL1 in the Hox loci may generate and stabilize a pattern of chromatin 
modifications (H3K4me3) required for Hox gene expression.  
     Progress has been made in understanding the versatile role of PcG proteins, especially PRC2 
protein. PRC is not only involved in the regulation of a broad array of biological processes, but it 
also establishes regulatory cues that are stable and propagated throughout embryonic 
development (Margueron and Reinberg, 2011). Previous studies have demonstrated PRC2 must 
be targeted to chromatin by a coordinated and intricate process to maintain the repression of 
different sets of genes dependent on cell types and developmental stages. These steps may 
require specific DNA sequences, non-coding RNA (nc RNA) and the chromatin structure 
proteins associated with its target genes (Margueron and Reinberg, 2011). Answering the 
questions such as: how ncRNA can recognize defined genomic locations? What is the exact 
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mechanism by which histone methyltransferase Ezh2 and histone demethylase JARID2 proteins 
contribute to PRC2 recruitment, will provide a future direction for pinpointing the aspects of 
PRC2-mediated processes on Hoxa2 gene promoter.  
     Studies developed during the last two decades have also shown the importance of GSH during 
the process of mammalian chromatin sperm decondensation (Maeda et al., 1998; Perreault et al., 
1984; Romanato et al., 2005). The alteration of nuclear redox conditions modulates chromatin 
conformation and stability (Markovic et al., 2010). Oxidants induce degradation of higher 
ordered chromatin structures (Bai and Konat, 2003). Oxidation of chromatin affects interaction 
between nucleosomes and the levels of reducing agents in the nucleus (Tas and Walford, 1982). 
However, the overall redox mechanisms that may regulate all these events remain unknown, 
although it has been speculated that ROS generation induced by a shift in the redox status of 
cells could affect gene expression by altering chromatin conformation (Hitchler and Domann, 
2007).  
     Glutathione is closely connected with epigenetic mechanisms. Indeed, synthesis of S-
adenosylmethionine (SAM) by SAM synthetases is a redox regulated process that depends on the 
GSH/GSSG ratio. When cells are depleted of glutathione by chemical means, methyl donors 
become deficient, leading to genome-wide DNA hypomethylation (Lertratanangkoon et al., 1996; 
Lertratanangkoon et al., 1997). However, we found VPA induced oxidative stress and also 
increased DNA methylation at Hoxa2 gene. There could be other mechanisms related to VPA-
induced hypermethylation at Hoxa2 gene. Therefore, it will provide valuable insight to showing 
chromatin remodeling events occurring or directly linking histone modification with GSH 
depletion induced by oxidative stress.   
     Telomere attrition is modulated by oxidant-antioxidant balance (Saretzki, 2009). GSH is the 
most abundant non-protein thiol in most cells. The thiol moiety of GSH is important in 
antioxidant defense metabolism (Ketterer 1982; Meister 1983; Ziegler 1985). The response of a 
cell to an oxidative stress often involves changes in thiol content, and is then replaced through 
either enzymatic reduction of a disulfide, or by de novo synthesis. These changes in thiol content 
and metabolism can have effects on signaling pathways (Arrigo 1999; Dickinson and Forman 
2002). We have shown the changes in telomerase activity by VPA associated with VPA-induced 
decreases in glutathione and thiol status (Fig.4.1.2, Fig. 4.1.5, Fig. 4.1.6, Fig. 4.1.8). Further 
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studies are needed to determine whether VPA-induced dysfunction in telomerase activity 
modulates apoptosis, and what is the enzyme machinery?  
     Telomerase regulation is complex and has prominent consequences not just for telomere 
length, but also for the development of many diseases (Koziel et al., 2011). Obtaining further 
insight into the role of telomerase gene regulation and therefore telomerase activity in disease 
development will assist in the generation of clinical therapies (Koziel et al., 2011). More recently, 
regulation of telomerase activity has been found not only to be controlled at the TERT 
transcriptional level, but also determined at the post-transcriptional level (Liu et al., 1999). 
Phosphorylation and nuclear translocation both play an important role in the post-transcriptional 
regulation of telomerase (Liu et al., 2001; Zhu et al., 2011). Therefore, understanding how 
telomerase is regulated at the epigenetic level will lead to improved targeting of telomerase as a 
therapy for genetic diseases and cancers. 
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Appendix 1 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from E6.5 mouse embryo genomic DNA 
239 
 
 
Appendix 2 
DNA sequence chromatogram of Hoxa2 promoter CpG island 2 from E6.5 mouse embryo genomic DNA  
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Appendix 3 
DNA sequence chromatogram of Hoxa2 promoter CpG island 3 from E6.5 mouse embryo genomic DNA  
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Appendix 4 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from E8.5 mouse embryo genomic DNA  
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Appendix 5 
DNA sequence chromatogram of Hoxa2 promoter CpG island 2 from E8.5 mouse embryo genomic DNA  
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Appendix 6 
DNA sequence chromatogram of Hoxa2 promoter CpG island 3 from E8.5 mouse embryo genomic DNA 
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Appendix 7 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from E10.5 mouse embryo genomic DNA  
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Appendix 8 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from VPA treated E10.5 mouse embryo 
genomic DNA (Time-pregnant mice were administered s.c. 400 mg/kg VPA once daily between 
E8 and E10 and the embryos analyzed at E10.5). 
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Appendix 9 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from untreated control E10.5 mouse 
embryo genomic DNA 
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Appendix 10 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from EG7 cell line genomic DNA  
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Appendix 11 
DNA sequence chromatogram of Hoxa2 promoter CpG island 2 from EG7 cell line genomic DNA 
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Appendix 12 
DNA sequence chromatogram of Hoxa2 promoter CpG island 3 from EG7 cell line genomic DN 
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Appendix 13 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from NIH3T3 cell line genomic DN 
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Appendix 14 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from VPA treated NIH3T3 cell line 
genomic DNA (NIH3T3 cells treated with VPA (100 µg/mL) for 24 h) 
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Appendix 15 
DNA sequence chromatogram of Hoxa2 promoter CpG island 1 from untreated control NIH3T3 cell line 
genomic DNA  
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Appendix 16 
DNA sequence chromatogram of Hoxa2 promoter CpG island 2 from NIH3T3 cell line genomic DNA  
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Appendix 17 
DNA sequence chromatogram of Hoxa2 promoter CpG island 3 from NIH3T3 cell line genomic DNA 
 
 
 
